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ABSTRACT 
The Histamine H4 receptor (H4R) is a classic G-protein coupled receptor (GPCR) and is 
expressed on a range of cell types in the body. To determine the roles of the H4R in 
the peripheral and central nervous system, four hypotheses have been addressed. 
(1) The H4R are expressed on sensory neurons in the peripheral and central nervous 
system; (2) The H4R is differentially expressed during acute inflammatory and 
neuropathic pain states; (3) Antagonism of the H4R with the antagonist JNJ 7777120 
ameliorates central inflammation observed during experimental autoimmune 
encephalomyelitis (EAE); (4) Antagonism of the central H4R with JNJ 777120 has 
anxiolytic effects and improves memory performance in mice. 
Based on immunofluorescence approaches we have demonstrated for the first time 
the presence of the H4R on both putative A-delta (Aδ) and C-fibre sensory neurons in 
the skin and dorsal root ganglia. Using the novel agonist selective H4R agonist, VUF 
8430 revealed functional expression of H4R on primary rodent dorsal root ganglia 
neurons. Using quantitative immunoblotting, we provide preliminary evidence for 
the rodent H4 receptor bilateral and unilateral upregulation in the skin, but not the 
spinal cord in the acute phase of Complete Freund’s adjuvant induced inflammatory 
pain and nerve constriction acute neuropathic pain, respectively.  
The H4R is an attractive target for the treatment of many inflammatory disorders. 
However, in contrast to the beneficial anti-inflammatory effects of H4R antagonism 
observed in literature, blockade of the receptor using JNJ 7777120 in acute EAE 
(autoimmune disease) appeared to exacerbate the pathology, and increased spinal 
cord inflammation, demyelination, microglia activation and functional deficits. 
Antagonism of the central H4R with JNJ 7777120 at 10 and 20 mg/kg (i.p.) appears to 
affect the behaviour of Balb/c mice but there is no indication of altering anxiety or 
non-spatial memory performance. However, the study did provide preliminary 
evidence for central behavioural effects with regard to time spent in the central part 
of the platform. Overall, this thesis provides new evidence for multiple roles of the 
H4R in the mammalian central and sensory neurons.                               
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Chapter 1 
Introduction 
 
1.1 Nociceptive afferent neurons and the perception of Pain  
 
Pain is defined as the bodily sensation which alerts the organism of a potential threat 
and tissue damage. The sensory component is called nociception and this is 
detection of noxious stimuli by unspecialised, free, unmyelinated nerve endings that 
transduce a variety of stimuli into nerve impulses and a protective response that 
generates a reflex withdrawal from the stimulus. Noxious stimuli provoke real or 
potential injury and cause complex behavioural strategies to avoid further contact 
with such stimuli (Almeida et al., 2004). While nociception refers to the 
neurophysiological mechanisms resulting from noxious stimuli, pain involves the 
perception of aversive stimuli and requires elaboration of sensory impulses.  
 
1.1.1 Nociception 
Nociception is the sensory mechanism which is used to detect noxious stimuli and 
the neurons that mediate nociception are termed nociceptors. Nociceptors 
correspond to free nerve endings and represent the distal part of a first order 
neuron consisting of small diameter fibres, with little myelin or unmyelinated fibres 
of the Aδ or C-type, respectively. Under physiological conditions, pain results from 
specific activation of nociceptors by mechanical, chemical or thermal stimulus (Woolf 
and Ma, 2007) rather than through the hyperactivity of other sensory modulators. 
They present higher thresholds and respond progressively according to the intensity 
of the stimulus. On the other hand, sensitisation of nociceptors can result in reduced 
activation threshold responses as well as spontaneous activity (Treede et al., 1992).  
 
1.1.2 Transduction 
During the activation of peripheral nociceptors, pain transduction is conducted 
through myelinated Aδ and unmyelinated C-fibres to the spinal cord.  Signals then 
travel along the spinothalamic tract to the thalamus and cortex for modulation and 
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motor responses. Prolonged activation of nociceptors and a reduction in 
transduction threshold can result in chronic stimulation. Research has focused on 
the identification of molecules involved in order to develop analgesic treatments to 
treat chronic pain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.1 A summary of the mammalian nociceptive pathway (Caspary and Anderson, 2003) 
Pain or nociception is initiated when peripheral nerve terminals (receptors) of a subgroup of sensory 
neurons (nociceptors) are activated by noxious chemical, mechanical or thermal stimuli.  The axons of 
sensory neurons project to the dorsal root ganglia, where the cell bodies lie and terminate within the 
superficial dorsal horn of the spinal cord. Pain and temperature are detected by nociceptors and the 
messages are transmitted to lamina I and II. Touch is mediated by mechanoreceptors in the periphery, 
which terminate in lamina III, IV and V. Proprioception, the perception of movement and spatial 
orientation, is mediated by the sensory neurons projecting through the dorsal horn to the motor 
neurons located in the ventral horn 
 
1.1.3 Conduction  
In the adult dorsal root ganglia (DRG), the large diameter cells contain high levels of 
neurofilament, producing myelinated Aβ fibres and a proportion of thinly myelinated 
Aδ fibres. Indicating about 40% of lumbar DRG neurons, they express trkB and trkC 
(Lin et al., 2011), which are high‐affinity tyrosine kinase receptors for brain‐derived 
neurotrophic factor (BDNF) and neurotrophin‐3 (NT‐3), respectively. Small diameter 
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cells give rise to unmyelinated axons. These cells can be differentiated 
histochemically into two distinct populations including those cells which 
constitutively synthesize neuropeptides substance P and calcitonin gene-related 
peptide (CGRP) and those which bind the lectin IB4 (Michael et al., 1997).  
Neurophysiological studies confirm that, under normal setting, rapidly conducting Aβ 
fibres (conduction velocities >30 m s–1) are concerned with non‐noxious input from 
specialized encapsulated receptors. On the contrary, most small diameter fibres, 
including Aδ fibres (conduction velocities of 2.5–30 m s–1) and C fibres (conduction 
velocities <2.5 m s–1), have free nerve endings and respond to noxious stimuli (Grigg 
et al., 1986).  
The primary peripheral sensory nociceptors have their cell bodies located within the 
dorsal root ganglia (DRG). DRG neurons have an extended pseudounipolar structure 
with one end forming a sensory terminal in the skin or visceral organ, and the other 
end synapsing in the spinal cord. Nociceptive neurons fire action potentials in 
response to thermal, chemical and mechanical stimuli and possess a high activation 
threshold as this prevents pain from harmless stimuli. These neurons relay 
information from the periphery to the central nervous system (CNS).  
 
1.1.4 Spinal transmission of pain 
The pharmacology of the spinal cord is complex, such that the candidate 
neurotransmitters found within the CNS and their receptors are also found here. 
These neurotransmitters are derived from either afferent fibres, intrinsic neurons or 
descending fibres. The majority of neurotransmitters are located within the 
substantia gelatinosa, a region vital for the reception and modulation of nociceptive 
messages transmitted via peripheral afferents. 
The peripheral afferent fibres emanating from the DRG enter the spinal cord via the 
dorsal roots, ending in the grey matter of the dorsal horn (Figure 3). Most of the 
nociceptive afferents terminate in the superficial region of the dorsal horn, the C 
fires and some Aδ-fibres innervating cell bodies in lamina I and II, while other A 
fibres penetrate deeper into the dorsal horn (lamina V). Cells in lamina I and V give 
rise to the projection pain pathways from the dorsal horn to the thalamus. The non-
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myelinated afferent neurons contain several neuropeptides including substance P 
and calcitonin gene-related peptide (CGRP) which are released as mediators at both 
peripheral and central terminals, and play an important role in the pathology of pain.  
There is evidence for the involvement of the excitatory amino acids, glutamate, 
aspartate and peptides in nociceptive transmission within the dorsal horn of the 
spinal cord. Functional roles have been established where antagonists for their 
receptors have been developed. Some of these have been discussed below;  
 
a) Neuropeptides  
Substance P is the neurotransmitter of the small diameter nociceptive afferent 
terminals (Takemura et al., 2006) whose biological actions are mediated through 
activation of the neurokinin receptors named NK1, NK2 and NK3. Substance P acting 
via the NK1 receptor has been implicated in the processing of noxious information 
within the spinal cord, due to its involvement in animal models of inflammatory and 
neuropathic pain (Lagraize et al., 2010). Peripheral injection of a NK1 agonist was 
shown to induce hyperalgesia in the rat hind paw (Chen et al., 2006). On the other 
hand, central administration of an NK1 antagonist before and after inflammation 
induced by complete Freund’s adjuvant, resulted in attenuation of thermal 
hyperalgesia (Lagraize et al., 2010).  
 
Calcitonin gene-related peptide is a potent vasodilator (Brain et al., 1985) and is 
involved in pain transmission, through its ability to sensitise nociceptors (Li et al., 
2008). Its role in the pathogenesis of migraine pain has been studied extensively 
(Arulmani et al., 2004). The antagonist BIBN4096BS was the first CGRP antagonist 
tested clinically. It abolished neurogenic increases in dural blood flow and was 
efficacious in migraine treatment (Doods, 2001). CGRP is involved in the sensitisation 
of path pathways, as it is an important signalling molecule along the peptidergic 
nociceptive pathway from primary afferents and spinal cord to the supraspinal 
regions. Systematically administered CGRP antagonists BIBN4096BS dose 
dependently reduce inflammatory pain induced by CFA and osteoarthritic pain 
induced by sodium monoiodoacetate (MIA) (Hirsch et al., 2013).  
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b) Somatostatin  
Somatostatin (SST) is polypeptide expressed in a subset of primary afferent neurons 
and reduces vascular and nociceptive components of inflammation. In experimental 
paradigms the main effect of SST receptor (SSTR) activation in the spinal cord is 
inhibition (Wang et al., 2009). Some studies show that central administration of STT 
is associated with spinal cord damage including neolysis of dorsal and ventral horn 
cells, pyknotic neurons, demyelination and inflammation (Gaumann and Yaksh, 
1988).  The rational that targeting peripheral STTRs would provide effective analgesia 
whilst avoiding the CNS side effects has been proposed. Carlton et al. (2001) 
investigated the presence of SSTRs on peripheral afferent fibres and the physiologic 
effects of the SST agonist octreotide on formalin-induced nociception in the rat. The 
results obtained demonstrated that SSTRs are present on 11% of primary sensory 
fibres in glabrous skin, intraplantar administration of octreotide dose-dependently 
reduced thermally-induced nociceptive behaviour and each of these actions can be 
inhibited by the SSTR antagonist cyclo-somatostatin (Carlton et al., 2001). Therefore 
activating peripheral SSTRs has anti-inflammatory and anti-hyperalgesic effects, 
while avoiding the deleterious CNS side effects and may be useful in the clinical 
setting. 
 
c) Excitatory neurotransmitters  
Sustained persistent activation of peripheral nociceptors due to nerve injury 
produced ectopic discharges in the injured sensory neurons, and subsequent release 
of excitatory neurotransmitters from central afferent terminals and enhance dorsal 
horn excitability (Dickenson, 1990). The actions of glutamate are mediated via the N-
methyl-D-aspartate (NMDA) receptor and other non-NMDA receptors, which consist 
of metabotropic, kainate and alpha-amino-3-hydroxyl-5-methly-4-
isoxazoleproprionic acid (AMPA) receptors (Mori and Mishina, 1995). The NMDA 
receptor consists of two homologous subunits NR1 and NR2, which have been 
implicated in long-term events in the CNS such as long-term potentiation in the 
hippocampus, synaptic plasticity and sustained motor activity (Latremoliere and 
Woolf, 2009).  
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Activation of the NMDA receptor requires glutamate release from neurons and 
binding to its receptor as well as the presence of glycine (co-agonist) and the means 
to remove the physiological Mg2+ that normally block the channel, by depolarisation. 
This results in an influx of Ca2+ ions and phosphorylation of proteins. Selective NMDA 
antagonists are reported to reduce pain resulting from inflammation and injury to 
peripheral nerves (Boyce et al., 1999, Chizh et al., 2001, Kristensen et al., 1994, 
Murray et al., 1991). 
 
d) Kinins 
The most active kinins are bradykinin and kallidin and these are produced following 
tissue injury by the proteolytic cleavage of their kininogen precursor. Bradykinin is a 
potent pain-producing substance that acts by releasing prostaglandins, which in turn 
enhance the effects of bradykinin on the nerve terminal. Bradykinin and kallidin have 
their effects through actions on the B1 and B2 receptors expressed on neurons and 
involved in the pathogenesis of pain and inflammation. More recently it has been 
suggested that when inflammation is prolonged, bradykinin B1 receptors, which are 
not expressed in healthy tissues to a significant degree, also play an important role in 
the maintenance of hyperalgesia (Dray and Perkins, 1993). Consistent with this, the 
non-peptide bradykinin B2 receptor antagonist, bradyzide showed long-lasting 
analgesic effects in the rat model of CFA-induced mechanical hyperalgesia (Burgess 
et al., 2000). 
 
e) Prostaglandins  
Prostaglandins are released following tissue inflammation and damage from cells 
such as mast cells, macrophages and neutrophils (Syriatowicz et al., 1999) and can 
sensitise nociceptors (Cunha and Ferreira, 2003). They are synthesised by the 
enzyme cyclooxygenase 1 (COX-1) and its isoform coenzyme COX-2, which is induced 
in the periphery by cytokines, growth factors and other inflammatory stimuli (Ballou 
et al., 2000). Generally considered to be sensitising agents, they act by increasing 
cyclic AMP and may enhance nociceptor sensitisation by reducing the activation 
threshold for protein kinase A-dependent tetrodotoxin-resistant sodium channels 
(England et al., 1996).  Studies using COX-1 and COX-2 knockout animals have 
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suggested that these enzymes may serve different mechanistic pathways. COX-1 
deficient mice showed reduced nociception to a variety of noxious stimuli (hot plate, 
stretching) compared to their wild type counterparts. Measurements of mRNA 
revealed a compensatory up-regulation of COX-1 mRNA in the spinal cords of COX-2 
null mice, but no increase of COX-2 in spinal cords of COX-1 null mice (Ballou et al., 
2000).   
In a model of carrageenan-induced inflammation, pre-treatment with 
dexamethasone (steroidal anti-inflammatory drug) prevented endogenous 
prostaglandins, and prevented the induction of mechanical hyperalgesia (Prado et 
al., 2013). 
 
f) Cytokines  
In addition to their stimulatory and inhibitory effects on immune inflammatory cells, 
cytokines may act directly or indirectly to sensitise nociceptors. During acute phases, 
cytokines appear to induce sensitisation through activation of receptor associated 
tyrosine kinases and phosphorylation of ion-channels, whereas in chronic 
inflammation, transcriptional up-regulation of receptors may play a larger role 
(Opree and Kress, 2000). Administration of tumour necrosis factor alpha (TNF-α) 
(Wagner and Myers, 1996), inter leukin-1 (IL-1), IL-6, IL-8 produce hyperalgesia, and 
antibodies against TNF-α reduce hyperalgesia in models of inflammatory pain (Opree 
and Kress, 2000). IL-6 deficient mice show reduced response to noxious mechanical 
and thermal stimulation (Xu et al., 1997), following carrageenan-induced 
inflammatory and chronic constriction injury (CCI) neuropathic pain (Murphy et al., 
1999).  
 
g) Growth factors  
Nerve growth factor (NGF) plays a key role in modulating pain sensitivity, and acts 
through activation of the tyrosine receptor kinase A. Administration of exogenous 
NGF was shown to induce thermal hyperalgesia in rodents (Andreev et al., 1995), 
through a mechanism involving mast cell degranulation, releasing algesic agents. 
Degranulation of mast cells delays the effects of NGF (Lewin et al., 1994) and 
attenuates CFA-induced hypersensitivity. On the other hand, sequestration of NGF 
 
 
28 
 
by anti-NGF antibodies prevented inflammation induced hyperalgesia (Woolf et al., 
1994). In human subjects, NGF produces cutaneous hyperalgesia at the application 
site, and widespread pain which persist for days. It is possible that these sensitising 
effects are mediated by direct effects on nociceptors. 
Brain derived neurotrophic factor (BDNF) is synthesised by small DRG neurons and 
transported within axons to the terminals in the spinal cord. BDNF in these cells is 
up-regulated by administration of NGF or induction of inflammation (Cho et al., 
1997) and consistent with this, BDNF antiserum temporarily reduced both 
mechanical and thermal hyperalgesia (Theodosiou et al., 1999).  
 
 
h) Other peripheral mediators 
Various metabolities are released from damaged or inflamed tissue which affects 
nociceptive nerve terminals including extracellular ATP (Prado et al., 2013), serotonin 
(Abbott et al., 1996), histamine and potassium (Marker et al., 2004).  
ATP excites sensory nerves by its actions on P2X3 receptors, which are ligand gated 
ion channels selectively expressed by these neurons. Activation initiates a transient 
depolarisation by Na+ influx through the ion channel coupled to the P2X3 receptor 
(Prado et al., 2013). Down-regulation of P2X3 receptors by antisense oligonucleotides 
technologies reduces inflammatory pain (Honore et al., 2002) and P2X3 knockout 
mice display significantly reduced pain-related behaviours in response to ATP or 
formalin (Honore et al., 2002), strengthening the evidence for a role of this P2X3 
receptor activation in acute inflammatory pain.  
Injection of Serotonin (5-HT) or its agonists into the plantar surface of the hind paw 
causes hyperalgesia in experimental animals and sensitises nociceptors. Evidence 
shows that 5-HT1A receptors (Millan et al., 1996), 5-HT2A receptors (Abbott et al., 
1996) and  5-HT3 receptors (Voog et al., 2000, Giordano and Sacks, 1997) all 
contribute to the hyperalgesic action of serotonin and their antagonists could have 
therapeutic potential.  
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1.1.5 Inflammatory pain  
Pain sensations could arise due to several reasons including inflammation (Linley et 
al., 2010). Inflammation is a complex immune response that occurs following bodily 
injury (wound, burn, infection, etc) which aims to remove the harmful stimulus and 
promote tissue regeneration.  Inflammation is classified into the acute and chronic 
phases, each characterised by a series of cellular and biochemical reactions (Linley et 
al., 2010).  
Acute inflammation is mediated by immune cells residing in the tissues, such as 
neutrophils, macrophages dendritic and mast cells. Following injury the cells release 
inflammatory mediators which cause inflammatory pain, by sensitising nociceptors. 
Inflammatory mediators involved in this process include histamine (Monroe et al., 
1997), bradykinin (Burgess et al., 2000), prostaglandins (Syriatowicz et al., 1999), 
growth factors (Welker et al., 2000), cytokines (Cowden et al., 2010a), and substance 
P (Hagermark et al., 1978). These mediators result in increased vasodilatation, 
vascular permeability and extravasation of serum proteins and leukocytes.  
Histamine (Schmelz et al., 1997) and bradykinin are known to sensitise nociceptors 
or directly excite the peripheral terminals of nociceptive neurons 
 
Chronic inflammation is prolonged inflammation resulting in the alteration of the 
types of cells present at the site of inflammation, characterised by destruction and 
healing simultaneously. This is caused by a variety of factors including bacterial, 
parasitic and viral infections, chemical irritants and non-digestible particles.  
 
1.1.6 Neuropathic pain  
Peripheral nerve injury causes both damaged and undamaged A- and C- fibres to 
generate spontaneous action. This is a form of ectopic output as it does not arise 
from the peripheral terminal and it has the ability to initiate and maintain activity-
dependent central sensitisation in the dorsal horn of the spinal cord. Injured, and to 
a lesser extent, non-injured neurons in the dorsal root ganglion exhibit 
transcriptional changes that alter membrane properties, growth and transmitter 
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function (Xiao et al., 2002, Obata et al., 2003). Among the many changes that occur, 
larger fibres begin to express new neurotransmitters and modulators including 
substance P and BDNF, which can drive sensitisation (Fukuoka et al., 2001, Noguchi 
et al., 1995). Peripheral nerve injury results in degeneration of C fibre terminals in 
lamina II (Arvidsson et al., 1986). This loss of presynaptic input provides an 
opportunity for myelinated Aβ fibres to sprout from lamina III-IV, into lamina I-II and 
make contact with nociceptive-specific neurons (Lekan et al., 1996). 
 
Peripheral nerve injury causes activation and changes in glial cells within the spinal 
cord as well as infiltration of peripheral immune-competent cells (Cao and DeLeo, 
2008). The response is much greater than that observed during peripheral 
inflammation and, activated microglia synthesise and release cytokines, growth 
factors and neurotransmitters (Romero-Sandoval et al., 2008) and play a role in the 
development of pain by triggering sensitisation through actions on neurons 
(Raghavendra et al., 2003). Microglia release cytokines which have their effects 
through activation of extracellular signal-regulated kinase (ERK) (Ji et al., 2009) and 
cAMP Response Binding Protein (CREB) (Kawasaki et al., 2008). Activated microglia 
also release BDNF (Coull et al., 2003). Astrocytes are also activated following 
peripheral nerve injury, with a slower but prolonged time-course in comparison to 
microglia and may play more of a role in the maintenance of neuropathic pain and 
hypersensitivity than microglia (Zhang and De Koninck, 2006).  
 
Reduced production of inhibitory neurotransmitters leads to a state of disinhibition 
(loss of inhibition), whose effects are similar to that produced by increases in 
strength of excitatory synapses and membrane excitability (Yaksh, 1989). In 
neuropathic pain states, disinhibition in the superficial dorsal horn with loss of 
GABAergic and loss of glycine inhibitory currents (Moore et al., 2002) can be 
attributed in part, to apoptosis of inhibitory neurons (Scholz et al., 2005). This 
neuronal death appears to be a result of NMDA receptor-induced excitotoxicity that 
develops over time, rather than the large amounts of glutamate released centrally 
upon injury (Scholz et al., 2005). 
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Another mechanism that contributes to the disinhibition observed in a 
subpopulation of lamina I neurons, following nerve injury is BDNF-dependent, as it 
modulates the anion transporter allowing changes in anion gradients across 
neuronal membranes to alter the inhibitory efficacy of GABA. Under physiological 
conditions, intracellular concentration of Cl- are maintained by the opposing effects 
of Cl- co-transporter K+ Cl- exporter 2 channels (KCC2) and Na+ -K+-Cl- exporter 1 
channels (NKCC1). NKCC2 drives Cl- ions out and NKCC1 allows influx of Na+, K+ and 
Cl- into the cells. The net effects of this mechanism is a steady-state Cl- concentration 
gradient in which Cl- entry into the cells hyperpolarises the neurons (Miletic and 
Miletic, 2008). Following nerve injury induced by ligation of the sciatic nerve, 
increases in BDNF released by activated microglia coincide with reduced KCC2 
expression in a subset of neurons within the superficial dorsal horn (Miletic and 
Miletic, 2008). GABA inhibition is dependent on KCC2 activity and the loss of this 
activity may lead to loss of GABA inhibition within the dorsal horn. Consequently, 
activation of GABA receptors results in the absence of Cl- entry into the neurons, the 
excitability sustained and enhanced exaggerated communication between primary 
afferents contributing to pain (Miletic and Miletic, 2008). The hyperalgesia caused by 
nerve injury was attenuated by TrkB blockers. 
 
 
1.1.7 Inhibition of peripheral sensitisation 
a) Opiates  
 
Three major types of opioid receptor have been discovered and these are µ, δ and κ. 
Opioid receptors are G protein coupled receptors that inhibit adenylyl cyclase, 
thereby reducing the intracellular cAMP content. Opiates typified by Morphine, are 
effective in the treatment of severe acute and chronic pain but their use in the clinic 
has been hampered by side effects such as respiratory depression, depression, 
nausea, tolerance and addiction. During inflammation, expression and axonal 
transport of opioid receptors increases in dorsal root ganglion neurons (Stein et al., 
2003). Activation of opioid receptors results in cAMP inhibition and activation 
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attenuates the hyperexcitability of nociceptive neurons which innervate inflamed 
skin. Subsequently, opioid agonists developed for peripheral use such as loperamide, 
show antinociceptive activity in inflammatory conditions such as experimental 
arthritis (DeHaven-Hudkins et al., 1999) and they have potent and long lasting 
analgesic effects (Decosterd et al., 2006). 
 
b) Non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs inhibit cyclooxygenase (COX) enzymes and reduce formation of 
prostaglandins. At present, three COX isoenzymes are known and these are COX-1, 
COX-2 and COX-3, which is a splice variant of COX-1 (Chandrasekharan et al., 2002). 
While non‐selective inhibition of COX enzymes produces a significant anti-
hyperalgesic effect and emphasises the importance of prostaglandins in 
inflammatory hyperalgesia, clinical use is limited by the gastrointestinal side effects. 
However, the development of selective COX-2 inhibitors has provided a means to 
avoid these effects. Since COX-2 is usually specific to inflamed tissue, there is less 
gastric irritation associated with COX-2 inhibition with a reduced risk of peptic 
ulceration. Etodolac, the COX-2 inhibitor was shown to attenuate heat-induced 
hyperalgesia in the CCI model of neuropathic pain (Suyama et al., 2004). However, 
analysis of clinical trial data revealed that COX-2 inhibitors are associated with a 
moderately increased risk of vascular events, attributable to an increased risk of 
myocardial infarction (Kearney et al., 2006).   
 
c) Cannabinoids  
Cannabinoids are constituents of the hemp plant and have been shown to produce a 
unique syndrome of behavioural effects in humans and animals that include 
disruption of short-term memory, cognitive impairments, and a sense of time 
dilation, mood alterations, and enhanced body awareness, a reduced ability to focus 
attention and to filter out irrelevant information, discoordination, and sleepiness. 
Two cannabinoid GPCRs have been discovered and they are Gi/o linked to the 
inhibition of adenylyl cyclase and voltage operated sodium channels causing 
hyperpolarisation. Initially it was believed that CB1 receptors were predominantly 
located in the CNS and the plasma membrane of nerve endings and inhibits 
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neurotransmitter release from presynaptic terminals, whereas CB2 receptors were 
non-neuronal and are mainly located in lymphoid tissue and immune cells. However, 
CB1 receptors have been located in peripheral tissues such as cardiovascular and 
gastrointestinal tract (Szabo et al., 2001). Cannabinoids are effective analgesics in 
acute and chronic pain (Pertwee, 2001) and the analgesic effect is mediated by 
cannabinoid receptors in the dorsal horn of the spinal cord and periacqueductal 
grey. The antihyperalgesic efficacy of locally administered CB1 agonist was increased 
because up-regulation of CB1 receptors is induced by peripheral inflammation 
(Amaya et al., 2006). This indicates the possibility to develop therapeutics that target 
the peripheral endocannabinoid system and provide pain relief without the side 
effects associated with central CB1 receptor activation (Mitrirattanakul et al., 2006). 
 
1.1.8 Central sensitisation  
 
Nociceptive signalling is crucial for preventing damage to the body. However, during 
pathophysiological conditions, this signalling may misinterpret sensory stimulation, 
resulting in pain. Here, the pain arises spontaneously, can be elicited by normally 
innocuous stimuli (allodynia), is exaggerated and prolonged in response to noxious 
stimuli. Sensitisation represents an enhancement in the function of neurons and 
circuits in nociceptive pathways caused by increases in membrane excitability and 
synaptic efficacy as well as to reduced inhibition. There are two types of 
sensitisation, peripheral and central sensitisation. Peripheral sensitisation represents 
the reduced threshold and amplified responsiveness of nociceptors that occurs when 
the peripheral terminals of these high-threshold primary afferent neurons are 
exposed to inflammatory mediators and nerve injury (Chen et al., 1999) and is 
therefore restricted to the site of injury.  
 
Central sensitisation on the other hand includes novel inputs to nociceptive pathway 
including those that do not normally drive them such as large low-threshold 
mechanoreceptor Aβ-fibre mediated pain. It also produces pain hypersensitivity in 
non-inflamed tissue by altering sensory responses elicited by normal inputs and 
increases hyperalgesia long after the initiating cause may have disappeared 
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(Latremoliere and Woolf, 2009). Since this is a result of alteration in the properties of 
neurons, the pain is no longer coupled to acute nociceptive input.  The pain is 
generated as a consequence of changes within the CNS that alter responses to 
sensory inputs, rather than reflect the presence of peripheral noxious stimuli. 
Central sensitisation corresponds to an enhancement in the functional status of 
neurons and circuits within the nociceptive pathway, caused by increased membrane 
excitability and reduced inhibition (Latremoliere and Woolf, 2009).   
 
Considerable numbers of substance P containing afferent fibres contain glutamate 
and aspartate suggesting that, both neuropeptides and excitatory amino acids are 
released in response to noxious stimuli. Evidence indicates that NMDA receptors 
influence development and maintenance of neuropathic pain (Dickenson, 1990). Gao 
et al. (2005) demonstrated an up-reregulation in the phosphorylation of the NR1 
NMDA receptor (Gao et al., 2005) following nerve injury. The increase in 
phosphorylation enhances the response of NMDA receptors to NMDA in the CNS. An 
increase in the amount of phosphorylated NR1 (pNR1) and pNR1 immunoreactivity 
in the dorsal horn neurons was observed in the ipsilateral dorsal horn spinal cord of 
rats with capsaicin induced secondary hyperalgesia. This supports the idea that 
phosphorylation of NR1 subunits is related to enhancement of synaptic efficacy and 
thus the development of central sensitization (Gao et al., 2005). 
 
1.1.9 Wind up  
In anaesthetised rats, during repeated electrical stimulation of dorsal horn neurons 
with the same intensity in the periphery that activates C fibres, the initial constant 
response to the first few stimuli suddenly increases dramatically and then levels off 
at a level many times greater than the original response (Davies and Lodge, 1987). 
This characteristic is called wind-up because, following cessation of stimulation, the 
cell continues to fire for several minutes. Despite abolition or reduction of wind up in 
the presence of NMDA receptor antagonists, the original response of the cell 
remains unaltered and the cell continues to respond steadily (Davies and Lodge, 
1987). Therefore, the NMDA may amplify, enhance and prolong ongoing nociceptive 
afferent activation and contribute to prolonged nociceptive states that underlie 
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central hypersensitivity (Woolf and Salter, 2000). In support of this, it has been 
shown that spinal responses caused by prolonged neuropathy are markedly reduced, 
in vivo by NMDA antagonists such as MK801 but not completely abolished (Smith et 
al., 1994).   
 
The modulation of pain is quite complex and despite years of research, more work is 
required to explore the various pathways that contribute to hyperalgesia, including 
the histaminergic system 
 
1.2 Histamine  
Histamine [2-(4-imidazolyl)-ethylamine] has been long known to be an important 
mediator in different physiological and pathophysiological conditions. It is an 
endogenous short-acting amine synthesised from L-histidine through the catalytic 
activity of the rate-limiting histidine decarboxylase (HDC) (Bodmer, 1999). The classic 
source of histamine is the pluripotent heterogeneous basophils and mast cells, 
where it is stored in cytostolic granules and released via exocytosis in response to 
various immunological and non immunological stimuli (Kakavas S, 2006). 
The diagram below shows the chemical reaction that forms histamine from the 
amino acid, Histidine, via catalysis with the enzyme histidine decarboxylase. 
      
 
Figure 1.2 Chemical structures of the amino acid L-Histidine that forms histamine via catalysis with 
histidine decarboxylase (HDC) (adapted from www.histamineintoerlanz.ch) 
 
Histidine  decarboxylase  
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Since its discovery over a century ago (Barger, 1910), it is one of the most studied 
substances in medicine possessing a spectrum of activities in immune modulation 
and neurotransmission. Histamine is synthesised in several types of peripheral and 
central tissues (Haas HL, 2008); but is found in particularly high concentrations in the 
lungs, skin and gastrointestinal tract.  
1.2.1 Histamine in the brain 
The histamine containing neurons are mainly located in the tuberomamillary nucleus 
(TMN) and adjacent areas within the posterior hypothalamus. The TMN is composed 
of several dense clusters of large, characteristic neurons, including scattered neurons 
with the same morphology in the surrounding heterogenous regions. Figure 1.3 
represents the brain histaminergic system of all mammalian species examined. The 
histaminergic neurons are mainly localised in the TMN (figure 1.3), with projections 
throughout the brain, including the hippocampus (HPO), the basal forebrain (BF), 
striatum (ST) (Panula et al., 1989), hypothalamus (HY) (Meynard et al., 2005), cortex 
(Haas, 2003), and olfactory bulb (OB) (Panula et al., 1989).  
 
 
 
Figure 1.3: Representation of the localisation and distribution of histaminergic system in the 
mammalian brain. The histaminergic neurons are emanate from the TMN within the posterior 
hypothalamus and have projections throughout the brain (Thakkar, 2011). 
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The brain histaminergic system contains both neuronal and non-neuronal histamine. 
Histamine synthesis occurs in two steps. Firstly, it is the neuronal uptake of L-
histidine by the L-amino acid transporter and secondly, decarboxylation of L-histidine 
by the enzyme L-histidine decarboxylase.  As shown in Figure 3, once synthesised, 
histamine is take up and stored in vesicles by vesicular monoamine transporter. In 
the absence of the high affinity uptake mechanism in the brain, released histamine is 
degraded through methylation by the enzyme histamine-N-methyltransferase which 
is located post-synaptically, and in glial cells to tele-methylhistamine. This metabolite 
does not possess any histamine-like activity.  
 
 
Figure 1.4 Histamine synthesis and metabolism in neurons. L-histidine is taken up by the L-amino acid 
transporter. The formed histamine is stored in synaptic vesicles and released by exocytosis. Free 
histamine in the synapse is inactive through methylation by the enzyme histamine-N-
methyltransferase (Thakkar, 2011). 
 
The central histamine system is involved in many central nervous system (CNS) 
functions including, arousal (Tasaka, 1989), activation of the sympathetic nervous 
system, stress-related release of hormones from the pituitary (Knigge et al., 1991) 
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and of central aminergic neurotransmitters (Schlicker, 1994), anti-nociception 
(Cannon, 2003) and appetite suppression (Gotoh et al., 2007). The histaminergic 
system is phylogenetically conserved (Haas, 2003) and in vertebrates, the 
tuberomamillary nucleus (TMN), a part of the posterior hypothalamus, is the source 
of histaminergic neurons and their projections (Lee et al., 2008). In humans, 
histamine-induced itch is mediated by specific mechanoinsensitive C fibres. These 
“itch” fibres are preferentially activated by pruritogens like histamine and react to 
histamine application with a time course of excitation that reflects the sensation of 
itch (Schmelz et al., 1997). Besides the histaminergic pathway, electrophysiological 
studies in humans suggest the existence of a second peripheral pathway for the 
transmission of itch (Schmelz, 2010).  
Confirming the existence of a different itch processing pathway, itch was induced in 
the absence of an axon reflex flare. The axon reflex flare response comprises 
neurogenic vasodilation, induced by neuropeptide release from mechano-insensitive 
C-fibres. This suggests that itch is independent of histamine-sensitive C-fibres 
(Schmelz, 2010). 
 
1.2.2 Anatomy, distribution and function of the Histamine receptors 
Histamine elicits its actions through binding to four distinct histamine receptors 
named H1-, H2-, H3- and H4- receptors, in chronological order of discovery. All four 
receptors belong to the rhodopsin-like G-protein coupled receptor (GPCR) family 
(Simons, 2011). Homology between these receptors is very low except between H3 
and H4 receptors. Despite this, all four contain negatively charged aspartate residue 
in transmembrane 3, which is considered to be the binding site for the amine 
function of histamine.  
1.2.2.1 The histamine H1 receptor 
The first classical anti-histamines antagonised the effects of histamine on the H1 
receptor expressed on various smooth muscles and (Hill et al., 1997) is ubiquitously 
expressed. It has been found to exert effects on smooth muscle cells, the gastro-
intestinal tract, the heart, lung smooth muscle cells and the CNS, including the 
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cortex, cerebellum, hippocampus and thalamus. The H1 receptor is expressed on 
numerous cell types including chondrocytes, hepatocytes, nerve cells, endothelial 
cells (Lo, 1987), neutrophils (Taniguchi, 1991) and dendritic cells (Ohtani, 2003). The 
presence of the H1 receptor in the brain explains the sedative effects of the first 
generation anti-histamines whereas second generation anti-histamines are largely 
BBB-impermeable and therefore lack this effect.  The H1 receptor is linked to the 
Gq/11 protein which stimulates phospholipase C (PLC) catalysed hydrolysis of 
membrane inositide phospholipids. Receptor activation leads to phosphatidyl-4,5-
bisphosphate (IP2) , producing inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG).  
Discovery of histamine involvement in allergic reactions led to the development of 
anti-histamines as successful therapies for allergic and inflammatory conditions 
(Simons and Simons, 2011). Classic (first generation) anti-histamines have sedative 
side-effects and also antagonise muscarinic and serotonergic receptors (Simons, 
2004). This lead to the design of second-generation anti-histamines which lack these 
effects and several are used therapeutically in the treatment of allergies. Examples 
include Loraditine (Claritin©), fexofenadine (Allegra©), cetrizine (Zyrtec©) and 
ketotifen (Zaditor©) have generated billions of dollars (Hill et al., 1997).  
The H1 receptor is expressed on peripheral sensory neurons and plays a role in 
histamine induced itch. Immunohistochemical analysis has shown the distribution of 
the H1 receptor in the superficial lamina I and II of the dorsal horn of the spinal cord 
(Vizuete et al., 1997). H1 receptor knockout mice show decreased inflammatory 
responses though loss of pronociceptive actions of histaminergic pathways in the 
dorsal horn (Mobarakeh et al., 2000) and intrathecal administration of H1 
antagonists elicit antinociceptoin in a dose-dependent manner (Parada et al., 2001). 
In vivo analysis has demonstrated that intradermal administration of H1 agonists 
provoke itch in mice and antagonism this receptor inhibits histamine and allergen-
induced itch (Rossbach et al., 2009). Although H1 receptor antagonists are prescribed 
clinically for the treatment of pruritic conditions such as atopic dermatitis, they are 
not always effective. 
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1.2.2.2 The histamine H2 receptor 
The H2 receptor was first described in the periphery where it modulates smooth 
muscle and gastric acid secretion (Hill et al., 1997). The H2 receptor is constitutively 
active (Leurs et al., 2002) and receptor activation is linked to the activation of 
adenylyl cyclase via Gs-proteins (Dy and Schneider, 2004). The H2 receptors are 
expressed in the superficial lamina I and II of the dorsal horn, which receives 
nociceptive information.  
H2 receptors located in the periacqueductal grey are implicated in antinociception 
caused by administration of µ-opioids (Mobarakeh et al., 2006). A study by Farzin et 
al. (2007) showed that intraperitoneal injection of the H2 receptor agonist dimaprit 
and antagonist ranitidine attenuated formalin-induced nociceptive responses in the 
early and late phases of the nociceptive response test (Farzin and Nosrati, 2007), 
suggesting that these compounds have antinociceptive effects. However, the 
antinociceptive effects of dimaprit were blocked by the opioid antagonist naloxone. 
These findings imply that central opioid receptors are involved in H2 receptor agonist 
induced analgesia. This data that shows that acute noxious stimuli enhance the 
activity of histaminergic neurons in the periacqueductal grey and dorsal horn of 
spinal cord  which are rich in both opioid peptides and opioid receptors (Farzin and 
Nosrati, 2007). 
1.2.2.3 The histamine H3 receptor 
The first evidence of the third histamine receptor was obtained and showed it to be 
a  pre-synaptic auto-receptor on histaminergic neurones in the brain (Arrang et al., 
1983). Subsequently, it has been shown to have pre-synaptic hetero-receptor 
properties in non-histamine neurones in both the peripheral and central nervous 
systems. Although the H3R is mostly expressed in CNS tissues, it has been detected in 
the periphery (e.g. mast cells, gut) where it modulated neurotransmission (Imamura, 
1995, Coruzzi, 2010). It is present on both histaminergic (auto-receptors) and non-
histaminergic (hetero-receptors) and activation of the H3 receptor can inhibit the 
release of histamine as well as other neurotransmitters e.g. dopamine, serotonin, 
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norepinephrine, glutamate, noradrenalin and γ-amino butyric acid (GABA) (Leurs, 
1998). 
The histamine H3 receptor is linked to Gi/o proteins and has been shown to be 
constitutive active, both in vivo and in vitro (Morisset, 2000). This receptor is 
pharmacologically distinct from the H1- and H2 receptors, given that activation of the 
H3 receptor inhibits production of cAMP via adenylyl cyclase.  Autoradiographic 
studies with the H3 receptor agonist [
3H] R-α-methylhistamine, have shown the 
presence of binding sites in several rat brain regions particularly the cerebral cortex, 
striatum, hippocampus and olfactory nucleus, which receive ascending histaminergic 
projections from the posterior hypothalamus (Pollard et al., 1993). 
Immunohistochemical studies confirmed the existence of H3 receptors on sensory 
neurons in the dorsal root ganglia and sensory fibres in the skin (Cannon et al., 
2007a). The size and calibre of the neurons observed where consistent with Aβ and 
Aδ fibre cutaneous innervations and where shown to be primarily medium to large 
DRG cells that co-expressed neurofilament and calcitonin gene-related peptide, 
respectively (Cannon et al., 2007a). 
 A subset of DRG neurons responded with an increase in intracellular calcium 
following stimulation with pitolisant, the H3 receptor may mediate histamine release 
directly from the DRG. On the other hand, the H3 receptor activation regulates the 
release of other neurotransmitters including substance p, which could activate the 
surrounding cells to release histamine. H3 receptor agonists are known to inhibit 
neuropeptides release from presumed sensory fibres in the skin and posses some 
anti-nociceptive and anti-inflammatory properties (Cannon et al., 2007b, Cannon and 
Hough, 2005).  
Systemic administration of the H3 receptor agonist immepip significantly attenuates 
formalin-induced paw inflammation (Cannon et al., 2007a). Subsequently, the H3 
receptor agonist immepip attenuated formalin-induced tail flinching responses in 
rats (Cannon and Hough, 2005). Conversely, H3 receptor antagonists have been 
shown to induce pruritus-like effects (Hossen et al., 2003). Intradermal injection of 
clobenpropit and histamine caused significant dose-dependent scratching behaviour 
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in both mast cell deficient and wild type mice (Rossbach et al., 2011). Thus injury-
induced release of histamine may play a pro-nociceptive, pro-inflammatory role 
through action on the H1 receptors and/or anti-inflammatory action through the H3 
receptor.  
 
1.2.3 The histamine H4 receptor  
1.2.3.1 Gene structure and expression 
The H4 receptor is present as a single copy on chromosome 18q11.2 and homology 
of the H4 receptor to the H1 and H2 receptors is approximately 19% (Coge et al., 
2001). It was discovered after the H3 receptor, with which it shares approximately 
37% homology (Lovenberg, 1999). The gene consists of 3 exons and 2 introns. The 
introns divide the coding regions into three parts, encoding amino acid number 1-65, 
66-119 and 120-390. This leads to the generation of alternatively spliced H4 receptor 
isoforms (van Rijn et al., 2008). The open reading frame consists of 1173bp, encoding 
for 390 amino acid protein belonging to the family of GPCRs.  
The H4 receptor protein consists of two asparagines in the N-terminus (Asn
5 and 
Asn9) which could function as possible gylcosylation sites. Through the use of 
western blot analysis, Nguyen et al.(2001) have showed an unglycosyated (44 kDa), 
glycosylated (85 kDa) and putative oligomeric (>250 kDa) forms of the H4 receptor 
(Nguyen et al., 2001). 
Using the DNA sequence of the H3 receptor, several research groups simultaneously 
and independently identified a previously unexplored GPCR sequence in the human 
genome as the histamine H4 receptor (Oda, 2001, Nguyen et al., 2001, Zhu et al., 
2001, Liu and Hokfelt, 2002a, Liu et al., 2001a, Morse et al., 2001). This receptor 
showed distinct high expression in immune cells (Morse et al., 2001, Oda et al., 2000, 
Zhu et al., 2001) and is now regarded as an interesting target for inflammatory 
disorders and pruritus (Thurmond et al., 2008b, de Esch et al., 2005).  
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After cloning of the human H4 receptor, genes corresponding to the H4 receptor were 
identified and cloned from mouse, rat, guinea pig, pig and monkey (Oda et al., 2002, 
Liu et al., 2001, Oda et al., 2005). The homology between the human and the rodent 
and the pig H4 is very low (65-75%). However, the monkey and human H4 receptor 
show higher homology (92%), explaining why the pharmacological profile of the 
human H4 receptor is similar to that of the monkey but quite different from that of 
the rodent H4 receptor. Delineating the sequences of the rat, mouse, guinea-pig, 
porcine, monkey and dog H4Rs has provided a very useful tool in comparing the 
binding activities of the H4 receptor ligands.  
1.2.3.2 Splice variants  
The H4 receptor gene contains 2 introns, resulting in the existence of alternatively 
spliced isoforms. The first splice variant results in the deletion of exon 2 and encodes 
a protein consisting of 302 amino acids H4R (302), from a deletion of 88 amino acids 
between TMII and TMIV. The second splice variant also results in the removal of 
exon 2. However the H4R (390) splice acceptor site of exon 3 is recognised, leading to a 
frame-shift and the introduction of an alternative stop codon. The end result is a 
severely truncated H4R (67) receptor containing only the first 67 amino acids of the H4 
receptor. Quantitative PCR showed that the H4 receptor splice variant mRNA was 
most abundant in eosinophils. In pre-monocytes, expression of H4R67 is similar to 
that of H4R390. The lower abundance for mRNA of H4R splice variants in other cell 
types could be due to reduced mRNA stability compared to the full length receptor.  
Both the H4R (302) and H4R (67) are predominantly expressed intracellularly as 
determined by ELISA and western blot experiments (van Rijn et al., 2008). Although 
these receptor isoforms are expressed to a lesser extent at the cell surface, they are 
non-functional when individually expressed in recombinant mammalian cells, are not 
constitutively active and lack the ability to bind the agonist [3] histamine as well as 
the non-imidazole antagonist radioligand [3] JNJ 7777120. However, when co-
expressed with the H4R (390) the two H4 receptor isoforms have a dominantly negative 
effect as they are able to decrease [3H] histamine binding to the H4R(390) and 
histamine potency (van Rijn et al., 2008).  
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1.2.3.3 Anatomical distribution  
Tissue distribution of the H4 receptor has been profiled at mRNA level in a wide array 
of human and mouse tissue.  In humans the H4 receptor is expressed in abundance in 
bone marrow, lung, spleen, peripheral blood, heart, thymus, small intestine and 
colon (Liu et al., 2001a) as has been revealed by quantitative polymerase chain 
reaction (qPCR), northern blot, in situ hybridization and microarray analysis (Dijkstra 
et al., 2007, Dijkstra et al., 2008, Rijn, 2007, Morini et al., 2008, L. E. Sander, 2006, 
Sander et al., 2006).  Other tissue including the stomach, liver, brain, spinal cord, 
kidney, placenta, trachea and the foetal brain (Liu et al., 2001a) and mouse 
hippocampus (Zhu et al., 2001). 
Anti-H4 receptor antibodies have been crucial to the study of the H4 receptor and 
have lead to the discovery that this receptor is predominantly expressed on cells of 
the haematopoietic lineage such as basophils, eosinophils, T cells, mast cells and 
dendritic cells (van Rijn et al., 2008, Dijkstra et al., 2007, Dijkstra et al., 2008, Oda T., 
2000, Oda et al., 2000) but just as important is the discovery of the receptor on non-
haematopoietic cells. It has been identified in subsets of endocrine cells in the 
gastrointestinal tract, distinct from those containing the histamine H3 receptor 
(Morini et al., 2008). Using immunological tools, the H4 receptor has been localised in 
the rat gastrointestinal tract. H4 receptor immunoreactivity was observed in the 
epithelium of endocrine cells in the gastric fundus (Morini et al., 2008) as well as the 
myenteric plexus. This provides evidence for the possible role of the H4 receptor in 
the mammalian parasympathetic nervous system.  
Other immunohistochemical studies have shown the presence H4 receptor on nerves 
from human nasal mucosa (Nakayama et al., 2004) as well as on small and medium 
sized diameter neurons of the dorsal root ganglia and lamina I and II of the lumbar 
spinal cord (Lethbridge and Chazot, 2010b, Connelly et al., 2009, Strakhova et al., 
2009). The latter results indicate the presence of the H4 receptor on terminals of 
primary sensory afferent neurons. This suggests a role for the H4 receptor in a 
plethora of conditions ranging from allergy and inflammation to neuropathic pain. 
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1.2.3.4 Histamine H4 receptor biochemistry  
H4 receptor signalling has been studied using cells in which it is endogenously 
expressed as well as in vitro model systems such as HEK293T cells, which have been 
predominantly useful in deciphering the exact mechanisms as well as ligand 
characterisation. Similar to other GPCRs, the H4 receptor functions as a ligand-
activated guanine nucleotide exchange factor for heterotrimeric G proteins. Agonist 
binding stabilises the receptor’s “active” conformation on the heterotrimeric G 
protein Gα subunit thereby promoting dissociation of the GTP-bound Gα subunit 
from the Gβγ subunit heterodimer (Luttrell and Gesty-Palmer, 2010). After 
dissociation, free Gα-GTP and Gβγ subunits regulate the activity of enzymatic 
effectors such as adenylyl cyclase. Most likely Gβγ subunits activate phospholipase C 
isoforms, generating diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (InsP3). 
InsP3 may release calcium from intercellular storage vesicles through interaction with 
an InsP3 receptor.  
a) Signal transduction 
H4 receptor activation results in inhibition of forskolin induced cyclic adenosine 
monophosphate (cAMP) production (Lovenberg, 1999). Morse et al. showed that the 
H4 receptor exhibits a significant level of constitute activity indicated by elevated 
basal levels of both [35S] GTPγS binding and MAP kinase phosphorylation in H4 
receptor expressing cells, compared to wild type cells (Morse et al., 2001). Receptor 
activation leads to the release of the Gα and Gβγ subunits. The Gβγ subunits activate 
phospholipase C, producing diacyglycerol (DAG) and inositol-1, 4, 5,-triphosphate 
(InsP3). InsP3 releases calcium from intracellular calcium vesicle stores, possibly 
through interaction with an InsP3 receptor. The proposed mechanism of H4 receptor 
activation is demonstrated in Figure 1.5. 
Histamine stimulation of H4 receptor leads to the activation of mitogen activated 
protein kinase (MAPK) in recombinant systems e.g. transfected HEK 293 cells, but 
this is absent in monocyte-derived dendritic cells (Gutzmer et al., 2005). This effect is 
eliminated by pre-treatment with pertusis toxin (PTX) suggesting that the receptor is 
coupled to Gα/i G-proteins (Oda, 2001).  Histamine activation of the H4 receptor 
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induces calcium mobilisation from intracellular calcium stores and chemotaxis in 
murine mast cells; both of which can be abolished by incubation with selective H4 
receptor antagonists such as JNJ 7777120, PTX pre-treatment and inhibiting 
phospholipase C (PLC) using the PLC inhibitor U-73122 (Oda, 2001). 
 
 
 
Figure 1.5 Overview of the H4R mediated signalling (Iwan, 2005). The GPCR inhibits cAMP production 
via inhibition of adenylyl cyclase. The reduction in cAMP leads to a reduction in PKA activation and 
subsequent phosphorylation of the transcription factor CREB. The decreased PKA causes an increase 
in MAPK. The Gβγ activates PLC, which in turn hydrolyze phosphatidylinositol-4, 5-bisphosphate to 
DAG and InsP3, releasing calcium from intracellular stores (Van Rijn, 2006).  
 
Histamine induces actin polymerisation through H4 receptor activation which is a 
prerequisite for cytoskeletal change in eosinophils (Barnard et al., 2008) and these 
effects are sensitive to PTX and are blocked by selective H4 receptor antagonists 
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(Morse et al., 2001, Buckland et al., 2003). In addition, histamine and H4 receptor 
agonists such as clozapine stimulate a rise in intracellular calcium, upregulation of 
adhesion molecules on the cell surface; CD11b and CD54 (Buckland et al., 2003) 
necessary for cell spreading during migration. O’Reilly et al. showed that histamine 
has a chemotactic effect on eosinophils via activation of the H4 receptor (O'Reilly et 
al., 2002) where as Buckland (2003) et al. where unable to do so, and these effects 
could be blocked by thioperamide. Nakayama et al. observed significant chemotaxis 
of eosinophils following CCl16/LEC which could be blocked using thioperamide 
(Nakayama et al., 2004) and pre-treatment with IL-5 resulted in a 4-fold increase in 
the chemotactic response of histamine (O'Reilly et al., 2002) 
b) Oligomerisation  
Use of biochemical and biophysical techniques has revealed that members of the 
GPCR family may exist as homo- and hetero-oligomers at the cells surface. Western 
blot analysis of tunicamycin treated cells indicates that the H4 receptor is normally N-
glycosylated. However, inhibition of N-glycosylation does not affect the presence of 
the putative H4 receptor dimer. On the other hand, cross linking experiments also 
revealed that H4 receptors in close enough proximity of each other are a pre-
requisite for oligomerisation.  Despite this, N-gylcosylation is not a prerequisite for 
dimerisation but it helps to stabilise the H4 receptor dimers (van Rijn et al., 2006).  
In vitro studies have been used to investigate the effects of ligands on H4 receptor 
oligomerisation. Oligomerisation was investigated using the Bioluminescence 
Resonance Energy Transfer (BRET) technique, which is used to demonstrate close 
associations of two proteins within the cell membrane. This assay relies on the 
transfer of bioluminescence from a luciferase–mediated oxidation of coelenterazine, 
donor to a fluorescent protein acting as an acceptor. Excitation of the acceptor 
results in a detachable bioluminescent emission (see figure 1.6) and transfers 
typically occur within a radius of 100 Å (Breton et al., 2010). 
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Figure 1.6 Schematic representation of the BRET assay adapted from Fiona Shenton PhD Thesis 
(Shenton, 2007). 
 
In this study, BRET was performed on COS-7 cells co-expressing the H4R-Rluc with the 
H4R-eYFP (Yellow fluorescent protein). Renilla luciferase is fused to the C-terminal of 
the receptor, catalyses the emission of light from the substrate coelenterazine at a 
wavelength of 470 nm. This can excite the eYFP fused to another H4R to emit light at 
530 nm when in close proximity (< 100Å). A robust BRET signal confirmed the 
formation of H4R homo-dimers, bringing the Rluc C-terminal within 100Å of the eYFP 
to allow energy transfer on addition of coelenterazine substrate (van Rijn et al., 
2006). The H4R homo-dimers are not only present in homologous expression 
systems, but are also present in spleen lysates endogenously expressing H4Rs 
(Shenton, 2007). 
Previous studies have reported that agonists can promote or reduce GPCR 
oligomerisation. However in the case of the H4R, no significant difference in signal 
was detected when cells were treated with the H4 receptor agonist histamine, the 
neutral H4 receptor antagonist iodophenpropit or the inverse agonist thioperamide 
(van Rijn et al., 2006). This suggests that H4 receptor ligands do not modulate H4 
receptor homo-oliogomerisation.  
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1.2.3.5 Histamine H4 receptor pharmacology 
 
a) Agonists  
 
Initial studies into the pharmacological and physiological functions of the H4 receptor 
proved difficult due to the lack of specific ligands for this receptor, therefore early 
pharmacological characterisations where performed using agonists originally 
designed for the homologous H3 receptor. OUP-16 was the first ligand optimised for 
H4 selectivity, with a 40-fold selectivity for the H4 receptor over the H3 receptor 
(Hashimoto et al., 2003). This was followed by the description of 4-methylhistamine, 
which has a high affinity for the H4 receptor while displaying a 100-fold selectivity 
over the other 3 histamine receptor subtypes (Lim et al., 2005).   Oda et al. (2000) 
described clozapine as the first non-imidazole ligand, with anti-psychotic properties.  
It has been shown to possess activity at several GPCRs but almost exclusively as an 
antagonist (Oda et al., 2000).  On the other hand, the clozapine analogue VUF6884 is 
also an H4 agonist with a 10 fold higher affinity for the H4 receptor than clozapine. 
Another H4 agonist is dimaprit and its analogue VUF 8430. VUF 8430 has full 
agonistic activity and a 30-fold selectivity at the H4 receptor, over the H3 receptor 
(Lim et al., 2009).  Together, 4-methylhistamine and VUF8430 form a useful pair of 
tools to study H4 receptor pharmacology (Lim et al., 2009).  
 
b) Antagonists 
 
The first H4 receptor antagonists used to characterise the H4 receptor where 
imidazole-containing dual H3- and H4 receptor compounds (Gbahou et al., 2006) with 
the most important being the H3- antagonist and H4 receptor inverse antagonist, 
thioperamide (Buckland et al., 2003, Hofstra et al., 2003). The identification of JNJ 
7777120 as a potent and highly selective antagonist at the human H4 receptor 
marked the initiation of investigations into the roles of the H4 receptor. JNJ 7777120 
binds to the H4 receptor with high affinity (Ki, 4 nM) and has at least 1000-fold 
selectivity over the H1- or H3 receptors (Fung-Leung et al., 2004). JNJ 7777120 has 
been utilised extensively to elucidate the roles of the H4 receptor in various allergic 
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and inflammatory processes (Coruzzi et al., 2012), including chemotaxis of 
eosinophils (Ling et al., 2004) and mast cells (inhibition of chemotaxis and calcium 
mobilisation) (Fung-Leung et al., 2004), plus allergic rhinitis (Takahashi et al., 2009) 
and allergic airway inflammation (Dunford et al., 2006). Although it has a reasonable 
bioavailability (22%), JNJ 7777120 has a very short in vivo half life in rats (0.8 hours) 
(Jablonowski et al., 2003). Overall, these data demonstrate that JNJ 7777120 has 
anti-inflammatory properties which suggest that H4 receptor antagonists may 
possibly constitute a new class of anti-inflammatory drugs. However, care needs to 
be taken when interpreting data because JNJ 7777120 is an antagonist at the human 
H4 receptor,  an agonist at the macaque, dog, guinea-pig and rat H4 receptor and an 
inverse agonist at the mouse H4 receptor (Liu et al., 2001). Therefore the effects of 
drug administration could be specific to the pathway that is activated. A direct 
analogue of JNJ 7777120 known as JNJ10191584 (VUF 6002) is another potent and 
highly selective H4 receptor antagonist.  
 
PF-3893787 was shown to inhibit imetit induced eosinophil cell shape change 
(Mowbray et al., 2011). Mowbray et al. (2011) showed that PF-3893787 is an inverse 
agonist at the human and macaque H4 receptor, antagonist at the dog H4 receptor 
and partial agonist at guinea pig and rodent H4 receptors (Mowbray et al., 2011).  
 
c) Biased signalling  
 
JNJ 7777120 has been shown to act as a biased agonist at the H4 receptor, acting as a 
neutral agonist with [3S] GTPγS binding and a partial agonist with β-arrestin 
recruitment (Rosethorne and Charlton, 2011).  β-arrestin belongs to a small family of 
proteins that are essential for the regulation of signal transduction. G protein 
coupled receptor kinase (GRK) phosphorylation prepares the activated (agonist 
occupied) receptor for β-arrestin binding and this prevents further G protein 
mediated signalling, targets the receptor for internalisation and redirects signalling 
to an alternative pathway independent of G proteins. Studies of GPCRs like the β-
adrenergic receptor have revealed that receptor activation promotes the 
translocation of β-arrestin from the cytoplasm to the cell membrane and subsequent 
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interaction of the β-arrestin with the activated receptor (Shenoy and Lefkowitz, 
2005b). Though traditionally, β-arrestin recruitment to the 7-TM has been associated 
with receptor-uncoupling from the G proteins and desensitization, it has been 
recently found that β-arrestin can also serve as a signal-transducing protein with the 
ability to stimulate G protein independent pathways such as ERK  (Luttrell and Gesty-
Palmer, 2010, Shenoy and Lefkowitz, 2005a).  
 
This phenomenon has been attributed to the existence of multiple active receptor 
conformations, with the agonist being able to stabilise a subtly altered state that 
may preferentially couple to one pathway over another. The data of Rosethorne and 
Carlton (2011) show that in the osteocarcinoma cell line (U2OS), JNJ 7777120 is able 
to stabilise a conformation in human H4 receptor that induces β-arrestin recruitment 
and stimulates a down-stream signalling pathway. Therefore, JNJ 7777120 can no 
longer be considered the “gold standard” H4 receptor antagonist, but depending on 
the parameter used, it may also act as an agonist (Rosethorne and Charlton, 2011).  
 
 
1.2.3.6 Potential clinical applications and histamine H4 receptor targeted therapies  
 
H4 receptor agonists and antagonist have an important role to play in the 
clarification of the (patho) physiological role of the histamine H4 receptor, as well as 
explore its therapeutic in human disease. 
 
a) Asthma  
Asthma is characterised by airway hyper-responsiveness and chronic inflammation of 
the airways. A role for the H4R in a murine ovalbumin-induced inflammation model 
of asthma was discovered by Dunford et al. This study showed that H4R antagonism 
by JNJ777120 reduced airway hypersensitivity and Th2 cytokine levels in diseased 
lung tissue, marked by attenuation of IL-13 driven pathologies (Dunford et al., 2006) 
such as airway remodelling. In a different study, UR-60427 a selective and high 
affinity H4R inverse agonist showed high efficacy and potency in a rat asthma model 
(Alfon et al., 2010). In contrast, the selective H4R agonist, 4-Methylhistamine 
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reduced airway hyperactivity, airway resistance and inflammation in a mouse model 
of allergic inflammation. This effect was attributed to increased migration of CD4+ 
CD25+ FoxP3+ Tregs (T regulatory) to the site of inflammation, where accumulated T 
cells released large amounts of the anti-inflammatory cytokine IL-10 (Morgan et al., 
2007). Furthermore, it has been reported that JNJ 7777120 decreased the levels of 
IL-17 in a mice asthma model (Dunford et al., 2006). However, these published data 
were for human Tregs and not their murine counterparts so it cannot be ruled out 
that human and mouse Tregs respond differently to stimulation of H4R.  
 
b) Autoimmune disorders 
Histamine has been implicated in the pathology of autoimmune diseases including 
Rheumatoid arthritis (RA), characterised by synovial tissue inflammation and 
subsequent cartilage erosion leading to joint deformity. Localisation of the H4 
receptor in vascularisation and cell walls of patients with RA (Grzybowska-Kowalczyk 
et al., 2007) and osteoarthritis (Grzybowska-Kowalczyk et al., 2008) and the 
identification of H4 receptor  in ﬁbroblasts and macrophage-like cells from RA 
synovial tissues (Ohki et al., 2007) support the contribution of the receptor in the 
pathophysiology of the disease. The antinociceptive effects of JNJ 7777120 in a rat 
model of osteoarthritis provides evidence that selective H4 receptor antagonists may 
be an attractive approach for the development of new drugs for the treatment of 
osteoarthritis pain (Hsieh et al., 2010a). 
 
Multiple sclerosis is an autoimmune disease of the CNS characterised by 
demyelination and axon loss and gliosis. Though the specific aetiology remains 
undefined, susceptibility is thought to result from genetic/epigenetic, 
environmental, immunological, hormonal and infectious agents. Experimental 
allergic encephalomyelitis (EAE) is the animal model of MS in which disease 
pathogenesis is associated with MHC Class II CD4+ T cells with the ability to secrete 
IFNγ and IL-17. Histamine modulates blood brain barrier permeability and enhances 
leukocyte rolling as well as vascular extravasation of leukocytes into the CNS. Studies 
have recently shown a role for H4R in modulation of the immune system during EAE. 
Saligrama et al. (2012) showed that H4RKO C57/BL6 and H3H4 receptor knockout 
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mice presented a more severe EAE pathogenesis, augmented neuroinflammation 
and increased blood brain barrier permeability compared to the WT and H1H2 
receptor knockout littermates respectively (Saligrama et al., 2012). The study also 
showed that H4 receptor signalling controls the frequency of regulatory T cells (Treg) 
in the CNS, including chemotaxis and the suppressive ability of the T regulatory cells 
(del Rio et al., 2012). These findings suggest that the use of peripheral and central 
acting H4 receptor agonists may be useful in treating patients with MS at the onset or 
upon relapse.  
 
Histamine has also been implicated in the Sjogren’s syndrome (SS), also known 
referred to as ‘autoimmune epithelitis’. This is because the tubuloacinar epithelial 
cells are believed to form auto-antigens.  Symptoms of the disease include dry 
mouth and dry eyes due to immune cells attacking the salivary gland and tear ducts. 
The H4 receptor was shown to be functionally expressed in human salivary glands 
and expression was reduced in patients with SS (Stegaev et al., 2012).  This was 
consistent with histamine producing cells stimulating the H4 receptor-positive 
tuboloacinar cells, leading to receptor down-regulation via clathrin-mediated 
endocytosis (Stegaev et al., 2013).  This suggests that H4 receptor may play some 
constitutive role in the maintenance of healthy salivary epithelium, a function which, 
based on changes in local histamine synthesis and/or greatly diminished H4R levels, 
is disturbed in SS (Stegaev et al., 2012). 
 
c) Cancer  
H4 receptor expression was shown to be down-regulated in colorectal cancers and 
this correlated with tumour progression (Boer et al., 2008). Down-regulation of H4 
receptor in gastric carcinomas plays a role in histamine-mediated growth control of 
GC cells. Melanoma cells express the H4 receptor at the messenger RNA and protein 
levels. Using histamine agonists, antagonists, and H4 receptor small-interfering RNA 
the inhibitory effect of histamine on proliferation was in part mediated through the 
stimulation of the H4 receptor and the decrease in proliferation was associated with 
an induction of cell senescence and an increase in melanogenesis, a differentiation 
marker of these cells (Massari et al., 2011). Another study showed that the H4 
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receptor agonist clobenpropit suppressed human cholangiocarcinoma progression 
by disrupting epithelial mesenchymal transition and tumour metastasis (Meng et al., 
2011). Interruption of invasion and tumourigenesis by histamine may add to 
therapeutic advances for cholangiocarcinoma.  
 
d) Gastrointestinal disorders and inflammatory bowel disease  
H4 receptor expression was detected by immunohistochemistry in different areas of 
the gut (Chazot 2007, Boer, Helinger et al. 2008) and various studies have revealed 
the protective effect of the antagonist JNJ 7777120 in several models of gastric and 
intestinal damage (Coruzzi 2010). JNJ 7777120 has protective effects against 
indomethacin-induced gastric lesions in rats and also prevented the aggravating 
effects of the H3 receptor antagonist immepip (Coruzzi et al., 2011). This information 
suggests a potential ulcerogenic role for the H4 receptor and there could be 
therapeutic value for H4 receptor targeting drugs in gastric pathology.  
Selective H4 receptor antagonists have been evaluated in the widely used 
experimental model of inflammatory bowel disease provoked by colonic instillation 
of the hapten, trinitrobenzene sulphonic acid. JNJ10191584 and JNJ 7777120 
significantly attenuated hapten induced macroscopic injury, score and fall in body 
weight (Varga et al., 2005). Both compounds dose-dependently reduced elevated 
levels of colonic myeloperoxidase and neutrophil influx. TNFα levels were reduced by 
treatment with JNJ10191584 and JNJ 7777120 (Varga et al., 2005) and it is possible 
that TNF-α level reduction reflects an action of the H4 receptor antagonists on the 
cellular transduction mechanisms promoting cytokine biosynthesis. This suggests a 
possible pro-ulcerogenic role of histamine H4 receptor in the rat gastric mucosa. The 
findings of a protective effect of H4 receptor antagonists could point to a novel 
pharmacological approach to the therapy for gut inflammation.  
 
e) Allergic rhinitis 
H4 receptor expression was significantly increased in the nasal mucosa of allergic 
rhinitis patients in both structural and immune cells, compared to healthy controls 
(Yan et al., 2010a). In a separate study, a H4 receptor antagonist was shown to 
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relieve the symptoms and inflammatory conditions of allergic rhinitis (Yan et al., 
2010b) though the effect was weak in comparison to that of Loratadine.  In contrast 
JNJ 7777120 significantly inhibited nasal symptoms and exhibited 
immunomodulatory functions in a mice model of allergic rhinitis (Takahashi et al., 
2009).  
Palau Parma has developed the first reported H4 receptor antagonist for the 
treatment of allergic respiratory disorders. The compound, UR-63325 has finished 
the phase I first-in-man clinical trial with promising interim data (Sisniega, 2010). 
 
f) Central Nervous System effects 
Evidence has shown that histamine release is a sensitive indicator of stress and the 
involvement of the histaminergic system in the modulation of anxiety behaviours in 
animals has been suggested. All four histamine receptors (H1-H4) are expressed in 
the brain. H4 receptor expression in the brain has only recently been reported but its 
function has not been elucidated. In a behavioural test using H4 receptor KO BALB/C 
mice, the KO mice presented an enhanced escape response to approach and 
struggled more when touched or restrained by the tail compared to the WT. On the 
other hand, the KO mice showed better performance in the Morris water maze test 
compared to the WT. This study revealed that there are differences in the 
behavioural phenotypes of the H4 receptor KO mice, but further studies are required 
to analyse the differences (Rossbach et al., 2012). 
The administration of histamine induces an anxiogenic effect and destruction of the 
rat TMN region, from which histaminergic neuronal fibres arise, can induce an 
apparent anxiolytic effect (Frisch et al., 1998). The effect of the H4 receptor agonist 
VUF 8430 on anxiety in the light dark box test was recently reported. Galeotti et al. 
(2013) demonstrated that intracerebroventricular (i.c.v) administration of this VUF 
8430 produced a dose-dependent increase in the time the mice spent in the light 
compartment.  The “light-dark” test exploits the conflict between the animal’s 
tendency to explore a new environment and its fear of bright light. These results 
indicated the induction of an anxiolytic effect comparable to that exerted by 
diazepam. The effect of VUF 8430 was abolished by pre-treatment with the H4 
receptor antagonist JNJ 10191584 (Galeotti et al., 2013).  
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Histamine has been implicated in learning and memory. Antagonism of pre-synaptic 
H3 receptors would enhance release of histamine and other neurotransmitter 
systems involved in cognition and indirectly ameliorate cognitive performance 
(Esbenshade et al., 2008). The effect of neuronal H4 receptors on the modulation of 
memory processes was investigated by Galeotti et al. (2013) in a model of 
scopolamine induced amnesia. Pre-treatment with the H4 receptor agonist VUF 8430 
was shown to prevent scopolamine induced memory impairment by enhancing the 
time taken to enter the dark compartment of the box. These results indicate a 
positive effect on neuronal H4 receptor activation on memory impairment, further 
clarifying the role of the histaminergic system on cognitive functions. 
A role for brain histamine on feeding behaviour has been postulated. The 
modulation of neuronal H4 receptors was observed in mice deprived of food for 12 
hours; these conditions were needed to highlight reduction in food consumption.  
Intracerebroventricular administration of the H4 receptor agonist VUF 8430 
significantly reduced food consumption, demonstrating an anorexant effect (Galeotti 
et al., 2013). However, more tests using other agonists and antagonists are required 
to clearly define the role of the H4 receptor in the regulation of appetite and satiety. 
 
g) Pruritus  
Pruritus is experienced as an unpleasant sensory and emotional sensation associated 
with an actual or perceived disruption to the skin that produces a desire to scratch 
(Magerl, 1996). Acute itch is a daily occurrence normally abolished by brief 
scratching near the affected area. However, chronic itch is debilitating and brief 
scratching provides no relief. Pruritus associated with chronic diseases such as atopic 
dermatitis is poorly controlled clinically due to its’ significant negative impact on the 
quality of life of the patient.  
 
Itch is reliably induced by a variety of chemical stimuli including kinins (e.g. 
bradykinin), neuropeptides (e.g. substance P), enzymes but the prime of which is 
histamine acting on the histamine H1 receptor located on nociceptive neurons. 
However, their effects appear to be largely mediated by histamine because the 
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magnitude of itch is significantly diminished by administration of H1 receptor 
antagonists. Histamine is the main mediator of itch and it acts through H1 receptor 
activation.  This was discovered as the presence of histamine sensitive central 
projection neurons responding to histamine ionophoresis and differed from other 
pain processing neurons in their central thalamic projections and resting activity 
(Craig, 2003). Although H1 receptor antagonists are effective in reducing 
experimental histamine-induced itch, they are ineffective in the clinical treatment of 
pruritus associated with chronic diseases like atopic dermatitis (Hong et al., 2011). In 
recent years, the roles of the H1 receptor and H4 receptor in pruritus have been 
documented. In mice, the selective H4 receptor agonist 4-Methylhistamine has been 
shown to induce itch in a dose dependent manner, similar to histamine (Dunford et 
al., 2007). This was significantly inhibited by dose-dependent administration of JNJ 
7777120, and this compound had a far superior effect on the attenuation of 
experimental pruritus and only the centrally acting H1 receptor antagonist 
diphenhydramine showed anti-pruritic activity (Dunford et al., 2007). On the other 
hand, this pruritic response could not be completely inhibited by the administration 
of either H1 receptor antagonist or H4 receptor antagonist alone, however when both 
antagonists where administered simultaneously, they had a synergistic effect in the 
complete abolition of scratching behaviour.  
 
Histamine is the main pruritogen released by mast cell degranulation. Mast cells 
release other pruritogens including substance P, which is a neuropeptides with the 
capacity to sensitise free nerve endings. In a study by Yamaura et al. (2009), 
histamine H4 receptor inhibition by orally administered JNJ 7777120 was shown to 
have a greater inhibitory effect on histamine induced pruritus, compared to 
fexofenadine, the selective histamine H1 receptor antagonist (Yamaura et al., 2009).  
Similarly, pruritic responses to intradermally induced substance P-induced were 
observed. In this study, the non-centrally acting H1 receptor antagonist fexofendaine 
had no effect on substance P-induced scratching (Yamaura et al., 2009). In contrast, 
oral dosing of JNJ 7777120 reduced substance P-induced scratching in a dose-
dependent manner (Yamaura et al., 2009).  
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A study by Suwa et al. (2001) utilising a model of trinitrochlorobenzene (TNCB) 
induced chronic atopic dermatitis in sensitised hairless mice, JNJ 7777120 had a 
dose-dependent inhibitory effect on TNCB-induced pruritus and mast cell 
accumulation (Suwa et al., 2011). On the other hand, the H1 receptor antagonist 
fexofenadine has no suppressive effects on the scratching bouts. In this regard, 
pruritus induced by TCNB is most likely regulated by other histamine receptors, 
namely the H4 receptor. 
The evidence derived from these studies suggests that H1 receptors have limited 
involvement in histamine-induced pruritus. The significant effects of the H4 receptor 
antagonist JNJ 7777120 suggest that histamine may have an involvement in diseases 
such as atopic dermatitis via the H4 receptor. Though this compound crosses the 
blood brain barrier, it lacks sedative effect and therefore, its pruritic inhibitory 
actions are not secondary to sedation (Dunford et al., 2007).  
Interestingly, itch-inducing properties of 4-methylhistamine and inhibitory effects of 
JNJ 7777120 were unaltered in mast cell deficient mice (Dunford et al., 2007). Due to 
these findings, a possible presence of the histamine H4 receptor on sensory neurones 
and the use of antagonists in the amelioration of skin inflammation and pruritus in 
patients with dermatitis were postulated.  
 
h) Pain 
The selective H4 receptor antagonist JNJ 7777120 was shown to readily cross the BBB 
and exert robust anti-hyperalgesic effects on several animal models of inflammatory 
and neuropathic pain (Hsieh et al., 2010a). The in vivo inflammatory pain models 
used include the carrageenan-induced acute inflammation, complete Freund’s 
adjuvant-induced chronic inflammation, zymosan-induced peritonitis and the knee-
joint osteoarthritis model. This data suggests that the H4R has a role in inflammatory 
pain in rats and it is possible that the anti-nociceptive effects of the H4R antagonists 
could be secondary to the anti-inflammatory actions of the antagonists.  Hsieh et al. 
(2010) provided the first evidence of the effectiveness of JNJ 7777120 as an analgesic 
in the reduction of chronic constriction injury of the sciatic nerve and spinal nerve 
ligation models of induced neuropathic pain.  
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1.2.4 Conclusions and Aims 
Histamine is available in many parts of the body and histamine receptor distribution 
is widespread. In the periphery, histamine mediates inflammatory and immune 
reactions, as well as control of vascular permeability, smooth muscle contraction and 
gastric secretion. Histamine in the CNS plays a role in the maintenance of 
homeostasis through regulation of arousal, the sleep-wake cycle, feeding behaviour, 
learning and memory. This is crucial for brain development, physiology and 
pathophysiology, danger recognition, and survival. Histamine interacts both directly 
and indirectly with a variety of receptors and chemical messengers to allow the body 
to respond to different situations allowing an integrated response to multiple 
influences.  
Molecular biology has rapidly increased our understanding of the cell signalling, 
progression of H4R ligands into the clinic has been limited by the variety of actions 
elicited by the H4R, depending on the anatomical, physiological and biochemical 
properties in cells as well as pathological and physiological conditions. Due to 
differential G-protein coupling, H4 receptor ligands may behave variably in different 
expression systems and animals species. Despite this, cloning of the H4 receptor has 
led to a rapid increase in our understanding of its structure and function, 
development of better experimental ligands with consistent in vivo and in vitro 
characteristics is required. Pre-clinical data supports the potential of the H4 receptor 
as a new drug target in inflammatory conditions.  Our laboratory developed a unique 
anti-human (Shenton, 2007) and anti-mouse H4R (Lethbridge and Chazot, 2010b) 
antibody and this has been used to map H4R distribution in CNS and immune cells. 
  
The major hypotheses addressed in this PhD thesis:  
 
1. H4Rs are expressed on primary sensory afferents. 
2. H4Rs are differentially expressed in the periphery and central nervous system 
in different pain states.  
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3. Antagonism of the H4R with the antagonist JNJ 7777120 ameliorates central 
inflammation observed during experimental autoimmune encephalomyelitis 
(EAE) 
4. Antagonism of the central H4R with JNJ 777120 has anxiolytic effects and 
improves memory performance in mice 
 
To test these hypotheses firstly, the previously validated anti-hH4R antibody (Fiona 
Shenton, PhD Thesis (Shenton, 2007)) was be used to confirm the expression of H4Rs 
on primary sensory afferents in the periphery as well as the dorsal horn of the spinal 
cord where they terminate. The next step was be to investigate functional 
expression of the neuronal H4R using the selective H4R agonist VUF 8430, in a dorsal 
root ganglia (DRG) model of calcium signalling.  An additional aim was to probe the 
potential differential expression in acute inflammatory and neuropathic pain 
conditions. The final step will probe the effects of H4R antagonism using selective 
ligand, JNJ 7777120 on the mouse model of experimental allergic encephalomyelitis 
(EAE) and on the behaviours of mice in a series of novel in vivo tests.  
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CHAPTER 2 
MATERIALS AND GENERAL METHODS 
2.1. Source of materials 
2.1.1 Sigma-Aldrich chemical company (Poole, Dorset, UK) 
Folin-ciolcalteau phenol reagent.  
Pre-stained molecular weight marker (molecular weight range 26-180kDa). 
Tween-20. 
p-coumaric acid. 
Luminol. 
Hydrogen peroxide (30%v/v). 
Kodak D-19 developer. 
Kodak fixer. 
Ampicillin  
Agarose. 
Agar. 
Dulbecco’s modified eagle medium/F12 
Dulbecco’s modified eagle medium, D5671 
L-glutamine (200mM) 
7.5% sodium bicarbonate  
Sodium hydroxide.  
Trypsin 0.5g, EDTA 0.2g per litre of Hanks. 
Ethylenediaminetetracetic acid (EDTA). 
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Ethylenebis(oxyethylenenitrilo)tetracetic acid (EGTA). 
Sodium phosphate.  
Sodium azide. 
Sodium citrate. 
Triton X-100. 
Anti-β-actin. 
Dithiothreitol (DTT). 
Dialysis tubing (visking size 11/4”). 
Sodium dodecyl sulphate (SDS). 
Β-mercaptoethanol. 
Bromophenol blue.  
Glycine. 
Phosphate buffered saline. 
Foetal bovine serum 
Poly-D-Lysine 
HAT media supplement (50x Hybri-Max) ™ 
Phosphate buffered saline solution. 10x concentrate. 
Dibutyryl cyclic AMP (db-cAMP)  
Magnesium chloride  
Hepes 
Histamine  
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2.1.2 Fisher scientific  
Acrylamide/bis-acrylamide 30%. 
Tris  
Methanol. 
Sodium chloride (NaCl). 
N, N, N’, N’ –Tetramethylethylenediamine (TEMED) 
Calcium chloride  
2.1.3 Amersham International (Aylesbury, Bucks, UK) 
Blotting paper. 
Nitrocellulose. 
Hyperflim™. 
HRP linked secondary antibody-rabbit. 
HRP linked secondary antibody-mouse. 
Binding filters 
 
2.1.4 Tocris (Bristol, UK) 
JNJ 7777120 
Sigma-Genosys (Cambridge, UK) 
Histamine H4R peptide.  
Chazot 3 human H4 (374-390) C-terminal CIKKQPLPSQHRSVSSS 
2.1.5 QIAGEN Ltd (Dorking,  Surrey, UK) 
QIAGEN® plasmid maxi kit. 
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2.1.6 Abcam (Cambridge, UK) 
Mouse anti-Calcitonin gene-related peptide (CGRP) 
Guinea pig anti-Substance P 
Mouse anti-CD11c 
 
2.1.7 Invitrogen (Paisley, UK) 
Alexa Fluor 594 Donkey anti-rabbit 
Alexa Fluor 488 Goat anti-mouse  
Fluo-4 AM 
2.1.8 BDH Laboratory Supplies (Poole, UK) 
Ammonium peroxodisulphate (APS) 
1,4-Dithiothreitol (DTT) 
N,N,N’,N’-teramethylethylenediamine (TEMED) 
Methanol 
Glycerol 
Isopropanol 
Ethanol 
Dimethyl Sulphoxide (DMSO) 
Sodium hydrogen carbonate 
Potassium phosphate 
Hydrochloric acid 
Citric acid 
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Sodium chloride    
Acetic acid 
DPX mountant 
Potassium chloride 
Diethylamine 
Glucose  
 
2.1.9 Jackson Immunoresearch (Suffolk, UK) 
Texas-red Donkey anti-rabbit. 
FITC-conjugated secondary goat anti-mouse. 
 
2.1.10 Cambrex Bio Science (Verviers, Belgium) 
Foetal calf serum 
 
2.1.11 Miscellaneous  
Human H4 cDNA was a gift from Professor Rob Leurs (Free University, Amsterdam, 
The Netherlands). 
VUF 8430 was a gift from Professor Holger Stark (University of Dusseldorff, Germany) 
Human embryonic kidney (HEK) 293 cells were obtained from the European 
collection of cell cultures, Salisbury, Wilts. 
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2.2 Instruments and Equipment  
Spectrophotometry: Jenway Genova Spectrophotometer  
Centrifuges: An eppendorf centrifuge, 5415R was used for all volumes less than 1.5 
ml. A refrigerated Harrier 18/80 EPS 301 was used for falcon tubes of volumes 15 ml 
or 50 ml. 
Incubators: shaking incubator, cell incubator Shel Lab (Sheldon Manufacturing Inc.). 
Mini Orbital shaker: Stuart scientific 505. 
Water bath: Nuve bath. 
Heat block: QBT2 heating block (Grant). 
Magnetic Stirrer/Hot plate: Stuart Scientific, Velp Scientific 
Vortex: Scientific Industries vortex-2 genie  
Rocker: Grant-Bio PMR-30 
Roller Mixer: A Stuart scientific roller mixer SRT2 was used for all falcon tubes with 
volumes of 15 ml or 50 ml. 
Balances: Milligram amounts were weighed using a Mettler Toledo classic. All other 
amounts were weighed using a Scouts Pro balance (Ohaus). 
Electrophoresis equipment: Polyacrylamide gels were cast in Hoefer SE 245 dual gel 
caster using gel plates of 10x8cm. Electrophoresis was performed using a Hoefer 
mini-vertical gel electrophoresis unit SE260 and transferred using a Hoefer TE 22 
tank transfer unit, power was from an Electrophoresis Power Supply EPS 301, all 
supplied by Amersham Biosciences. 
Microscopes: Zeiss Axioskop 2 
 Nikon eclipse TE-2000E 
Photography: Nikon digital camera used for immuohistochemistry 
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Other equipment: immunoblotting cassette, pH meter was a Mettler Toledo MP220, 
automatic pipetteman. 
Glassware, plastics and disposables: Hamilton syringe. Dounce glass/glass 
homogeniser. Cell scrapers, 250 ml sterile cell culture flasks, petri dishes and sterile 
pipettes from Greiner. Sterile filters: 0.2 µm Sartorius Sartolab-V150 filter unit. 
Cryogenic vials. Sterile pipettes and 250ml sterile filter lid cell culture flasks from 
Greiner.  Falcon tubes.  Columns. Eppendorf tubes, and pipette tips from Starlabs, 
UK.  Glass slides and cover-slips from VWR.  
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2.3. Preparation of standard solutions   
2.3.1 Lowry reagent A: 
2% (w/v) sodium carbonate, 0.1 M sodium hydroxide and 5% (w/v) SDS 
2.3.2 Lowry reagent B: 
2% (w/v) sodium potassium tartrate. 
2.3.3 Lowry reagent C: 
1% (w/v) copper sulphate 
2.3.4 Stacking gel buffer: 
0.5 M Tris-glycine, pH 6.8 containing 8 mM EDTA and 0.4% (w/v) SDS. 
2.3.5 Resolving gel buffer: 
50 mM Tris, 384 mM glycine, 1.8 mM EDTA, pH 8.8 and 0.1% (w/v) SDS. 
2.3.6 Stock acrylamide: 
40% (v/v) acrylamide and N,N’-methylenebisacrylamide. 
2.3.7 Electrode buffer: 
50 mM Tris, 384 mM glycine, 1.8 mM EDTA and 0.1% (w/v) SDS pH 8.8 
2.3.8 Sample buffer: 
30 mM sodium hydrogen phosphate, pH 7.0, 30% (v/v) glycerol, 0.05% (v/v) 
bromophenol blue and 7.5% (w/v) SDS. 
2.3.9 Pre-stained molecular weight markers:  
Pre-stained molecular weight marker stored in sample buffer  
2.3.10 Ammonium Peroxodisulphate (APS): 
1 mM in dH2O 
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2.3.11 Dithiothreitol (DTT): 
200 mM in dH2O 
2.3.12 Transfer buffer: 
25 mM Tris, pH 8.4, 192 mM glycine and 20% (v/v) methanol. 
2.3.13 Tris buffered saline:  
50 mM Tris-HCl, 0.9% NaCl pH 7.4. 
2.3.14 Tris/EDTA (TE) buffer: 
10 mM Tris, 1 mM EDTA, pH 8.0.  
2.3.15 Homogenisation buffer:  
50 mM Tris-HCl pH 7.4, containing 5 mM EDTA and 5 mM EGTA. 
2.3.16 H4 receptor binding buffer: 
50 mM Tris-HCl, pH 7.4 
2.3.17 Immunoblotting blocking buffer: 
5% marvel (w/v), 0.2% tween 20 (v/v) and TBS pH 7.4 
2.3.18 Immunoblotting incubation buffer: 
2.5% marvel (w/v), TBS pH 7.4 
2.3.19 Immunoblotting wash buffer: 
2.5% (w/v), 0.2% (v/v) tween 20, TBS pH 7.4 
2.3.20 ECL Developing solution A:  
1 ml 250mM luminal, 0.44 ml 90 mM coumaric acid, 10 ml 1 M Tris-base pH8.5. 
Make up to 100 ml with dH2O 
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2.3.21 ECL Developing solution B: 
64 μl 30% H2O2, 10ml 1 M Tris-base, pH 8.5. Make up to 100 ml with dH2O 
2.3.22 Kodak developing solution: 
100 ml stock developer and 400 ml dH2O. Photosensitive therefore cover tub. 
2.3.23 Kodak fixative solution:  
125 ml stock fixer and 37 5ml dH2O. Photosensitive therefore cover tub 
2.3.24 HEK293 freezing media: 
70% foetal bovine serum, 20% DMEM, 10% DMSO 
2.3.25 Preparation of HEK293T cell growth media: 
DMEM, 10% (v/v) foetal bovine serum, 2 mM L-glutamine. Media was filtered using a 
0.2 m Sartorius Sartolab V150 filter unit and stored at 40C until use. 
2.3.26 Preparation of F11 cell growth media: 
DMEM, 15% (v/v) foetal bovine serum, 2 mM L-glutamine, HAT media supplement 
(50x Hybri-Max) ™. Media was filtered using a 0.2 m Sartorius Sartolab V150 filter 
unit and stored at 40C until use.  
2.3.27 Preparation of F11 cell differentiation media: 
DMEM, 15% (v/v) foetal bovine serum, 2 mM L-glutamine, 0.5 mM dibuytryl cyclic 
AMP (db-cAMP). Filter sterilised.  
2.3.28 Loading buffer: 
0.25% (w/v) bromophenol blue, 30% (v/v) glycerol and 60 mM EDTA pH 8.0 
2.3.29 Ringer buffer:  
160 mM Sodium chloride , 2.5 mM Potassium chloride, 5 mM Calcium chloride, 1 
mM Magnesium chloride, 8 mM Glucose, 10 mM Hepes 
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2.3.30 High potassium buffer: 
112.5 mM Sodium chloride, 50 mM Potassium chloride, 5 mM Calcium chloride, 1 
mM Magnesium chloride, 8 mM Glucose, 10 mM Hepes 
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2.4 General methods 
2.4.1 Membrane preparation for immunoblotting  
Adult male Wistar rats and C57bl/6 mice supplied by Charles River Laboratories 
(Kent, UK) were euthanised by Schedule 1 methods under the Scientific Procedures 
Act (1986), either stunned or placed in a CO2 chamber and 100% CO2 was added at a 
flow rate of 20% of the chamber volume per minute. The mice were then 
decapitated.  Following decapitation, spinal cords from the lumbar region and skin 
from the plantar hind surface of the hind paw were dissected and kept cool on ice. 
Using 200 µl of cold homogenisation buffer (50 mM Tris-HCl, pH 7.4 containing 5 mM 
EDTA, 5 mM EGTA), spinal cord tissue was homogenised in a Dounce glass/glass 
homogeniser. Membrane debris was pelleted by centrifugation of the homogenate 
at 1,200 x g, 40C for 10 minutes.  
The supernatant was transferred to a clean JA20 centrifugation tube; the volume 
was made up to 10 ml with homogenisation buffer + sucrose and was spun at 20,000 
x g, 4oC for 30 minutes. The supernatant was discarded and the pellet re-suspended 
in 5 ml of homogenisation buffer, for every gram of starting material. The 
homogenate was stored in 100 µl aliquots at -20oC. The remaining pellet was 
resuspended in cold homogenisation buffer and the latter two steps repeated. The 
spinal cord preparation was then aliquoted into 100µl fractions and frozen at -200C. 
The protein concentration was determined by a Lowry assay (Lowry et al. 1951).    
 
2.4.2 Lowry assay for protein determination 
The protein concentration was determined using the method of Lowry et al. (1951) 
employing bovine serum albumin (BSA) as the standard protein.  All samples were 
assayed in triplicate. A stock solution of BSA (10 mg/m) was serially diluted in water, 
to give a range of standard BSA concentrations ranging from 0-100 µg/ml. Lowry 
reagent A [2% (w/v) sodium carbonate, 0.1 M sodium hydroxide, 0.5% (w/v) lauryl 
sulphate (SDS)],  Lowry reagent B [2% (w/v) sodium potassium tartrate] and Lowry 
reagent C [1% (w/v) copper sulphate] were mixed in a volume ratio of A (100): B (1): 
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C (1) respectively to form reagent D. To both the BSA standards and the unknown 
protein samples (50 µl) 0.5 ml of reagent D was added to each sample and vortexed 
before incubation at room temperature for 10 minutes. On the addition of 50 µl of 
Folin-Ciocalteau phenol reagent (1 M, 1:1 mix of Folin reagent and water) each 
sample was mixed and incubated at room temperature for 30 minutes. The reaction 
was terminated by the addition of 500 µl of water. The absorbance of each tube was 
determined and the optical density (O.D). At λ = 750 nm, was determined for each 
sample using a Jenway Genova Spectrophotomer.   
A calibration curve was constructed of O.D. at λ = 750 nm for the BSA samples. This 
was then used to determine the unknown protein concentration. 
2.4.3 Preparation of resolving gel 
The resolving gel (10%) was prepared by mixing water (6 ml) with resolving gel buffer 
(3 ml), TEMED (6 µl), stock acrylamide (3 ml) and 10% (w/v) ammonium 
peroxodisulphate (APS) (60 µl). The polyacrylamide solution was immediately poured 
into a Hoefer SE 245 dual gel caster, using 2 gel plates of 10 x 8 cm and spacers of 1 
mm width. Saturated butanol (10% w/v) and water solution (100 µl) was added over 
the top of each gel. The gels were covered with parafilm and were allowed to 
polymerise for 60 minutes at room temperature. Gels were individually wrapped in 
tissue and stored in electrode buffer at 40C until use. 
 
2.4.4 SDS-Polyacrylamide Gel Electrophoresis     
The resolving mini-slab gel was clamped into a Hoefer mini-vertical gel 
electrophoresis unit SE260. The stacking gel was prepared by mixing water (2.3 ml) 
with stock acrylamide (650 µl), stacking gel buffer (1 ml) and  TEMED (5 µl) and 10% 
(w/v) ammonium persulphate (80 µl) was added to the stacking gel and this was 
immediately poured into the mini-slab gel above the resolving gel. A welled comb 
was inserted into the stacking gel and removed after the polymerisation of the 
stacking gel and the wells were washed with buffer.  Approximately 300 ml of 
electrode buffer was poured into the wells and into the base of the electrophoresis 
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unit. 15 µl of protein samples and pre-stained standards (protein molecular weight 
range of 180 - 26 kDa, 15 µl) were loaded to the wells of the stacking gel using a 
Hamilton syringe.  Electrophoresis was carried out at 180 V, 10 mA (per gel) and was 
increased by 5 mA (per gel) once the samples reached the resolving gel. The gel was 
run for approximately 2 hours until the appropriate pre-stained molecular weight 
marker (25 kDa) reached the bottom of the gel.    
 
2.4.5 Immunoblotting  
After SDS-PAGE, the proteins from the gels were transferred to nitro cellulose 
membranes. A transfer cassette sandwich was constructed with the following order 
of components which had been pre-equilibrated in transfer buffer; sponge, two 
sheets of blotting paper and nitrocellulose membrane.  The SDS-PAGE gel, two 
sheets of blotting paper and a final piece of sponge were added to the transfer 
cassette sandwich. On the addition of each component to the transfer cassette 
sandwich air bubbles were carefully removed by pressing each layer with a test tube. 
Proteins were transferred at a constant voltage of 50 V for 2.5 h using a Hoefer TE 22 
tank transfer unit containing transfer buffer kept cool with ice and cold packs. 
Following the transfer of the proteins, the nitrocellulose membrane was briefly 
rinsed with TBS and incubated with blocking buffer which was TBS, containing 5% 
(w/v) dried milk and 0.02% (v/v) Tween-20 (15 ml) for 1 h at room temperature with 
gentle shaking. After blocking of the non-specific antibody sites the nitrocellulose 
membranes were washed with ~ 10 ml of Tris Buffered Saline. The appropriate 
affinity-purified primary antibodies were diluted in incubation buffer of TBS, pH 7.4 
containing 2.5% (w/v) dried milk to working concentrations (0.5-5 µg/ml). The 
nitrocellulose membranes were incubated with the diluted primary antibody 
solution (10 ml) overnight at 40C with gentle shaking. 
After incubation with the primary antibodies the nitrocellulose membranes were 
washed four times in wash buffer containing TBS with 2.5% (w/v) dried milk and 
0.2% (v/v) Tween-20 (10 ml) at 10 minute intervals with gentle shaking at room 
 
 
75 
 
temperature. Nitrocellulose membranes were then incubated for 1 hour with gentle 
agitation with horseradish peroxidise (HRP) labelled secondary antibody, either anti-
rabbit or anti-mouse depending on what primary antibody was raised in, at a dilution 
of 1/2000 in incubation buffer (10 ml). The unbound secondary antibody was 
removed by washing the membrane as described above. The membrane was then 
drained of excess buffer and briefly rinsed in TBS. Immunoreactive bands on the 
nitrocellulose membrane were developed by processing in a solution containing Tris-
HCl pH 8.5 (1 M), luminol (250 mM), coumaric acid (90 mM) and hydrogen peroxide 
(30%, 64 µl) for 1 minute at room temperature with gentle shaking. After removal of 
the reagents, the immunoblot was wrapped in cling film, placed in a film cassette 
and exposed to HyperfilmTM for various times (1-10 minutes). The film was then 
developed in KodakD-19 Developer until the immunoreactive bands were visible and 
fixed in Kodak Unfix for 5 minutes at room temperature.  
 
2.4.6 Immunofluorescence analysis  
Immunohistochemical analysis was carried out by conventional procedures as 
described previously by (Chazot et al., 2001). The lumbar spinal cord sections from 
healthy and pain models kindly provided by Pfizer (Freund’s complete adjuvant 
model) were perfusion fixed with 4% (w/v) paraformaldehyde, 0.05% (v/v) 
glutaraldehyde in 0.1M phosphate buffer, pH 7.4. The spinal cords were removed, 
post-fixed in paraformaldehyde overnight and then cryoprotected by incubation in 
30% (w/v) sucrose in 0.1 M phosphate buffer, pH 7.4 at 40C for 48 hours. The tissue 
was then frozen in isopentane at -800 C for 1.5 minutes and horizontal sections (20 
μm) were cut on a cryostat. Skin from the plantar surface of the hind paw was 
processed similarly and 8 μm sections were cut on the cryostat. 
 
Free floating sections of the lumbar spinal cord were initially treated with 10% (v/v) 
methanol and 3% (v/v) hydrogen peroxide in 50 mM TBS, pH 7.4 for 30 minutes to 
quench endogenous peroxidase activity (Wendelboe and Bisgaard., 2009). The 
sections were then given 3 X 5 minute washes in 0.2% triton x-100 (v/v) TBS solution. 
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Sections were incubated in TBS, 0.2% (w/v) glycine to mop up residual unreacted 
aldehyde groups from the fixative. Non-specific binding sites in the tissue were 
blocked by incubating with foetal calf serum 2% (v/v) in TBS/triton x-100 0.2% (v/v) 
for 60 minutes at room temperature with gentle agitation. Sections were then 
incubated overnight at 40C in anti-hH4(374-390) antibody at a final concentration of 1 
μg/ml in foetal calf serum/TBS 1% foetal calf serum, (v/v). After the overnight 
incubation, sections were given 3 X 5 minutes washes with 0.2% triton-x 100 and 
TBS, before 2 hour room temperature incubation in anti-rabbit Alexa Fluor 594. After 
the incubation period, the sections were given 3 X 5 minute washes with 0.2% triton-
x 100 and TBS. In addition, a control was carried out where the primary antibody was 
left out, so as to rule out non-specific binding of the secondary antibody to the slice. 
 
After immunostaining, all sections were mounted onto gelatin-coated slides, dried, 
dehydrated and cleared in xylene. Coverslips were applied with DPX-mount 
mounting medium. Sections were examined using a Zeiss Axioskop 2 equipped for 
epifluorescence.  
 
 
2.4.7 Immunofluorescence for histamine H4 receptor antibodies and Neuronal 
markers  
 
Refer to the immunofluorescence protocol in section 2.4.6 
 
After blocking of non-specific binding sites, the sections were then incubated 
overnight at 40C in anti-hH4 antibody at a final concentration of 1 μg/ml in foetal calf 
serum/TBS (1% serum, v/v) guinea pig anti-substance P (1:300 dilution) or anti-hH4 at 
1 μg/ml and mouse anti-calcitonin gene-related peptide (1:300 dilution). After the 
overnight incubation, sections were given 3 X 5 minutes washes 0.2% triton-x 100 
and TBS, before a 2 hour room temperature incubation in anti-rabbit Alexa Fluor 
594, anti-mouse Alexa Fluor 488 or anti-guinea pig Alexa Fluor 488 secondary 
antibodies.  In addition, a control was carried out where the primary antibody was 
left out, so as to rule out non-specific binding of the secondary antibody to the slice.  
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2.4.8 Poly-D-Lysine coating of cover-slips 
 
5 mg of poly-D-lysine was dissolved in 50 ml of tissue culture grade water and mixed 
vigorously until the contents had dissolved. 1 ml per 25 cm2 of dissolved poly-D-
lysine was used to coat the cover slips and the plate was rocked gently to ensure 
uniform coating of culture surface and left to dry overnight under UV light in the 
tissue culture hood. After overnight drying, the coverslips were rinsed with PBS. 
Media and cells were introduced to the poly-D-lysine coated cover slips and 
incubated at 370C, 5% CO2.  
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CHAPTER 3 
The histamine H4 receptor is expressed on sensory neurones  
3.1 Objectives  
The aim of this chapter was to determine the expression of the histamine H4R on 
sensory nerve fibres. The next aim was to perform a series of pharmacological 
experiments to determine the functional expression of this receptor on dorsal root 
ganglion neurons in order to define a new model system. 
3.2 Introduction 
Histamine is the best known endogenous agent implicated for the induction of itch 
and also produces pain upon release from mast cells. Itch or ‘pruritus’ is defined as 
an unpleasant cutaneous sensation associated with the desire to scratch (Steinhoff 
et al., 2006). Chronic intense itching can lead to the development of skin lesions and 
release of inflammatory mediators by epithelial, endothelial or immune cells that 
induce or aggravate pruritus, resulting in reinforcement of scratching.  This is 
referred to as the “itch-scratch cycle” (Figure 3.1) 
                   
Figure 3.1 The itch scratch cycle (Steinhoff et al., 2006).  
Exogenous and endogenous factors (released by endothelial cells, epithelial cells, and immune cells) 
activate signalling pathways from the periphery via the dorsal root ganglia (DRG) and spinal cord, to 
the brain. Activation of specific areas in the brain results in the perception of itch, which produces a 
scratching response.  
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Histamine receptor involvement in itch 
Histamine acts via four G-protein coupled receptors H1-, H2-, H3- and H4 receptors. 
The H1Rs are involved in histamine-induced itch, as agonists for these receptors 
provoke itch in mice, and antagonism of these receptors prevents histamine and 
allergen-induced itch (Rossbach et al., 2009, Bell et al., 2004). Although traditional 
H1R antagonists are widely used and moderately effective in the treatment of 
histamine-induced itch, they are not clinically effective in conditions such as atopic 
eczema. The H2R is only partially involved in the mediation of itch as the H2R 
antagonist cimetidine, did not significantly reduce histamine-induced itch (Bell et al., 
2004). The H3R antagonists thioperamide and clobenpropit dose-dependently 
induced scratching, but these compounds have been shown to possess affinity for 
the H4R (Tiligada et al., 2009). According to Bell et al. (2004), intradermally 
administered thioperamide induced itch in mice, while systemic administration dose-
dependently reduced histamine or clobenpropit-induced scratching behaviour (Bell 
et al., 2004).  
The H4R agonist 4-Methylhistamine dose-dependently induced scratching in wild-
type and mast cell deficient mice, an effect that was inhibited by administration of 
the specific H4R antagonist JNJ 7777120 (Dunford et al., 2007). Several studies have 
presented the inhibition and amelioration of pruritus using H4R antagonists 
(Yamaura et al., 2009, Suwa et al., 2011, Dunford et al., 2007). Based on these 
findings, the presence of the H4R on sensory neurones was proposed and H4R 
expression was detected in the peripheral nervous tissue. High H4R mRNA was 
detected the human and rat DRG (Strakhova et al., 2009).   DRG neurons contain the 
cell bodies of sensory afferents and this further supports the hypothesis of the 
potential involvement of the H4R in the neural transmission of itch.  
 In humans, histamine-induced itch is transmitted by specific mechanosensitive C-
fibers, which are preferentially activated by pruritogens like histamine (Schmelz et 
al., 1997). Recently, the functional expression of the H4R on sensory neurones was 
reported. Activation of the H4R with 4-Methylhistamine induced a strong 
intracellular calcium increase comparable to that induced by capsaicin, in subset of 
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capsaicin-sensitive DRG sensory neurones. This effect was absent in transient 
potential receptor vanilloid knockout (TPRV -/-) mice (Rossbach et al., 2011). This 
further implies that the H4R is a promising target for the management of chronic 
pruritus.  
Histamine plays complex role in the modulation of pain as it is an established 
mediator of acute and chronic inflammatory conditions (Thurmond et al., 2008b). 
The close proximity of mast cells, microvessels and sensory fibres may permit the 
contribution of histamine and other mast cell products such as prostaglandins to the 
pain sensation. Central activation of the H1R induces antinociception, where as 
histamine was demonstrated to stimulate nociceptive fibres through H1R activation 
in rodents (Parada et al., 2001). Activation of peripheral and central H3R has been 
shown to inhibit formalin-induced nociception (Cannon et al., 2007b, Cannon, 2003). 
Recent studies also suggest that the H4R could be involved in the acute carrageenan-
induced inflammatory pain (Coruzzi et al., 2007) and neuropathic pain (Hsieh et al., 
2010b). 
In light of this, we set out to localise the expression of the histamine H4R on 
peripheral sensory afferent fibres in the skin, DRG and spinal cord using 
immunohistochemical methods. During itch and nociception, nerve endings release 
neuropeptides such as substance P and calcitonin gene-related peptide (CGRP) 
(Mogil et al., 2005), which contribute to and aggravate the condition by sensitising 
peripheral afferents. Therefore, we analysed expression of histamine H4R in relation 
to sensory fibres that express these neuropeptides. Another aim was to develop a 
functional expression model of the H4R in primary rodent DRG neurons, using 
calcium signalling.  
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3.3 Methods   
3.3.1 Tissue preparation 
Following cervical dislocation, spinal cord, dorsal root ganglia and skin from four 
adult male Wistar rats were dissected and stored in 4% formalin before snap 
freezing, in preparation for cryostat sectioning. Immunohistochemical analysis was 
then performed on skin from the plantar surface of the hind paw, lumbar spinal cord 
and dorsal root ganglia using the panel of selective antibodies. Controls were carried 
out in the absence of primary antibodies.  
3.3.2 Immunofluorescence for histamine H4R and substance P/CGRP  
Refer to section 2.4.7 
3.3.3 Isolation of DRG neurons 
Three 14 day old male Wistar rats were deeply anaesthetised with isoflurane and 
then decapitated. The spinal column was opened and 10-12 DRG along the whole 
vertebral column were dissected. Isolated ganglia were enzymatically digested in 
Ca2+ and Mg2+ free filter sterilised Hanks Balanced Salt solution (HBSS) supplemented 
with collagenase crude type 1A (1 mg/ml) and dispase (10 mg/ml), at 370C for 20-30 
minutes. Neurons were dissociated by trituration using fire-polished Pasteur pipettes 
of decreasing tip pore size. Cells were washed in 10 ml of fresh growth media, 
DMEM GlutaMax I supplemented with 10% foetal calf serum, penicillin 50 U/ml and 
streptomycin 50 µg/ml. Neurons were then collected by centrifugation at 800 rpm, 
40C for 5 minutes and the supernatant discarded. The pellet was then washed with 
fresh growth media and gently triturated using a 1 ml Gilson pipette.  Neurons were 
then collected by centrifugation at 800 rpm, 40C for 5 minutes and the pellet 
resuspended in 800 ml of warmed growth media. The neurons were plated onto 
coverslips at 100 µl per 10 mm coverslip in a 24 well plate. The plate was then 
incubated at 370C for 2-3 hours to allow the cells to adhere to the coverslips, after 
which the wells were flooded with 1 ml of pre-warmed DMEM media. The cells were 
cultured for 2-3 days at 370C in 5% CO2.  
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3.3.4 Calcium2+ imaging of DRG neurons stimulated with the H4R agonist, VUF 8430 
Changes in the intracellular calcium concentration [Ca2+]free of single DRG cells were 
measured by digital microscopy, using a Nikon eclipse TE-2000E connected to 
equipment for recording of single cells.  
Coverslips containing the DRG neurons were loaded with Fluo-4 AM (fluorescent cell 
permeant acetoxymethyl ester) in DMSO (1 µl/µl), in Ringer solution (artificial 
cerebral spinal fluid) containing 10% Pluronic-F127 solution (0.5 µl/ml) and 
incubated for 40 minutes at 370C in 5% CO2. For imaging, the coverslip was placed in 
a chamber on the stage of the microscope and constantly perfused with Ringer 
solution at 350C. The field of cells was monitored by observing epifluorescence after 
excitation at the 488 nm and images were acquired every 1 second, by programming 
the NiS Elements™ software to automatically do so. Neurons were initially identified 
at the beginning of each experiment by exposure to 50 mM KCl solution. Neurons 
were initially exposed to control (Ringer solution), followed by 50 mM KCl, 100 µM 
Histamine, 1 µM VUF 8430 (specific H4R agonist, kind gift of Prof Rob Leurs, 
Amsterdam), 1 µM Capsaicin and 10 µM JNJ 7777120 (specific H4R antagonist). 1 ml 
of each stimulus was applied to the coverslip and the cells were washed with fresh 
buffer for at least 2 minutes after application of each stimulus, to allow the cells to 
recover the cells prior to addition of the next stimulus.   
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3.4 Results  
3.4.1 IHC showing substance P and CGRP labelling of peptidergic C fibres in the 
dorsal horn of the rat lumbar spinal cord 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Immunohistochemistry of rat lumbar spinal cords probed with A anti-Calcitonin gene-
related peptide (red) B anti-substance P (green). C represents a double labeled merged image of anti-
CGRP and anti-substance P immunoreactivity in the rat lumbar spinal cord. Immunostaining of rat 20 
µm transverse lumbar spinal cord slices (X20). Scale bar = 10 µm and represents all images shown. All 
immunohistochemistry data shown are representative images from 3 experiments. 
Figure 3.1 shows IHC labelling of sections of the dorsal horn from the lumbar region 
of the spinal cord. CGRP is expressed in lamina I and outer lamina II. Substance P is 
expressed in lamina II of the dorsal horn. There is no evidence of overlap between 
the two neuropeptides. 
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3.4.2 IHC showing substance P and CGRP labelling of cell bodies in the dorsal root 
ganglia of the rat  
 
 
 
 
 
 
 
 
 
  
Figure 3.2 Immunohistochemistry of rat L4-L5 DRG cells probed with A anti-calcitonin gene-related 
peptide (red) B anti-substance P (green). C represents a double labeled merged image of anti-CGRP 
and anti-substance P immunoreactivity in the rat DRG. Immunostaining of 6 µm transverse rat DRG 
slices (X20). Scale bar = 50 µm and represents all images shown. All immunohistochemistry data 
shown are representative images from 3 experiments. 
Figure 3.3 shows IHC labelling of the cells the dorsal root ganglia. CGRP is expressed 
on a subset of DRG neurons, which are putative Aδ fibres and substance P on a 
subset of putative C-fibres. There is no evidence of overlap in expression of the 
neuropeptides.          
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3.4.3 IHC showing substance P and Isolectin B4 labelling of peptidergic and non-
peptidergic C fibres in the dorsal horn of the rat lumbar spinal cord 
 
 
 
Figure 3.3 Immunohistochemistry of rat lumbar spinal cords probed with A anti-substance P (red) B 
anti-IB4 (green). C represents a double labeled merged image of anti-substance P and anti-IB4 
immunoreactivity in the rat lumbar spinal cord. Immunostaining of rat 20 µm transverse lumbar spinal 
cord slices (X20). Scale bar = 10 µm and represents all images shown. All immunohistochemistry data 
shown are representative images from at 3 experiments. 
 
Figure 3.3 shows the IHC of the peptidergic putative C-fbres in dorsal horn of the 
spinal cord with anti-substance P, and the non-peptidergic C-fibres with Isolectin B4. 
Substance P is expressed on neurons terminating in lamina I and outer II, where as 
Isolectin B4 is expressed on neurons terminating within inner lamina II. 
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3.4.4 IHC showing substance P and Isolectin B4 labelling of cell bodies in the dorsal 
root ganglia of the rat 
  
Figure 3.4 Immunohistochemistry of rat L4-L5 DRG cells probed with A anti-substance P (red) B anti-
IB4 (green). C represents a double labeled merged image of anti-substance P and anti-
IB4immunoreactivity in the rat DRG. Immunostaining of 6 µm transverse rat DRG slices (X20). Scale 
bar = 50 µm and represents all images shown. All immunohistochemistry data shown are 
representative images from 3 experiments. 
 
Figure 3.4 shows the IHC of the peptidergic and non-peptidergic putative C-fibre 
neurons in the dorsal root ganglia. There is no observed overlap in expression of the 
substance P-expressing and Isolectin B4- expressing neurons. 
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3.4.5 IHC showing H4R and Substance P labelling in the skin from the plantar 
surface of the hind paw of the rat 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 3.5 immunohistochemistry of skin from the plantar hind surface of the hind paw probed with 
A, anti-H4R antibody (green), B anti-substance P (red), C represents a double labeled merged image of 
A and B. D is the control experiment without the primary or secondary antibody. Immunostaining of 
skin from the plantar surface of the right hind paw of the rat, 8 µm transverse skin slices (X20). Scale 
bar = 50 µm and represents all images shown. All immunohistochemistry data shown are 
representative images from 3 experiments. 
Figure 3.5 shows IHC of skin from the plantar surface of the hind paw of the rat. The 
H4R antibody appears to label the substance P-positive C-fibres, which innervate the 
blood vessels (arrows). This represents the co-expression of the histamine H4R on 
substance P C-fibres. 
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3.4.6 IHC showing H4R and Substance P labelling in the dorsal root ganglia of the 
rat 
 
    
 
Figure 3.6 Immunohistochemistry of rat L4-L5 DRG cells probed with A anti-H4R antibody (green), B 
anti-substance P (red), C represents a double labeled merged image of anti-substance P and anti- H4R 
immunoreactivity in the rat DRG. Immunostaining of 6 µm transverse rat DRG slices (X20). Scale bar = 
50 µm and represents all images shown. All immunohistochemistry data shown are representative 
images from 3 experiments. 
 
Figure 3.6 shows the IHC labelling of neurons of the DRG. The H4R appears to be 
expressed on a subset of neurons which are positive for substance P. This represents 
the co-expression of the histamine H4R on a subset of substance P-expressing 
putative C-fibres. 
 
3.4.6.1 Quantification of DRG neurones that express H4R and substance P 
immunoreactivity (IR)   
 
Table 3.1 represents shows the percentage of DRG sensory neurons positive for substance P 
expression, H4R and double labelled substance P-H4R immunoreactivity. The neurons were counted 
and the diameters measured using Image J software.  
Neuron size Percentage of neurons (%) 
 Substance P-IR  H4R-IR  Sub P/H4R-IR 
 
Small (<25 µm) 
 
7.7 (20/259) 
 
10 (26/259) 
 
4.6 (12/259) 
 
Medium (25-50  µm) 
 
15 (39/259) 
 
10.8 (28/259) 
 
6.5 (17/259) 
 
Large (>50  µm) 
 
13.5 (35/259) 
 
10.4 (27/259) 
 
16.6 (43/259) 
A B C 
A C B 
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3.4.7 IHC showing histamine H4R and substance P labelling of C fibres in the dorsal 
horn of the rat lumbar spinal cord 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Immunohistochemistry of rat lumbar spinal cords probed with A H4R antibody (green), B 
anti-substance P (red) C represents a double labeled merged image of anti-substance P and anti-IB4 
immunoreactivity in the rat lumbar spinal cord. Immunostaining of rat 20 µm transverse lumbar spinal 
cord slices (X20). Scale bar = 10 µm and represents all images shown. All immunohistochemistry data 
shown are representative images from 3 experiments. 
 
Figure 3.7 shows IHC of the dorsal horn of the lumbar region of the spinal cord. 
There is some labelling of the histamine H4R on neurons terminating in the dorsal 
horn. Substance P is expressed on neurons terminating within lamina I and II of the 
dorsal horn. There is no observed co-expression of the H4R and substance P on the 
neurons within the spinal cord. 
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3.4.8 IHC showing H4R and CGRP labelling in the skin from the plantar surface of 
the hind paw of the rat 
 
 
Figure 3.8 immunohistochemistry of skin from the plantar hind surface of the hind paw probed with 
A, anti-H4R antibody (green), B CGRP (red), C represents a double labeled merged image of A and B, 
and yellow indicated double labelling. Immunostaining of skin from the plantar surface of the right 
hind paw of the rat, 8 µm transverse skin slices (X20). Scale bar = 50 µm and represents all images 
shown. All immunohistochemistry data shown are representative images from 3 experiments. 
Figure 3.8 shows IHC labelling of skin from the plantar surface of the hind paw of the 
rat. There is expression of the histamine H4R on the fibres innervating the blood 
vessels (arrow) as well putative Aδ-fibres innervating the dermis (asterix). There 
appears to be co-expression of the H4R on CGRP expressing fibres. 
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3.4.9 IHC showing H4R and CGRP labelling in the dorsal root ganglia of the rat 
 
Figure 3.9 Immunohistochemistry of rat L4-L5 DRG cells probed with A anti-H4R antibody (red), B anti-
CGRP (green), C represents a double labeled merged image of anti-CGRP and anti- H4R 
immunoreactivity in the rat DRG. Immunostaining of 6 µm transverse rat DRG slices (X20). Scale bar = 
50 µm and represents all images shown. All immunohistochemistry data shown are representative 
images from 3 experiments. 
Figure 3.9 represents IHC labelling of neurons from the DRG. The anti-H4R antibody 
has labelled a subset of DRG neurons. CRGP has labelled a subset of putative Aδ-
fibres. There appears to be a subset of double labelled neurons, putative Aδ-fibres 
within the DRG. 
 
3.4.9.1 Quantification of DRG neurones that express H4R and calcitonin gene-
related peptide immunoreactivity (IR) 
 
Table 3.2 shows the percentage of DRG sensory neurons positive for CGRP expression, H4R and 
double labelled CGRP-H4R immunoreactivity. The neurons were counted and the diameters measured 
using Image J software.  
 
 
Neuron size Percentage of neurons (%) 
 CGRP-IR  H4R-IR  CGRP/H4R-IR 
 
Small (<25 µm) 
 
23.2 (57/246) 
 
12.2 (30/246) 
 
17.5 (43/246) 
 
Medium (25-50  µm) 
 
10.9 (27/246) 
 
17.1 (42/246) 
 
10.9 (27/246) 
 
Large ( >50  µm) 
 
1.2 (3/246) 
 
3.7 (9/246) 
 
0 
A 
A B C 
 
 
92 
 
3.4.10 IHC showing histamine H4R and CGRP labelling of C fibres in the dorsal horn 
of the rat lumbar spinal cord 
 
Figure 3.10 Immunohistochemistry of rat lumbar spinal cords probed with A H4R antibody (red), B 
anti-CGRP (green) C represents a double labeled merged image of anti-CGRP and anti-H4R 
immunoreactivity in the superficial layers of the rat lumbar spinal cord, yellow represent double-
labelling. Immunostaining of rat 20 µm transverse lumbar spinal cord slices (X20). Scale bar = 100 µm 
and represents all images shown. All immunohistochemistry data shown are representative images 
from 3 experiments. 
 
Figure 3.10 shows IHC labelling of the dorsal horn of lumbar spinal cord. There 
appears to be co-expression of H4R and CGRP on some putative Aδ fibres terminating 
within the deeper layers of the lumbar spinal cord  
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3.4.11 Functional expression of the histamine H4 receptor in the dorsal root ganglia 
of rat using the selective H4 receptor agonist VUF 843 
      
          
 
 
 
Figure 3.11 Changes in normalised fluorescent intensity of DRG neurons in response to control, 50mM 
KCl, 1 µM VUF 8430, 100 μM histamine and 1 μM capsaicin induced Ca
2+
 release. Following KCl 
stimulation, the cells were washed with fresh buffer for at least 2 minutes to recover the cells, prior to 
the addition of the next stimulus. The fluorescent intensity of each cell was normalised for graphical 
representation.  
Figure 3.11 [A] Neurons were identified as cells responsive to 50 mM KCl.  [B] The 
capsaicin sensitive cells were responsive to histamine and the H4R agonist, VUF 8430. 
There is an increase in the observed normalised fluorescent intensity following 
administration of VUF 8430, histamine and capsaicin. The normalised fluorescent 
intensity was used to measure H4R activity through intracellular calcium mobilisation 
from intracellular stores. This is consistent with an increase in the release of 
intracellular calcium from the DRG neurons.  
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Figure 3.12 Neurons were preanalysed with KCl for 2 minutes and then washed for 5 minutes. Cells 
were then continuously washed with control buffer before drug application. 10 µM JNJ 7777120 was 
applied to the cells for 2 minutes followed by solution containing 1 µM VUF 8430 and 10 µM JNJ 
7777120. Cells were washed for 2 minutes with the control solution before the addition of 10 µM JNJ 
7777120. The graph shows the normalised fluorescence induced by Ca
2+
 release from 100 mM KCl 
responsive cells, from 11 experiments.  
 
Figure 3.12 shows that following administration of the selective H4R antagonist JNJ 
7777120, there is a reduction in the normalised fluorescence intensity observed in 
the cells. Addition of the solution containing the agonist produces an apparent 
increase of the normalised fluorescent intensity of the neurons. However, this effect 
was surmounted through application of 1 µM VUF 8430, shown by the increase in 
the fluorescent intensity.  
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D Dose-response relationship between VUF 8430 concentration and the 
normalised calcium intensity 
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3.4.13 Neurons were detected by KCl stimulation for 2 minutes and washed for 5 minutes before VUF 
8430 application for 3 minutes. The concentrations used ranged from VUF 8430 1x10
-9 
M to 1x10
-5 
M. 
Each concentration was repeated 3 times. pEC50 value = 7.3 ± S.E.M. 
Figure 3.4.13 represents functional activity of the selective H4R agonist VUF 8430 at 
the rat H4R in the dorsal root ganglia neurons. The normalised fluorescent intensity 
was used to measure H4R activity through intracellular calcium mobilisation from 
intracellular stores. 
VUF 8430 acted as a full agonist at the rat H4R, measured by the normalised 
fluorescent intensity and displayed a pEC50 value of 7.3 (n=3) at the rat H4R.   
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3.5 Discussion  
This chapter describes the immunohistochemical localisation of the histamine H4R on 
putative C- and Aδ nociceptive fibres. The H4R is the most recently identified 
member of the histamine GPCR family, abundantly expressed on haematopoietic 
cells and its role in eosinophils, mast dendritic and T cell function points to a role in 
various allergic and inflammatory functions (Barnard et al., 2008, Dunford et al., 
2006, Simon et al., 2010, Hofstra et al., 2003). In our attempts to determine the 
expression of H4R on sensory neurones, antibodies were used to investigate the 
associations between the histamine H4R, calcitonin gene-related peptide (CGRP) and 
substance P in skin, dorsal root ganglia neurons and the dorsal horn of the lumbar 
spinal cord of the adult male rat.  
 
Histamine and other pruritogens are released from cutaneous mast cells which are 
located close to sensory fibres in the skin. Microdialysis experiments in human skin 
revealed that trauma such as insertion of a needle into the skin, can lead to a 
transient histamine release (Anderson et al., 1992). Histamine can excite a 
subpopulation of C-fibres nociceptors and a subpopulation of these has been shown 
to be insensitive to mechanical and heat stimuli but not histamine (Schmelz et al., 
1997). Sensory receptors function as the first component in the ascending sensory 
pathway and respond to nerve growth factors as well as neuropeptides like 
substance P and calcitonin gene-related peptide. Immunohistochemistry was used to 
localise the distribution of substance P and our results are consistent with previously 
published data which shows that this neuropeptides is prominently expressed in 
small sensory primary C fibre afferents involved in the modulation of pain-related 
information in the dorsal horn of the spinal cord. The central terminations of 
substance P-containing neurons occur mainly in lamina I and outer lamina II (Mcleod 
et al., 1998). On the other hand, CGRP is expressed in small and intermediate sized 
lightly myelinated putative-Aδ neurons in lamina I and II, also involved in nociception 
and the transmission of pain. This is consistent with our immunohistochemical 
findings. 
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3.5.1 H4R expression on putative C- and Aδ- sensory afferent neurons in skin from 
the plantar surface of the hind paw 
Substance P-containing nerve endings originating from the DRG have been 
demonstrated immunohistochemically in nerves supplying small dermal vessels 
(O'Flynn et al., 1989) and free nerve endings and dermal papillae (Deguchi et al., 
1989) in the epidermis. These are postulated to be nociceptors initiating pain 
transmission. Our data show the expression of the H4R on substance P-positive nerve 
fibres innervating the dermis as well as surrounding the blood vessels in the dermis 
of the skin. Substance P has been proposed to be the main mediator of nociception 
and neurogenic inflammation through the initiation of plasma extravasation and 
vasodilatation by action on arterioles, after release by sensory C-fibres. NK1 
antagonists have been shown to reduce hyperalgesia (Cahill and Coderre, 2002) and 
the symptoms of neurogenic inflammation (Moussaoui et al., 1993).  
CGRP has been shown to exert vasodilative effects in the skin, where fmol-pmol 
amounts have produced prolonged increased blood flow (Brain et al., 1986). It has 
also been suggested that this neuropeptide may magnify the extravasation induced 
by mediators of increased vascular permeability, such as tachykinins (Gamse and 
Saria, 1985). Our IHC data shows the co-expression of the H4R on fibres innervating 
the blood vessels in the skin, and fibres innervating the dermis. A study by Dunford 
et al. (2007) showed that the H4R antagonist JNJ 7777120 was superior to the 
commonly used H1R antagonist, diphenyhydramine in the attenuation of 
experimental pruritus and lacked the sedative effects. The observation that the 
histamine-induced itch and the inhibitory effects of the H4R antagonist were 
unaltered in mast cell-deficient mice (which have few or no mast cells in skin), 
indicated that the H4R on mast cells was not required for initiation of H4R-mediated 
pruritus. Substance P appears to be involved in the mediation of histamine-induced 
itch as scratching behaviour induced by the H4R agonist, clobenpropit was reduced in 
mice treated with the neurokinin 1 (NK1) antagonist spantide (Hossen et al., 2006). 
Similarly, substance P-induced itch was attenuated in mice pre-treated with the H4R 
antagonist JNJ777120 (Yamaura et al., 2009). The anti-allergic effects of H4R 
antagonists were evaluated in other models of dermatitis in mice.  Rossbach et al. 
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(2009) showed that JNJ 7777120 pre-treatment significantly inhibited hapten-
induced scratching but was unable to reduce the allergic inflammatory response, 
suggesting a non-immune cell acting site for the drug. The observation of the H4R on 
substance P and CGRP positive neurons in the rat skin supports the hypothesis of a 
peripheral acting site for the H4R antagonists which exert their effects by reducing 
inflammation (Hsieh et al., 2010a) and hapten-induced scratching in rodent models 
of pruritus (Dunford et al., 2007). 
3.5.2 Expression of the H4R in the dorsal root ganglia and spinal cord 
Immunohistochemical detection revealed that the H4R are expressed on the soma of 
sensory neurons, with more intense staining of the small and medium diameter sized 
neurons. In the lumbar spinal cord, expression was predominant in the superficial 
layers, lamina I and II, where the immunoreactivity pattern suggests possible 
localisation with the terminals of primary sensory afferent neurons from the DRG. In 
the rat, H4R mRNA expression appears to be strongest in the nervous system with 
the highest expression detected in the DRG (Strakhova et al., 2009) by RT-PCR, in 
contrast to the human, where the strongest mRNA expression was observed in the 
spinal cord, cortex and cerebellum (Strakhova et al., 2009). The existence of the H4R 
on peripheral afferent nerve terminals which mediate itch has been previously 
postulated (Dunford et al., 2007); therefore the location of the H4R on soma of 
sensory neurons that express substance P and CGRP could provide the anatomical 
basis for the antipruritic efficacies of H4R antagonists.  
Detection of the H4R on the soma of DRG neurons and the spinal cord further 
supports the interesting possibility that these receptors may have a role in the 
mediation of nociception.  There is numerous data to support this potential role; the 
selective H4R antagonists VUF 6002 and JNJ 7777120 were shown to have high 
efficacy in the attenuation of acute inflammatory pain. In this model, the drug 
reduced paw oedema and hyperalgesia induced by the subplantar injection of 
carrageenan (Coruzzi et al., 2007). JNJ777120 was shown to be efficacious in various 
models of inflammatory pain including Complete Freund’s adjuvant, osteoarthritis, 
carrageenan thermal hyperalgesia (Hsieh et al., 2010a) and non-inflammatory such 
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as the skin incision model. JNJ777120 effectively reduces hyperalgesia in the chronic 
constriction and spinal nerve ligation models of neuropathic pain in the rat (Hsieh et 
al., 2010a). 
3.5.3 Functional expression of the rat H4R in the DRG 
The H4R mediates its effects by coupling to Gαi/o G-proteins. Activation of the H4R 
results in calcium mobilisation from intracelluar stores (Hofstra et al., 2003).  Due to 
the antinociceptive and antipruritic effects of H4R antagonists in the absence of mast 
cells, the functional presence of the H4R on sensory neurons was hypothesised. In 
the present study, it has been demonstrated that the H4R is functionally expressed 
on sensory neurones using the potent highly selective agonist VUF 8430. VUF 8430 is 
a full agonist at human and rodent H4R in both endogenous and recombinant H4R 
expressing systems (Lim et al., 2009). Our results show that VUF 8430 induced a 
[Ca2+] influx in primary rat DRG neurons, which were sensitive to the H4R selective 
antagonist, JNJ 7777120. VUF 8430 increased the normalised calcium intensity in a 
dose-related manner, demonstrating functional expression of the rat H4R in the DRG. 
VUF 8430 displayed a pEC50 value of 7.3 at the rat H4R. However, this differs slightly 
from the pEC50 6.9 obtained by Lim et al. (2009). The difference could be due to the 
systems used; our data were collected using primary rat DRG cultures while Lim et al. 
used SK-N-MC cells stably transfected with the rat H4R. These findings further 
corroborate those of Rosbbach et al. (2011) and, Connelly et al. (2009) Strakhova et 
al. (2009) which demonstrated the functional expression of the H4R in the 
mammalian CNS and the hypothesis that the H4R is involved in the transmission of 
itch and pain. Whole cell voltage recordings taken from layer IV somatosensory cells 
in adult mouse brain slices demonstrated that the H4R agonist 4-Methylhistamine 
induced a reversible hyperpolarisation in the majority of neurons tested (Connelly et 
al., 2009) further supporting a functional role of the central H4R.  
The H4R appears to be present on both peptidergic C and Aδ fibres innervating the 
blood vessels and dermis of the skin, DRG and spinal cord.  In contrast, the closely 
related H3R was absent on the substance P positive putative C fibres (Cannon et al., 
2007a), and immunoreactivity was only observed on CGRP positive putative Aδ fibres 
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in cutaneous innervation. The neurons were primarily medium to large DRG neurons. 
Consistent with spinal H3R inhibition of hyperalgesia, H3R immunoreactivity was 
observed on small calibre CGRP-positive fibres ramifying the superficial lamina of the 
dorsal horn. The H3R is a postsynaptic inhibitory heteroreceptor and administration 
of H3R agonists has been shown to exhibit anti-inflammatory and anti-nociceptive 
properties, through inhibition of neuropeptides release. This mechanism may be 
important in controlling the extent of inflammation that occurs during injury, and 
subsequently released CGRP and substance P. It is possible that activation of the H3R 
could attenuate the inflammatory effects induced by CGRP and substance P release 
and H4R activation.  
Our results show the presence of the H4R on peripheral unmyelinated C- and Aδ- and 
central primary afferents. This suggests both peripheral and central acting sites for 
H4R antagonists that have antinociceptive and antipruritic effects. Previous studies 
showed that 4-Methylhistamine induced [Ca2+] in a subset of capsaicin-sensitive DRG 
neurones; capsaicin sensitivity is an essential characteristic of a major population of 
nociceptive sensory neurons, most of which are C-fibres but a small population are 
Aδ fibres (Rossbach et al., 2011). The observed increase in free intracellular [Ca2+] 
observed in the DRG is related to capsaicin sensitivity because histamine induced 
[Ca2+] influxes in sensory neurones from wild type but not TPRV-/- mice. Similarly, 
pre-treatment with a TPRV antagonist resulted in significantly attenuated scratching 
behaviour in response to histamine application (Shim et al., 2007).   
This chapter provided an anatomical and functional basis for H4R in rodent sensory 
neurotransmission. The next chapter investigates changes in H4R expression in a 
range of acute and chronic inflammatory and neuropathic pain models. 
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Chapter 4 
DIFFERENTIAL EXPRESSION OF THE HISTAMINE H4 RECEPTOR IN ACUTE 
INFLAMMATORY AND NEUROPATHIC PAIN CONDITIONS 
4.1 Objectives  
To quantify the changes in histamine H4 receptor expression during acute 
inflammatory and neuropathic pain conditions. The aim of this chapter was to 
perform a series of western blotting experiments to help understand the 
heterogeneity of H4 receptor expression during different pain states. 
4.2 Introduction  
The histamine H4 receptor, which was cloned in 2000 (Oda et al. 2000) is the latest 
most recently identified member of the histamine receptor family of G protein–
coupled receptors with potential functional implications in inflammatory diseases. 
The H4 receptor is primarily expressed in cells of the haematopoietic system such as 
eosinophils, mast cells and dendritic and T cells and has been postulated to possess 
immunomodulatory functions in these cells such as activation, migration, and 
production of chemokines and cytokines (Hofstra et al., 2003). In human eosinophils, 
activation of the H4 receptor can induce an increase in intracellular calcium levels as 
well as cytoskeletal shape changes (Barnard et al., 2008).  These findings support the 
participation of the H4 receptor in immunity and inflammation and there are many in 
vivo studies that support this. For example in models of neutrophilia (Takeshita et al., 
2003), allergic conjunctivitis (Varga et al., 2005), allergic rhinitis (Takahashi et al., 
2009), asthma and allergic dermatitis (Ohsawa and Hirasawa, 2012).  
Histamine appears to play a complex part in pain modulation as its release from 
mast cells is an established mediator of acute allergic reactions and chronic 
inflammation (Thurmond et al., 2004a). The relationship between the H4 receptor 
and circulating immune cells and cytokine production is thought to participate in 
both the mechanism of inflammation and maintenance of inflammation via the H4 
receptor. H4 receptor expression has also been reported in peripheral nerves 
(Nakaya et al., 2004), the neurons of the submucous plexus (Breunig et al., 2007) and 
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the close association between mast cells, microvessels, and sensory fibres has been 
confirmed (Alving et al., 1991). It is therefore highly possible that histamine 
alongside other mast cell products such as prostaglandins may contribute to pain 
sensation via the H4 receptor.  
 A recent study suggested that H4 receptor might be involved in the early phase of 
acute carrageenan-induced inflammation in the rat (Coruzzi et al. 2007). This study 
showed that the highly selective H4 receptor antagonist JNJ 7777120 greatly reduced 
oedema in the rat model of acute inflammatory pain. Detection of H4 receptors in 
the spinal cord and on cell bodies of DRG neurons also raises an intriguing possibility 
that these receptors may potentially have a role in mediation of nociception 
(Strakhova et al., 2009).  Immunohistochemical detection in Chapter 3 revealed that 
H4 receptors are present on the soma of sensory neurons with more intense staining 
observed in the small and medium diameter cells and lumbar spinal cord, primarily 
within lamina I and II, where the pattern suggests localization with primary afferent 
neurons from the dorsal root ganglia (DRG) (Strakhova et al., 2009).  A study by Hsieh 
et al. (2010) showed the attenuation of hyperalgesia in rat models of inflammatory 
and neuropathic pain by the selective H4 receptor antagonist JNJ 7777120, 
suggesting a role for this receptor in pain transmission (Hsieh et al., 2010a). 
This chapter will describe the methods used to create the preclinical inflammatory 
and neuropathic pain models. Quantitative immunoblotting will be used to quantify 
the histamine H4 receptor in sham treated, neuropathic and in the inflammatory 
models. The antibody used to label the histamine H4 receptor is the anti-human H4 
receptor antibody, which recognises the C-terminal tail of the receptor (374-390) 
amino acid sequence (Shenton, 2007).   
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4.3 Methods 
4.3.1 In vivo models of inflammatory pain  
4.3.1A Rat model of Complete Freund’s Adjuvant-induced (CFA) acute 
inflammatory pain 
This procedure was done by our collaborators at GSK and they provided us with the 
tissue samples. Adult male Wistar rats (180-200 g) were used. Inflammatory 
hyperalgesia was induced in by intraplantar injection of 150 µl of Freund’s complete 
adjuvant (containing 1 mg/ml Mycobacterium tuberculosis), into the plantar surface 
of the right hind paw. Sham control animals were injected with a saline solution. 16 
days post-injection the rats were sacrificed by cervical dislocation (n=4 CFA, n=4 
Sham) and spinal cords dissected and either snap frozen on dry ice or fixed in 4% 
paraformaldehyde until processing.   
4.3.1B Behavioural testing  
On the day of testing, the Hargreaves test was used to assess the acute nociceptive 
thermal threshold and induction of inflammatory pain. Animals were placed in a 
Perspex box resting on an elevated glass plate maintained at 300C.  Following an 
acclimation period, a high intensity infra-radiation (IR) source was placed directly 
beneath the hind paw. A trial was started by pressing a key on the IR source. The 
average time over three trials for the rat to remove the paw from the thermal 
stimulus was recorded in seconds as the paw withdrawal latency (PWL), and the IR 
source switched off with the reaction time counter stopped. The intensity of the 
beam was set to produce basal PWLs of 10-12 s.  A maximal PWL of 20 s was used to 
prevent excessive tissue damage due to repeated application of the thermal 
stimulus. The withdrawal latency to the nearest 0.1 s was automatically determined 
and recorded. This was repeated three times and the average values determined.  
In the contralateral paw, paw withdrawal latency (comparable with historical data), 
of less than 5 s was considered an exclusion criterion in behavioural studies. All CFA 
animals in this study would have been utilised for pharmacological testing if a 
behavioural study were being carried out. The spinal cords and paw skin from the 
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plantar surface was dissected following cervical dislocation, 24 hours after CFA 
injection and snap frozen in isopentane (Sham n=2, CFA n=5).   
 
4.3.2 In vivo models of neuropathic pain  
4.3.2A Rat Chronic Constriction injury-Induced (CCI) model of neuropathic pain  
This procedure was done by our collaborators at Pfizer and they provided us with the 
tissue samples. 
Adult male Wister rats (210-235 g) were used. As previously described in the method 
of Bennet and Xie (Bennett and Xie, 1988); the right  sciatic nerve was isolated at 
mid-thigh level and loosely ligated by 3 chromic gut (5-0) ties separated by an 
interval of 1 mm.  
 
Figure 4.1 The diagram illustrates the location of the ligatures on the sciatic nerve. The sciatic nerve 
innervates the hind paw and its cell bodies of the sciatic nerve lie in dorsal root ganglia located in L4, 
L5 and L6. [Chronic constriction injury (CCI), partial nerve ligation (PNL), spared nerve injury (SNI), 
spinal nerve ligation (SNL)] (Ueda, 2006). 
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4.3.2B Behavioural testing and stimulus presentation 
24 hours after surgery, static allodynia scores were taken using the method of 
Chaplan et al.  (Chaplan et al., 1994) using calibrated Von Frey filaments ranging 
from 0.4-15 g. On the day of testing, rats were placed in a plastic cage with a wire 
mesh floor that allowed access to the paws. Behavioural accommodation was 
allowed for approximately 15 minutes until cage exploration and grooming has 
ceased. The area tested was the mid-plantar right hind paw in the sciatic nerve 
distribution, avoiding the less sensitive foot-pads. The paw was touched with 1 of a 
series of 8 von Frey hairs with logarithmically incremental stiffness (0.41, 0.70, 1.20, 
2.00, 3.63, 5.50, 8.50 and 15.10 g). The von Frey hair was presented perpendicular to 
the plantar surface with sufficient force to induce a slight buckling against the paw, 
where it was held for approximately 6-8 s. The stimuli were presented at intervals of 
several seconds, allowing resolution of any behavioural responses to previous 
stimuli.  
A positive response was noted if the paw was sharply withdrawn. Flinching 
immediately upon removal of a hair was also considered a response. Based on 
observations on normal, un-operated and healed sham-treated rats, the cut off of a 
15.10 g von Frey hair was selected as the upper limit since stiffer hairs tended to 
raise the entire limb rather than to buckle, substantially changing the nature of the 
stimulus (Chaplan et al., 1994).  
4.3.2C Testing paradigm  
Von Frey hairs were presented in ascending order of strength 24 hours after CCI. 
Each hair was presented 10 times and the number of positive responses multiplied 
by 10 was recorded as the percent response. For each rat, ascending stimuli were 
tested either until the maximum stimulus of 15.10 g was reached or until hair 
strength was reached that caused 100% response.  
The 50% paw withdrawal threshold was determined using the Dixon method (1980). 
Testing was initiated with the 2 g hair and stimuli were presented in consecutive 
fashion whether ascending or descending. In the absence of paw withdrawal to the 
initially selected von Frey hair, a stronger stimulus was presented; in the event of 
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paw withdrawal, a weaker stimulus was chosen. According to Dixon, optimal 
threshold calculation requires 6 responses in the immediate vicinity of the 50% 
threshold. Since the threshold is unknown, strings of similar responses may be 
generated as the threshold is approached from either direction. Rats with a 50% paw 
withdrawal threshold (PWT) below 4g on the ipsilateral paw were considered 
alloydnic. 
The paw skin, lumbar spinal cords and sciatic nerve from the CCI’s were dissected 
following cervical dislocation, 24 hours after CCI induction and frozen to be used in 
western blots.  
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4.4 Results  
Analysis of H4 receptor expression in the rat model of acute inflammatory pain  
4.4.1A Baseline PWLs of the control and CFA treatment groups  
Initial experiments confirmed induction of inflammatory thermal hyperalgesia 
through the Hargreaves test.  
 
 
The Hargreaves test was used to assess the nociceptive thermal threshold and 
induction of inflammatory pain. Animals were placed in a Perspex box and following 
an acclimation period, a high intensity infra-radiation (IR) source was placed directly 
beneath the hind paw. A trial was started by pressing a key on the IR source. When 
the animal felt pain and withdrew their hind paw, the IR source switched off and the 
reaction time counter stopped. The withdrawal latency to the nearest 0.1 second 
was automatically determined and recorded. This was repeated three times and the 
average values determined. 
There was no difference in the paw withdrawal latencies to thermal stimulation 
obtained between the two groups. 
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Figure 4.2 Effect of saline injection on paw withdrawal latency in the ipsilateral and contralateral hind 
paw of rats  
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4.4.1B Paw withdrawal latencies following saline and CFA treatment  
 
Figure 4.3 Effect of Freund’s complete adjuvant on paw withdrawal latency in the ipsilateral and 
contralateral hind paw of rats.  
Following CFA treatment, the paw withdrawal latency was markedly reduced in the 
ipsilateral hind paw after CFA injection, p value≤0.0001. Statistical significance was 
determined through GraphPad Prism, using the Student’s T-test, where p<0.05 was 
considered to show significance. (CFA n=10, sham n=4) 
 
 
 
 
 
 
 
 
 
C
on
tr
al
at
er
al
 
Ip
si
la
te
ra
l 
C
on
tr
al
at
er
al
 
Ip
si
la
te
ra
l 
0
5
10
15
P
a
w
 W
it
h
d
ra
w
a
l 
L
a
te
n
c
y
 (
s
)
 
 
 
Contralateral 
Ipsilateral 
Basal 24 h 
*** 
 
 
109 
 
4.4.2 Effect of CFA treatment on the expression of the H4 receptor in the 
contralateral paw skin of CFA and saline treated rats  
 
                   
 
      
 
                                                                                                                     
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                    
 
 
Approximately 50 µg of protein/ well was loaded onto a 10% separating gel. Once transferred the 
membrane was probed with affinity purified anti-hH4 antibody (1 µg/ml concentration).  Mean ± SD 
[sham n=2, CFA=6].  Immunoreactive bands detected with the anti-H4R antibodies were normalized to 
β-actin. Data show the mean immunoreactive intensity ±SD for n=3 determinations. Statistical 
significance was determined through GraphPad Prism, using the Student’s T-test, where p<0.05 was 
considered to show significance. 
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Figure 4.4 Anti-hH4 immunoreactivity with protein 
extractions from contralateral paw skin of Complete 
Freund’s adjuvant treated and control rats. Lower panel 
shows the corresponding β-actin, probed with 
monoclonal mouse anti β-actin antibody (1:2000) 
 
Figure 4.5 Mean reactive immunointensity of the Mr 39, 
000 rH4R bands detected, using the anti-hH4R antibody 
in the contralateral paw skin of sham and CFA treated 
rats.    P value=0.0004. 
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Figure 4.7 Mean reactive immunointensity of the Mr 
90, 000 rH4R bands detected, using the anti-hH4R 
antibody in the contralateral paw skin of sham and 
CFA treated rats. P value=0.4474. 
Figure 4.6 Mean reactive immunointensity of the Mr 
60, 000 rH4R bands detected, using the anti-hH4R 
antibody in the contralateral paw skin of sham and 
CFA treated rats.  P value=0.0322. 
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Figure 4.4 shows the three immunoreactive bands detected in rat paw skin using the 
anti-hH4 antibody. The bands represent the full length H4 receptor monomer 
migrating at approximately Mr 39, 000 and a dimeric form of the receptor migrating 
at Mr 60, 000. The largest fragment migrating at approximately at Mr 90,000 is likely 
to represent the oligomers of the receptor.  
Figure 4.5 shows there were significant differences in the immunoreactive bands 
detected at approximately Mr 39,000 with the anti-hH4 receptor antibody, between 
the CFA and saline treated rats. The bands detected in the CFA treated rats had 
significantly higher immunoreactivity, suggesting that during CFA induced peripheral 
inflammatory pain; there is a bilateral increase in the expression of the full length H4 
receptor in the skin of rats. 
Figure 4.6 shows a significant increase in the immunoreactive bands detected at 
approximately Mr 60,000 with the anti-hH4 receptor antibody, between the CFA and 
saline treated rats. 
Figure 4.7 There was no significant difference in the expression of the Mr 90 000 rH4 
receptor in the contralateral paw skin of saline and CFA animals.  
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4.4.3 Effect of Complete Freund's adjuvant treatment on the expression of the H4 
receptor ipsilateral (treated) paw skin of adjuvant and saline treated rats  
 
  
 
 
  
 
 
  
 
 
 
 
 
 
 
 
                                                  
 
   
 
 
 
Approximately 50 µg of protein/ well was loaded onto a 10% separating gel. Once transferred the 
membrane was probed with affinity purified anti-hH4 antibody (1 µg/ml concentration). Mean ± SD 
[sham n=2, CFA=6].  Immunoreactive bands detected with the anti-H4R antibodies were normalized to 
β-actin. Data show the mean immunoreactive intensity +SD for n = 3 determinations. Statistical 
significance was determined through GraphPad Prism, using the Student’s T-test, where p<0.05 was 
considered to show significance 
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Figure 4.9 Mean reactive immunointensity of the Mr 
39, 000 rH4R bands detected, using the anti-hH4R 
antibody in the ipsilateral paw skin of sham and CFA 
treated rats.  P value=0.0255. 
Figure 4.10 Mean reactive immunointensity of the Mr 
60, 000 rH4R bands detected, using the anti-hH4R 
antibody in the ipsilateral paw skin of sham and CFA 
treated rats.  P value=0.0005. 
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Figure 4.11 Mean reactive immunointensity of the Mr 
90, 000 rH4R bands detected, using the anti-hH4R 
antibody in the ipsilateral paw skin of sham and CFA 
treated rats.  P value=0.2522. 
 
Figure 4.8 Anti-hH4 immunoreactivity with protein 
extractions from ipsilateral paw skin of Complete 
Freund’s adjuvant treated and control rats. Lower panel 
shows the corresponding β-actin, probed with 
monoclonal mouse anti β-actin antibody (1:2000). 
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Figure 4.8 shows three immunoreactive bands detected in rat skin using the anti-hH4 
antibody represent the H4 receptor monomer migrating at approximately Mr 39, 000 
and a dimeric form of the receptor migrating at Mr 60, 000. The largest fragment 
migrating at approximately at Mr 90,000 is likely to represent the oligomers of the 
receptor 
Figure 4.9 shows there was a significant difference in the immunoreactive bands 
detected at approximately Mr 39,000 with the anti-hH4 receptor antibody, between 
the CFA and saline treated rats. The bands detected in the CFA treated rats had 
significantly higher immunoreactivity suggesting that during CFA induced peripheral 
inflammatory pain; there is an increase in the expression of the H4 receptor 
monomer in the skin of rats. 
Figure 4.10 shows there were significant differences in the immunoreactive bands 
detected at approximately Mr 60,000 with the anti-hH4 receptor antibody, between 
the CFA and saline treated rats.  
Figure 4.11 shows there was no significant difference in the expression of the Mr 90 
000 rH4 receptor in the contralateral paw skin of saline and CFA treated animals.  
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4.4.4 Immunoreactivity of the anti-hH4 (374-390) on spinal cord tissue obtained from 
acute Freund’s Complete Adjuvant and saline treated rats  
 
      
 
 
 
 
Figure 4.12 Immunoblot of spinal cord sections obtained from the lumbar section of Freund's 
complete adjuvant treated and saline treated rats. Immunoreactive bands were detected with the 
anti-hH4 receptor antibody and normalised to β-actin. Lanes 1- 5 represent CFA treated animals and 
lanes 6-7 represent saline treated animals 
Approximately 50 µg of protein/ well from whole spinal was loaded onto a 10% separating gel. Once 
transferred the membrane was probed with affinity purified anti-hH4 antibody (1 µg/ml 
concentration). The antibody detected one band of immunoreactivity at Mr 60,000. Lower panel 
shows the corresponding β-actin, probed with monoclonal mouse anti β-actin antibody (1:2000). 
Figure 4.12 shows the immunoreactivity detected when the anti-hH4 (374-390) antibody 
was used to probe the rat lumbar spinal cord homogenates. The band detected at 
Mr 60,000 is consistent with the molecular weight corresponding to the size of the 
H4 receptor dimer. On the other hand, the molecular weight corresponding to the 
monomer was not detected. 
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4.4.5 Mean reactive immunointensity of the Mr 60, 000 rH4R bands detected using 
the anti-hH4R antibody, in spinal cord tissue obtained from acute Freund’s 
Complete Adjuvant and saline treated rats  
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Figure 4.13 Comparing expression of the Mr 60, 000 rH4R in the lumbar spinal cord of CFA treated and 
saline treated rats probed with anti-hH4 antibody. P value=0.3518. Mean ±SD [sham n=2, CFA=6].  
Immunoreactive bands detected with the anti-H4R antibodies were normalized to β-actin. Data show 
the mean immunoreactive intensity +SD for n = 3 determinations. Statistical significance was 
determined through GraphPad Prism, using the Student’s T-test from the generated p value, where 
p<0.05 was considered to show significance.  
Figure 4.13 shows that there was no significant difference in the immunoreactive 
banding detected between the complete Freund’s Adjuvant-treated rats and the 
saline treated sham controls. This suggests that there is no significant difference in 
H4R expression in the spinal cord during the acute phase of inflammatory pain. 
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Analysis of H4 expression in the rat model of acute neuropathic pain 
4.4.6 The effect of chronic constriction injury of the sciatic nerve on paw 
withdrawal latency in the ipsilateral and contralateral hind paw of rats  
 
 
 
 
 
 
 
 
 
Figure 4.14 Effect of chronic constriction of the sciatic nerve on paw withdrawal threshold in the 
ipsilateral (right) and contralateral (left) hind paws of rats.  
Figure 4.14 shows that following CCI, the paw withdrawal threshold in the ligated 
hind limb were significantly reduced, compared to the sham treated hind limb. (CCI 
n=8, sham n=4) 
Statistical significance was determined through GraphPad Prism, using the Student’s 
T-test, where p<0.05 was considered to show significance.  
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4.4.7 Immunoreactivity of the anti-hH4 (374-390) on paw skin tissue obtained from 
ipsilateral plantar paw of CCI –induced neuropathic pain model (CCI) and Sham rats 
  
 
 
 
 
 
 
Figure 4.15 Immunoreactivity of anti-hH4R on skin from the ipsilateral paw skin of CCI-induced 
neuropathic pain and control rats 
Lanes 1-4 represent CCI animals, lanes 5-6 sham animals. Proteins extracted from the ipsilateral and 
ipsilateral hind paw skin were subjected to immunoblotting and immunoblots probed with the anti-
hH4 (374-390) antibody at 1µg/ml.  
Approximately 50 µg of protein/ well was loaded onto a 10% separating gel. Once transferred the 
membrane was probed with affinity purified anti-hH4 antibody (1 µg/ml concentration). The antibody 
detects two major species in rat skin, Mr 39,000 and 60,000. Lower panel shows the corresponding β-
actin, probed with monoclonal mouse anti β-actin antibody (1:2000). 
 
In figure 4.15, the two immunoreactive bands detected in rat paw skin using the 
anti-hH4 antibody represent the rH4R monomer migrating at approximately  Mr 39 
000 and a dimeric version of the receptor migrating at Mr 60,000.  
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4.4.8 Mean reactive immunointensity of rH4R bands detected using the anti-hH4 
receptor antibody, in the ipsilateral paw skin of CCI-induced neuropathic pain 
compared to the sham treated rats 
 
                          
 
 
 
 
 
 
 
 
Immunoreactive bands detected with the anti-H4R antibodies were normalized to β-actin. Data show 
the mean immunoreactive intensity. Statistical significance was determined through GraphPad Prism, 
using the Student’s T-test from the generated p value, where p<0.05 was considered to show 
significance. Mean ±SD [Sham n=2, CCI=4] for n = 3 determinations 
 
Figure 4.16 shows significant differences in the immunoreactive banding of the Mr 
39, 000 rH4 receptor detected, in the CCI rats compared to the saline treated sham 
controls. The bands detected in the CCI treated rats had significantly higher 
immunoreactivity, suggesting that during CCI induced peripheral neuropathic pain; 
there is an increase in the expression of the H4 receptor monomer in the skin from 
the plantar surface of the hind paw of rats. 
Figure 4.17 shows that there were no significant differences in the expression of the 
Mr 60,000 H4 receptor dimer in the skin from the plantar surface of the ipsilateral 
paw. 
 
Figure 4.16 Mean reactive immunointensity of the Mr 
39, 000 rH4R bands detected in the ipsilateral paw skin of 
CCI rats compared to the saline treated sham controls.  P 
value=0.0033. 
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Figure 4.17 Mean reactive immunointensity of the Mr 
60, 000 rH4R bands detected in the ipsilateral paw skin of 
CCI rats compared to the saline treated sham controls.   
P value=0.0849 
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4.4.9 Immunoreactivity of the anti-hH4 (374-390) on paw skin tissue obtained from 
contralateral paw of CCI–induced neuropathic pain model and Sham rats 
 
 
                                       
                                       
 
Figure 4.18 Immunoreactivity with protein extractions from contralateral paw skin of CCI-induced 
neuropathic pain and control rats 
Lanes 1-4 represent CCI animals, lanes 5-6 sham animals. Proteins extracted from the contralateral 
and ipsilateral hind paw skin were subjected to immunoblotting and immunoblots probed with the 
anti-hH4 (374-390) receptor at 1µg/ml.  
Approximately 50 µg of protein/ well was loaded onto a 10% separating gel. Once transferred the 
membrane was probed with affinity purified anti-hH4 antibody (1 µg/ml concentration). The antibody 
detects two species in rat skin, Mr 48,000 and 60,000. Lower panel shows the corresponding β-actin, 
probed with monoclonal mouse anti β-actin antibody (1:2000). 
 
Figure 4.18 shows the immunoreactive bands detected represent the H4R monomer 
migrating at approximately Mr 39, 000 and the dimer migrating at Mr 60,000.  
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4.4.10 Mean reactive immunointensity of the rH4R bands detected using the anti-
hH4 receptor antibody, in the contralateral paw skin of CCI-induced neuropathic 
pain rats 
 
           
 
 
 
 
 
 
 
 
Comparing expression of the Mr 39, 000 and Mr 60, 000 rH4R in the plantar paw skin of CCI and saline 
treated rats, probed with anti-hH4 antibody. Immunoreactive bands detected with the anti-H4R 
antibodies were normalized to β-actin. Data show the mean immunoreactive intensity + SD for n = 3 
determinations. Statistical significance was determined through GraphPad Prism, using the Student’s 
T-test from the generated p value, where p<0.05 was considered to show significance. [Sham n=2, 
CCI=4].  
 
Figure 4.19 shows that there were no significant differences in the immunoreactive 
banding of the Mr 39,000 rH4 receptor detected in the CCI rats compared to the 
saline treated sham controls.   
Figure 4.20 shows that there were no significant differences in the immunoreactive 
banding of the Mr 60 000 rH4 receptor detected in the CCI rats compared to the 
saline treated sham controls.   
 
 
 
Figure 4.20 Mean reactive immunointensity of the Mr 
60, 000 rH4R bands detected in the ipsilateral paw skin of 
CCI rats compared to the saline treated sham controls.   
P value=0.3896. 
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Figure 4.19 Mean reactive immunointensity of the Mr 
39, 000 rH4R bands detected in the ipsilateral paw skin of 
CCI rats compared to the saline treated sham controls.   
P value=0.6465. 
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4.4.11 Immunoreactivity of the anti-hH4 (374-390) on lumbar spinal cords obtained 
from CCI –induced neuropathic pain (CCI) rats 
 
 
 
 
 
 
Figure 4.21 Anti-hH4 immunoreactivity with protein extractions from contralateral paw skin of CCI-
induced neuropathic pain and control rats 
Lanes 1-4 represent CCI animals, lanes 5-6 sham animals. Proteins extracted from the contralateral 
and ipsilateral hind paw skin were subjected to immunoblotting and immunoblots probed with the 
anti-hH4 (374-390) receptor at 1µg/ml.  
Approximately 50 µg of protein/ well were loaded onto a 10% separating gel. Once transferred the 
membrane was probed with affinity purified anti-hH4 antibody (1 µg/ml concentration). The antibody 
detects one major species in rat spinal cord at Mr 60,000. Lower panel shows the corresponding β-
actin, probed with monoclonal mouse anti β-actin antibody (1:2000). 
 
Figure 4.21, the anti-hH4 (374-390) was used to probe the rat lumbar spinal cord 
homogenates. The banding detected at Mr 60,000 is consistent with the rH4 receptor 
dimer. The molecular weight corresponding to the monomer was not detected. 
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4.4.12 Mean reactive immunointensity of the Mr 60, 000 rH4R bands detected in 
the lumbar spinal cord of CCI-induced neuropathic pain model  
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Figure 4.22 Comparing expression of the Mr 60, 000 rH4R in the lumbar spinal cord of CCI and saline 
treated rats, probed with anti-hH4 antibody. P value=0.9798. Mean ±SD [Sham n=2, CFA=4].  
Immunoreactive bands detected with the anti-H4R antibodies were normalized to β-actin. Data show 
the mean immunoreactive intensity + SD for n = 3 determinations. Statistical significance was 
determined through GraphPad Prism, using the Student’s T-test from the generated p value, where 
p<0.05 was considered to show significance.  
 
Figure 4.22 shows that there were no significant differences in the immunoreactive 
banding of the Mr 60,000 rH4 receptor detected in the CCI rats compared to the 
saline treated sham controls.   
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4.4.13 Immunoreactivity of the anti-hH4 (374-390) receptor antibody on the sciatic 
nerve obtained from CCI –induced neuropathic pain (CCI) rats 
 
 
                 
                          
 
 
Figure 4.23 Anti-hH4 immunoreactivity with protein extractions from the sciatic nerve of the CCI rats 
Lanes 1-4 represent sciatic nerve samples from the contralateral limb and lanes 5-8 represent the 
sciatic nerve from the ipsilateral limb of CCI-induced neuropathic pain models. Proteins extracted 
from the contralateral and ipsilateral hind paw skin were subjected to immunoblotting and 
immunoblots probed with the anti-hH4 (374-390) receptor at 1µg/ml.  
Approximately 50 µg of protein/ well was loaded onto a 10% separating gel. Once transferred the 
membrane was probed with affinity purified anti-hH4 antibody (1 µg/ml concentration). The antibody 
detects one major band in the rat sciatic nerve at Mr 60,000. Lower panel show the corresponding β-
actin, probed with monoclonal mouse anti β-actin antibody (1:2000). 
Figure 4.23, the anti-hH4 (374-390) was used to probe the rat sciatic nerve 
homogenates. The banding detected at Mr 60,000 is consistent with the rH4 receptor 
dimer, while the monomer was not detected.  
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4.4.14 Mean reactive immunointensity of the Mr 60, 000 rH4R bands detected in 
the sciatic nerve of CCI-induced neuropathic pain model  
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Figure 4.24 Comparing expression of the Mr 60, 000 rH4R in the sciatic nerve of CCI rats, probed with 
anti-hH4 antibody. P value=0.0019. Mean ±SD [contralateral n=4, ipsilateral n=4].  Immunoreactive 
bands detected with the anti-hH4R antibodies were normalized to β-actin. Data show the mean 
immunoreactive intensity + SD for n = 3 determinations. Statistical significance was determined 
through GraphPad Prism, using the Student’s T-test from the generated p value, where p<0.05 was 
considered to show significance 
Figure 4.24 shows that there were significant differences in the immunoreactivity of 
between the sciatic nerve obtained from the contralateral and ipsilateral hind limb 
of the CCI rats. The banding detected at Mr 60,000 which is consistent with the rH4 
dimer was significantly reduced in the ipsilateral sciatic nerve.   
 
 
 
 
 
 
** 
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4.4.15 Summary of results obtained through quantitative immunoblotting of tissue 
from acute inflammatory and neuropathic pain models 
    
Table 4.1 Summary the results obtained regarding H4R expression in the skin and 
spinal cord of the acute inflammatory and neuropathic pain models 
 
 
 
 
 
 
 
 
 
Rat model Acute inflammatory 
pain 
Acute neuropathic 
pain 
Skin  Ipsilateral ↑ ↑ 
Contralateral ↑ - 
Sciatic nerve Ipsilateral - ↓ 
Contralateral - - 
Spinal cord   No change  No change  
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4.5 Discussion  
The histamine H4 receptor was initially reported in bone marrow, spleen, lung and 
small intestine but is largely found on cells of the haematopoietic system such as 
dendritic cells (Damaj et al., 2007, Gutzmer et al., 2005), eosinophils (Barnard et al., 
2008) and mast cells (Oda, 2001) where it mediates chemotaxis (O'Reilly et al., 
2002). Chapter 3 has shown that the H4R is present in the central nervous system, 
leading to the hypothesis of potential role for the H4 receptor in the transmission 
and maintenance of nociception and pain, respectively. H4R expression was analysed 
in the skin from the plantar surface of the hind paw, and lumbar spinal cord. Herein 
we will evaluate H4R expression during acute inflammatory and neuropathic pain. 
Inflammatory pain is the result of inflammatory mediators such as chemokines and 
leukocytes, whereas neuropathic pain is produced by injury to the central nervous 
system including peripheral nerves, dorsal root ganglion, spinal cord or brain 
(Milligan et al., 2003).   
Acute inflammatory pain 
Peripheral administration of Complete Freund’s adjuvant (CFA) creates an 
inflammatory pain model characterised by spontaneous pain, heat hyperalgesia and 
mechanical allodynia (Raghavendra et al., 2004). Consistent with previous data (Chen 
et al., 2012), injection of CFA into the plantar surface of the hind paw, caused a 
significant reduction in the paw withdrawal latency (in seconds) to mechanical 
stimuli during the Hargreaves test. The reduction in paw withdrawal observed in our 
model following CFA administration was unilateral, and is consistent with Complete 
Freund’s adjuvant-induced acute inflammatory pain (Hsieh et al. 2010).  
Quantification of the protein extracted from skin excised from the plantar hind 
surface during the acute phase of inflammation revealed an apparent, non-selective 
increase in H4R expression in acute CFA inflammatory model of pain in both 
ipsilateral and contralateral skin but no change at spinal cord level. CFA induces a 
localised inflammatory reaction and recruitment of neutrophils, activated mast cells, 
Langerhan’s cells and eosinophils. These cells express the H4R which plays a role in 
migration and chemotaxis (Hofstra et al., 2003, Ling et al., 2004). The up-regulation 
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in H4R expression observed in the protein extractions from the skin is possibly due to 
increased recruitment immune cells to the site of inflammation. Dendritic cells 
express the H4R and are recruited to the inflamed site by chemokines in the 
microenvironment. Nerve terminals influence neurogenic inflammation through the 
generation of impulses, which release vasoactive neuropeptides substance P, CGRP 
and histamine at peripheral branches. H4 receptor antagonism was shown to inhibit 
dendritic cell maturation through reduced expression of maturation markers, CD80, 
CD86 and CD40 in treated cells (Lundberga et al., 2011), supporting  H4R 
involvement. In addition, has been observed that H4R levels in monocytes increase 
with the progression of inflammatory stimuli (Dijkstra et al., 2007).  
The changes observed in the contralateral side were unexpected and could be a 
result of a systemic inflammatory response. On the other hand, the response could 
be neurogenic since substance P, CGRP and their receptors have been observed 
within the spinal cord and DRG contralaterally following CFA induced lesions.  The 
contralateral responses seem to require the inﬂammatory stimulus to be of a certain 
magnitude before appearing. For example, adjuvant arthritis in the rat induced with 
intradermal injections of small doses of CFA around the tibiotarsal joint causes 
contralateral arthritis if the dose is increased from 75 to 150 µg (Shenker et al., 
2003). These contralateral changes appear to be topologically precise. Decaris et al 
(1999) placed latex spears in the knee joint before examining the contralateral knee 
and both ankles for cartilage metabolism and histological damage and observed that 
only the contralateral knee showed a decrease in cartilage anabolism and signs of 
histological damage, and these were absent in both ankles (Decaris et al., 1999). This 
implies a neurogenic mechanism rather than systemic effect.   
The contralateral changes are also stimulus-specific (if proinflammatory response is 
induced unilaterally, the contralateral response is proinflammatory) (Shenker et al., 
2003) and are only a fraction of the original lesion. One hypothesized role is that 
contralateral mirror imaging phenomena can up-regulate protective 
proinflammatory responses in the contralateral limb in preparation for an insult that 
has already occurred (Herdegen et al., 1991). Biologically, this could be protective 
mechanism as the inﬂammatory response could be up-regulated and, should a 
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similar noxious insult appear on the contralateral side, then it could be dealt with 
more effectively. 
The anti-hH4R (374-390) was also used to detect changes in H4R expression at the level 
of the spinal cord after acute inflammation. Western blot analysis of whole lumbar 
spinal cord from the acute inflammatory pain model shows no difference in 
expression of spinal H4R in the CFA-treated acute model animals compared to the 
sham treated controls. This shows that inflammatory pain experienced during the 
acute phase may not be mediated by differential expression of the H4R.  
  
Acute neuropathic pain 
Chronic constriction injury was produced by tying constrictive ligatures around the 
sciatic nerve, evoking intraneural oedema. In this model, hyperalgesia was present in 
the whole area of the damaged sciatic territory and neuropathic animals exhibit 
signs of increased mechanical sensitivity at the 4 g threshold. In the rats, chronic 
construction injury of the sciatic nerve produced a decreased in paw withdrawal 
latency to mechanical stimulation 24 hours after injury. The hyperalgesia is 
consistent with the development of mechanical allodynia and withdrawal thresholds 
can remain reduced for up to 38 weeks.  (Lindenlaub and Sommer, 2000). 
The results show that following CCI of the sciatic nerve, there was a selective 
increase in Mr 39 000 rH4 receptor expression in skin from the ipsilateral the hind 
paw. The observed increase in H4R expression in the CCI rats is possibly situated on 
peripheral afferent fibres, as expression was detected in Chapter 3. CCI induces a 
neurogenic inflammatory response, mediated by the release of neuropeptides from 
the nerve endings of antidromically acting nociceptive C fibres. Antidromic activation 
of unmyelinated primary afferents C-fibres produces the physiological characteristics 
of inflammation including plasma extravasation, vasodilatation and sensitisation of 
nociceptors (Levine et al., 1990). 
Peripheral afferents are sensitised by the inflammatory mediators released from 
leukocytes which accumulate around the lesion of the injured peripheral nerve, 
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thereby contributing to the generation of neuropathic pain (Perkins and Tracey, 
2000). Neutrophils transmigrate through the perineurium 2 mm proximally and 
distally to the injury (Perkins and Tracey, 2000). Several mediators attract and 
activate neutrophils at the site of injury including nerve growth factor, which is 
involved in both inflammatory and peripheral neuropathic hyperalgesia and 
leukotreine B4 (Jankowski and Koerber, 2010). Neutrophils release  prostaglandins 
which sensitize primary nociceptive afferents and contribute to nerve injury 
associated hyperalgesia (Syriatowicz et al., 1999). 
The anti-hH4 antibody detected the expression of the Mr 60,000 rH4 receptor dimer 
in the sciatic nerve, which innervates nearly the whole skin of the lower limbs, 
muscles, biceps femoris, feet and legs. Quantitative analysis detected a selective 
reduction in the expression of the Mr 60,000 H4 receptor in the ipsilateral sciatic 
nerve compared to the contralateral.  Previous data from this model (Bennett and 
Xie, 1988) showed extensive demyelination and reduction in the diameter of the 
sciatic nerve 24 hours following surgery.  The nerve damage produced in this model 
is due to chronic compression, a consequence of intraneural oedema, which is 
subsequent to partial occlusion of the nerve’s vasculature. The force of the oedema 
opposes the ligature beneath, causing the nerve to self-strangulate (Bennett and Xie, 
1988). Mast cells that reside in the nerve degranulate at the site of injury, releasing 
algesic mediators such as histamine, prostaglandins and pro-inflammatory cytokines 
like TNFα (Wagner and Myers, 1996) and IL-1 (Sommer et al., 1999) which contribute 
to neuropathic pain behaviour.  
Following CCI-induced neuropathic pain there is no change in expression of the H4 
receptor in the whole spinal cord between the two groups. However, nerve injury 
causes changes in spinal cord neuropeptide expression. The selective loss of non-
peptidergic IB4 positive nociceptive afferents in the dorsal horn has been observed 
following peripheral nerve injury (Kim and Moalem-Taylor, 2011, Bailey and Ribeiro-
da-Silva, 2006) and denotes substantial damage to non-peptidergic C-fibre 
nociceptor terminals entering the spinal cord. CGRP expression remains unchanged 
in the dorsal horn up to 70 days following sciatic nerve ligation (Bailey and Ribeiro-
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da-Silva, 2006). Substance P produces thermal hyperalgesia and expression is initially 
enhanced in the DRG following sciatic nerve injury (Xu et al., 1996).  
We have shown that the H4R is differentially expressed in these models of acute 
inflammatory and neuropathic pain.  There is an apparent non-selective increase in 
expression in acute CFA inflammatory model of pain in both ipsilateral and 
contralateral skin. This could be a result of the systemic effect of inflammatory cells. 
However, no changes in H4R expression are observed in the spinal cord. Changes in 
receptor expression or function can occur in the chronic phase of inflammatory pain. 
Data obtained from our laboratory (Chaffey et al. unpublished) demonstrated that 
the presence of chronic pain in the CFA-induced inflammatory pain model was as 
due, in part, to up-regulated phosphorylation of the NMDA NR2B subunit. This was 
observed in the dorsal horn of the lumbar cord (Chaffey et al.), showing enhanced 
receptor activity at the site of afferent neuron entry into the spinal cord, where 
nociceptive afferents from the injured paw synapse with dorsal horn neurons. On 
the other hand, in the CCI model, there is a selective increase in H4R expression at 
ipsilateral skin level but not in the contralateral. A reduction in H4R expression in 
sciatic nerve ipsilateral versus contralateral is also observed, but no change at the 
level of spinal cord.  This provides evidence for the potential functional role of 
histamine acting via the H4R in pain. The peripheral and central localisation of the H4 
receptor makes it a possible therapeutic target for the amelioration of inflammatory 
pain processes.  
These results further the understanding of H4R expression in acute inflammatory and 
neuropathic pain conditions. The selective H4 receptor antagonist JNJ 7777120 was 
shown to readily permeate through the BBB and exert analgesic effects on several 
animal models of inflammatory and neuropathic pain (Hsieh et al., 2010a). Examples 
of the in vivo inflammatory pain models used include the carrageenan-induced acute 
inflammation, complete Freund’s adjuvant-induced chronic inflammation, zymosan-
induced peritonitis (Takeshita et al., 2003) and the knee-joint osteoarthritic model.  
Similarly, Hsieh et al. (2010) provided the first evidence showing the effectiveness of 
JNJ 7777120 as an analgesic in the reduction of CCI- induced neuropathic pain in 
animal models. The anti-nociceptive effects of the H4R antagonists could be 
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secondary to the anti-inflammatory actions of the antagonists. It is possible that the 
acute phase of inflammatory pain is mediated by influx of inflammatory leukocytes 
which release mediators of hyperalgesia.  
In Chapter 5, we investigate the effects of H4 receptor antagonism using the 
antagonist compound JNJ 7777120, on a murine model of experimental autoimmune 
encephalomyelitis. Current literature shows that the histamine H4 receptor has a 
primary role in inflammatory functions, making it an attractive therapeutic target 
and the discovery of JNJ 7777120 as a selective and potent antagonist made it 
possible to elucidate some of the roles of the H4 receptor in inflammatory processes 
(Thurmond et al., 2008a).  
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Chapter 5 
The role of histamine H4 receptor in Experimental Autoimmune encephalomyelitis 
(EAE) 
5.1 Objectives  
To elucidate the effects of histamine H4 receptor antagonism with JNJ 7777120 on 
several parameters of the murine model of MOG35-55 induced experimental 
autoimmune encephalomyelitis.  
5.1.1 Introduction  
In Chapter 4, we have shown the changes in H4R expression in different 
inflammatory and neuropathic pain states, which indicated that antagonism of the 
receptor, may have beneficial therapeutic effects. Multiple Sclerosis (MS) is a chronic 
multicentric inflammatory, demyelinating disease of the CNS. Clinically, MS 
manifests with fatigue and disturbed function in the sensory, motor, bladder and 
bowel, cerebella, brainstem, optic nerves and cognitive realms. Morphologically, it is 
characterised by inflammation, demyelination, axonal loss and gliosis. The 
inflammatory lesions are characterized by high infiltration of various populations of 
cellular and soluble mediators of the immune system, such as T-and B cells and 
microglia (Moore and Esiri, 2011). Several models of CNS demyelinating disease exist 
but the most commonly used model is the Experimental Allergic Encephalomyelitis 
(EAE). This is induced by subcutaneous immunisation with myelin antigens 
emulsified in adjuvant, or adoptive transfer of encephalitogenic T cells into 
susceptible animals mainly mice (Stromnes and Goverman, 2006). In the majority of 
EAE susceptible rodent strains, disease presents clinically as ascending flaccid 
paralysis beginning with a limp tail and progressing to the hind and forelimbs 
(Stromnes and Goverman, 2006). This is referred to as “classic” EAE. The clinical signs 
observed in classic EAE reflect inflammation localised predominantly in the spinal 
cord (Robinson et al., 2010). Central neuropathic pain is a frequent symptom 
accompanying MS and pain syndromes include musculoskeletal pain, painful spasms, 
trigeminal neuralgia and central pain caused by sclerotic plaques (O'Connor et al., 
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2008, Truini et al., 2012). However, pain is not present in all MS patients and the 
reasons for this are unknown. One theory suggests that a lesion in the CNS may 
result into a state of hyperexcitability and spinal cord injury (SCI) has been shown to 
increase spontaneous neuronal activity at the site of injury (Zeilig et al., 2012). Some 
studies in SCI indicate that lesion of the spinothalamic tract is necessary for the 
development of central pain whereas others have failed to find any difference in 
spinothalamic function between pain-free and patients with central pain.  A study by 
Svendsen et al. reported that MS patients with pain frequently presented with cold 
allodynia and lower threshold for mechanical pressure than pain-free patients 
(Svendsen et al., 2005).  These findings reflect a degree of hyperexcitability possibly 
caused by lesions of descending inhibiting pathways of the CNS or decreased sensory 
input to second or third order neurons (Davies et al., 1983). 
 
Sensory processing is significantly affected during MS as a result of axonal 
demyelination. Although neuronal degeneration is mainly found in demyelinating 
lesions and correlates with degree of inflammation, there is evidence for immune-
mediated damage in the absence of directly co-localised active demyelinating 
process (DeLuca et al., 2006). Analysis of sensory neuropeptides in previous studies 
showed that CGRP expression is increased in the epidermal nerve fibres and 
keratinocytes of Theiler’s Murine Encephalomyelitis Virus MS model. Theiler’s virus 
induces in susceptible mice, an acute disease resembling encephalomyelitis followed 
by chronic demyelinating disease (Oleszak et al., 2004). In contrast, evaluation of 
CGRP expression in the dorsal horn of MOG35-55 induced EAE did not reveal any 
significant changes in expression between the EAE animals and CFA-treated controls 
(Olechowski et al., 2009).  
 
Microglia, referred to as macrophages of the CNS represent 12% of the cells present 
in the CNS. Their functions include phagocytosis, antigen presentation and 
production of cytokines. Microglia also produce excitatory amino acids such as 
glutamate, oxidative radicals and nitric oxide (Banati et al., 1993). Treatments that 
target glial cell metabolism and inhibit activation and proliferation of astrocytes and 
microglia have proven effective at preventing, or reversing neuropathic pain 
 
 
133 
 
behaviour in animal models of spinal cord and peripheral nerve injury (Hains and 
Waxman, 2006). Three states of microglia have been identified based on 
development and pathology (Luo and Chen, 2012); first, the resting and ramified 
microglia present in the healthy CNS. Secondly, the activated, non-phagocytic 
microglia found in areas involved in CNS inflammation and thirdly, the reactive, 
phagocytic microglia observed in areas of trauma and infection (Banati et al., 1993).  
In EAE, changes in glial cell reactivity within the superficial dorsal horn of the spinal 
cord correlate with the development of cold and tactile allodynia (Olechowski et al., 
2009). 
Histamine has been implicated in the pathogenesis of both MS and EAE (Jadidi-
Niaragh and Mirshafiey, 2010). Upon release from mast cells, it modulates blood 
brain barrier permeability thereby enhancing leukocyte rolling, adhesion and 
extravasation of inflammatory cells into the CNS (Abbott, 2000). Tissue levels of 
histamine correlate with the onset of EAE (Ichigi, 1999) and increased concentrations 
of histamine in cerebral spinal fluid correlate with relapses in MS patients (Tuomisto 
L., 1983). Research shows that inhibitors of mast cell degranulation as well as 
sedating H1 antagonists modify MS severity and a small study showed that, patients 
treated with H1 antagonists remained stable or improved neurologically (Longothetis 
L.I., 2005). Genetic studies show that histamine and H1, H2 and H3R play important 
roles in disease progression and EAE susceptibility either by regulating antigen 
presenting cell (APC) function, the encephalitogenic T cell responses and BBB 
permeability (Ma, 2002, Musio, 2006).  
However the role of the H4 receptor in autoimmune inflammatory demyelinating 
disease of the CNS is yet to be elucidated. To assess the role of H4 receptor signalling 
in the regulation of autoimmune inflammatory demyelinating disease of the CNS, we 
studied the effect of the selective H4 receptor antagonist JNJ 7777120 on MOG35-55 
induced EAE severity. This chapter will look at the effects of JNJ 7777120 treatment 
on the expression of the H4R on lymphocytes infiltration into the spinal cord, T cell, 
microglial, neuronal expression and correlation to disease severity.  
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5.2 Methods 
This chapter summaries a collaborative study performed in collaboration with 
Professor Beatrice Passani (University of Florence), including an STSM (COST Action 
BM0806) spent in Florence during the PhD period. 
5.2.1 Experimental animals   
All animal manipulations were performed according to the European Community 
guidelines for animal care (DL 116/92, application of the European Communities 
Council Directive 86/609/EEC) and approved by the Committee for Animal Care and 
Experimental Use of the Universita’ di Firenze (I). All studies involving animals are 
reported in accordance with the ARRIVE guidelines for reporting experiments 
involving animals (McGrath et al., 2010). A total of 38 Female C57BL/6 mice were 
used for immunization experiments. Mice were randomly assigned to standard 
cages, with four to five animals per cage, and kept at standard housing conditions 
with a light/dark cycle of 12 hrs (8.00-20.00) and free access to food and water. 
A total of sixteen 6-8 week old female C57BL/6J mice were used weighing 16-20 g. 
The mice were purchased from the Jackson Laboratory (Bar harbour) and were 
housed in standard laboratory cages and had free access to food and water 
throughout the study period. The experimental procedures were under the 
guidelines of the Animal Care and Use Committees of the University of Florence 
(Italy). These sets of procedures were performed in Professor Passani’s laboratory  
5.2.2 Induction and evaluation of EAE 
These sets of procedures were performed by Professor Passani’s laboratory.  
C57Bl/6 female mice, 6–8 weeks of age were obtained from Harlan, Italy, Srl. (Milan, 
Italy). The mice were housed in macrolon cages on a 12 hour light/dark cycle at 23 °C 
room temperature (RT), with ad libitum access to food and water. Adequate 
measures were taken to minimize pain or discomfort. Mice were immunized 
subcutaneously (s.c.) in the flanks and at the base of the tail with a total of 200 μg of 
MOG35–55 (synthesized by EspiKem Srl., Universita’ di Firenze, Italy) per animal 
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emulsified in complete Freund adjuvant (Sigma, Milan, Italy) supplemented with 
4 mg/ml of Mycobacterium tuberculosis (strain H37Ra; Difco Laboratories, Detroit, 
Michigan, USA). Immediately thereafter, and again 48 hours later, the mice received 
an intraperitoneal (i.p.) injection of 500 ng pertussis toxin (Sigma, Milan, Italy) in 
100 μl phosphate buffer saline (PBS). The animals were examined daily for weight 
loss and disability, and were clinically graded by investigators blind to group identity, 
as follows: zero indicates no signs; 0.5, partial loss of tail tonicity; 1, paralyzed tail; 2, 
ataxia and difficulty in righting; 3, paralysis of the hind limbs and/or paresis of the 
forelimbs; 4, tetraparalysis; 5, moribund or death.  
5.2.3 Pharmacological treatments 
The H4 receptor antagonist JNJ 7777120 (Johnson & Johnson, San Diego USA) was 
dissolved in 1% ethanol in physiological saline to give the final dose of 10 mg/kg in 
100 µl per mouse. JNJ 7777120 or vehicle was administered by daily intraperitoneal 
(i.p.) injections for 10 days commencing at D10 post-immunisation and observations 
for pathology were made for the entire duration of the disease.  Mice were 
randomly assigned to 2 different experimental groups. The mice received daily 
injections of either JNJ 7777120 or vehicle beginning at D10 p.i. and were sacrificed 
at D28 p.i. 
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5.2.4 Clinical grading of mice with classical EAE  
These sets of procedures were performed in Professor Passani’s laboratory.  
The clinical severity of classic EAE is typically scored using a grading scale of 0-5 
outlined in table 5.1. Despite the use of genetically identical mice, variability in day 
of onset and severity of EAE among individual animals in the same experimental 
group has been obvserved. The reasons for this variability are unknown. The disease 
course in EAE experiments is reported in literature by depicting the mean clinical 
score of an entire group over time (Stromnes and Goverman, 2006). 
 
Table 5.1 Outline of the guidelines used to grade the pathological progression of clinical EAE. Adapted 
from (Stromnes and Goverman, 2006). 
 
Grade  Clinical sign  Observation  
0 No clinical signs Extended hind legs; tail extends up and moves, wraps around 
cylindrical object; normal gait 
1.5 Partially limp tail Extended hind legs; tip of tail droops, does not wrap around 
cylindrical object; normal gait 
1 Paralysed tail Extended hind legs; tail droops, does not wrap around 
cylindrical object; normal gait 
2 Loss of coordinated movement; 
hind limb paresis 
Hind legs contract when held at the base of the tail; 
uncoordinated movement; hind limbs reflex when toes are 
pinched; limp tail 
2.5 One hind limb paralysed  Mouse drags one hind limb; one hind limbs does not respond 
to tail pinch; limp tail 
3 Both hind limbs paralysed  Mouse drags both hind limbs; both hind limbs do not respond 
to toe pinch; limp tail 
3.5  Hind limbs paralysed; weakness in 
forelimbs 
Mouse drags hind limbs with difficulty using forelimbs to pull 
body; forelimbs respond to toe pinch; limp tail 
4 Forelimbs paralysed Mouse cannot move; forelimbs do not respond to toe pinch, 
limp tail 
5 Moribund  No movement; cold to the touch, altered breathing 
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5.2.5 Determination of serum antibodies by enzyme-linked immunosorbent assay 
(ELISA) 
Serum was obtained from three animals in each treatment group at D28 p.i. five 
serum dilutions ranging from 1:50 to 1:2500 were distributed onto polystyrene ELISA 
plates pre-coated with MOG35-55 peptide in order to obtain a titration curve. Serum 
from non-immunised mice age and gender matched was distributed as control 
samples. Bound antibodies were revealed with goat anti-mouse IgM+IgG+IgA (H+L) 
immunoglobulin conjugated to alkaline phosphate and p-nitrophenyl phosphate as 
substrate. Absorbance was measured at 405 nm. Results are reported as optical 
density (O.D) 
5.2.6 Cell isolation  
These sets of procedures were performed in Professor Passani’s laboratory.  
Cells were isolated from lymph nodes, spleen and spinal cord and analysed for 
proliferative response and phenotype as previously described (Gourdain et al., 
2012). Lymphocytes from MOG35-55-immunized mice treated or not were cultured in 
complete Rosewell Park Memorail Institute media (RPMI) in 96 wells plates (2x105 
cells/well) and stimulated with antigen  at day 3, and the proliferative response was 
measured by [3H] thymidine incorporation test after 48 hours as described above 
(Luccarini et al., 2008). To determine mononuclear cell phenotype, surface markers 
have been evaluated by means of anti-mouse conjugated monoclonal antibodies 
[CD4 (AlexaFluor 488), IFN-γ (PerCP-Cy5.5), anti-rabbit H4 receptor antibodies 
(Lethbridge and Chazot, 2010a), revealed with anti-rabbit Alexafluor-488 secondary 
antibodies/Cy3 secondary antibodies, CD11c (PerCpCy5), CD11b(PE), CD3 (PE) from 
AbCam (Cambridge, UK), BioLegend and eBioscience (both San Diego CA, USA), 
respectively. Cells were analyzed on a four-color Epics XL cytometer (Expo32 
software; Beckman Coulter). Cell viability was tested by means of propidium iodide 
or 7-actinomycin staining (Molecular Probes). Staining was performed in PBS 1% FCS 
for 25 min at 4°C followed by two washes. Later on, cells were analyzed by flow 
cytometry. 
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5.2.7 Cytokine determination assay  
This procedure was performed in Professor Beatrice Passani at the University of 
Florence.  
Cells isolated from the draining lymph nodes at D18 p.i were cultured at 1x106 
cells/well in a 48-well plate with phytohemagglutinin (PHA, 5 µg/ml, SIGMA Aldrich) 
or MOG35–55 (2 µg/ml, EspiKem Srl., Universita’ di Firenze, Italy); supernatants were 
collected after 48 hours and evaluated by ELISA for cytokine contents (IFN-γ, IL-6 and 
IL-10). For IL-4 determination, samples were collected after 5 days. All ELISAs were 
performed with ELISA Ready-SET-Go! (eBioscience)  
 
5.2.8 Histology  
This procedure was performed in Professor Beatrice Passani at the University of 
Florence.  
At the time of sacrifice, the mice were anesthetized with pentobarbital (65 mg/kg, 
i.p.) The spinal cord was removed from the column and fixed in 4% (v/v) 
paraformaldehyde in PBS for 48 hours.  The spinal cord samples were dehydrated 
through a series of ethanol changes from 70%, 80%, 95% and 100% with 2 changes at 
each concentration and left in the ethanol for 1 hour each time. This was followed by 
3 xylene changes of 1 hour each time and then 2 paraffin wax changes of 1.5 hours 
at 56-580C. The final step was embedding the tissue in molten paraffin molds until 
the paraffin solidified. 
5 µm slices were cut using a microtome and then placed in a heated water bath to 
unravel the slices. These were removed and mounted onto glass slides. The sections 
were dried overnight at 370C as lower baking temperatures are better for 
subsequent antibody detection. Once dry, the glass slides were put in a slide box and 
stored at room temperature. To rehydrate the paraffin sections for subsequent 
methods (paraffin to water), the sections were put through 2, 3 minute changes of 
xylene followed by a descending series of ethanol changes (i.e. 100%, 90%, 70%) for 
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3 minutes each and then rinsed in distilled water for 5 minutes. Serial sections were 
stained with haematoxylin and eosin (H&E), Luxol Fast Blue (LFB)-cresyl violet 
 
5.2.9 Immunofluorescence  
Following rehydration, the glass mounted paraffin embedded sections were treated 
with 10% (v/v) methanol and 3% (v/v) hydrogen peroxide in 50 nM TBS, pH 7.4 for 30 
minutes to quench endogenous peroxidase activity. The sections were then given 3, 
5 minute washes in 0.2% triton x-100 (v/v) TBS solution. Sections were incubated in 
TBS, 0.2% (w/v) glycine to mop up residual unreacted aldehyde groups from the 
fixative. Non-specific binding sites in the tissue were blocked by incubating with 
donkey/horse serum (10% v/v) in TBS/triton x-100 (0.2% v/v/) for 60 minutes at 
room temperature. Sections were then incubated overnight at 40C in anti-mouse H4 
antibody at a final concentration of 1 μg/ml in donkey serum/TBS (1% serum, v/v).  
Following overnight incubation, the sections were given 3 5 minute washes in 
TBS/triton x-100 (0.2% v/v/) before a 2 hour incubation in a fluorescent secondary 
antibody (1:500 dilution) in 1% serum and TBS pH7.4. After the second incubation 
the slides were given 3, 5 minute washes in TBS/triton x-100 (0.2% v/v/), left to air 
dry in the dark, mounted with DPX mounting solution and stored in the freezer 
before or after microscopy. The majority of these studies were performed in the 
University of Durham. 
 
5.2.10 Data analysis and statistics 
Statistical analyses were performed using GraphPad Prism version 5 (San Diego, CA, 
USA). Mean and SEM were calculated for illustration in figures. For each animal, the 
onset day was recorded as the day post immunization (D) when the first clinical 
manifestations appeared (score > 0). Differences between groups were tested by 
Mann–Whitney test, for their score course. Significant differences between controls 
and JNJ 7777120 treated-mice were established using the Student's t-test for the day 
of onset and of maximum score. Comparisons of parameters such as cytokines, cell 
proliferation and phenotypes, MOG antibodies were performed using the unpaired 
 
 
140 
 
Student’s t-test. In all cases, p values less than 0.05 were considered statistically 
significant.  
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5.3 Results 
5.3.1 Exacerbation of Experimental Autoimmune Encephalomyelitis in mice treated 
with JNJ 7777120 compared to saline treated controls. 
  
 
            
 
 
Fig 5.1 Clinical progression of disease was observed in the saline and JNJ 7777120 treated mice.  
Increase in the clinical score is proportional with a worse pathological state in the 
EAE mice. Disease onset was similar in the two groups with symptoms of EAE 
becoming apparent approximately D11 p.i. Clinical scores begun diverging at D15 p.i. 
after initial onset of disease EAE mice treated with JNJ 7777120 gave a higher clinical 
score, compared to the saline treated EAE controls. Data is according to maximal 
clinical score achieved at any time during the experiment. P<0.05 by Mann-Whitney 
(n=6-8/group).  
 
 
 
 
Time (d) post immunisation  
Clinical 
score 
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5.3.2 Immunohistochemical assessment of spinal cord pathology in the saline and 
JNJ 7777120 treated EAE mice 
The level of inflammatory infiltrates was assessed immunohistochemically through 
the use of haematoxylin and eosin. 
                            
 
 
 
 
 
 
 
 
 
 
Fig 5.2a EAE was induced in C57/Bl6 mice with MOG35-55 (100 µg s.c. and PTX 500 ng i.v.) on days 1 
and 3.   
The two panels show lumbar spinal cord sections stained with haematoxylin and 
eosin. This shows infiltration of autoreactive immune cells within the spinal cord. JNJ 
7777120 treated mice had visually more infiltrates than saline-treated control mice 
with the arrows pointing to clusters of infiltrating immune cells. This is 
representative data from three experiments. 
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Demyelination was observed through the use of luxol fast blue staining  
 
 
 
    
 
  
 
 
 
 
 
 
Fig 5.2b EAE was induced in C57/Bl6 mice with MOG35-55 (100 µg s.c. and PTX 500 ng i.v.) on days 1 
and 3.   
Luxol fast blue (LFB) staining was used to visually assess the degree of myelin loss in 
the lumbar sections of the spinal cord. LFB staining revealed larger plaques of 
demyelination at the sites of inflammatory infiltrates in the spinal cord of JNJ 
7777120, compared to saline treated EAE mice show more clusters of inflammatory 
infiltrates in the dorsal spinal cord compared to the untreated EAE controls [asterix]. 
This is representative data from three experiments. 
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5.3.3 Evaluation of astrocyte activation in the lumbar spinal cord of JNJ 7777120 
treated EAE and saline treated control mice 
 
             
 
            
 
 
Fig 5.3 Immunofluorescence labelling of the lumbar spinal cord from saline and JNJ 7777120 treated 
EAE mice.  The lumbar spinal cord sections have been labelled with the anti-GFAP antibodies (red) an 
intermediate filament protein expressed in astrocytes and NeuN (green) a marker for neurons. The 
nucleus has been stained with DAPI (blue). This is representative data from three experiments. 
In the saline treated EAE mice, a small number of hypertrophic astrocytes were 
observed.  In JNJ 7777120 treated mice, an intense glial activation with cells stained 
for GFAP with enlarged cells bodies and long processes was observed.  The results 
show an increased presence of activated astrocytes with outwardly extending 
processes in the in JNJ 7777120 treated EAE mice [B] compared to the saline treated 
EAE control mice [A]. 
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5.3.4 Effect of the H4R antagonist JNJ 7777120 on microglia activation in the spinal 
cord of EAE mice 
 
 
 
Fig 5.4 Immunofluorescence labelling of the lumbar spinal cord from saline treated EAE controls.  
A shows a magnified section of the ventral median fissure of the lumbar spinal cord. B sections were 
double labelled with anti-Iba1 antibodies (green) to detect macrophages and microglia, and C anti-
IFNγ antibodies (red) and counterstained with DAPI (blue). Sections were visualised with 20x and 40x 
lenses. D superimposed image of B and C. This is representative data from at least three experiments. 
The presence of IFNγ+ activated microglia in the spinal cord of the saline treated 
control EAE mice is undetectable, as represented by the lack of staining. 
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5.3.5 Effect of the H4R antagonist JNJ 7777120 on microglia activation in the spinal 
cord of EAE mice 
             
             
Fig 5.5 Effect of JNJ 7777120 on microglia activation in the spinal cord of EAE mice 
A shows a magnified section of the ventral median fissure of the lumbar spinal cord. B sections were 
double labelled with anti-Iba1 antibodies (green) to detect macrophages and microglia, and C anti-
IFNγ antibodies (red) and counterstained with DAPI (blue). Sections were visualised with 20x and 40x 
lenses. D superimposed image of B and C.  All experiments were performed on mice D28 p.i. with 
comparable scores (<2.0). This is representative data from three experiments. 
The results show increased microglia activation through intense staining with Iba1, 
which is up-regulated during activation of macrophages and microglia. IFNγ+ staining 
is representative of activated macrophages. There is increased macrophage and 
microglia activation in JNJ 7777120 treated mice compared to the saline treated EAE 
controls. 
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5.3.6 Expression of calcitonin gene-related peptide in the lumbar spinal cord of the 
saline and JNJ 7777120 treated EAE mice. 
Expression of the neuropeptide CGRP between the saline and JNJ 7777120 treated 
EAE mice was assessed immunohistochemically through the use of the antibody for 
CGRP. 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
Figure 5.6 shows lumbar spinal cord sections stained with anti-CGRP antibodies 
saline treated (A) and JNJ 7777120 treated (B) EAE animals taken from the acute 
phase of the disease. CGRP is significantly upregulated in the superficial lamina of 
the JNJ 7777120 treated EAE mice [Control n=4, JNJ 7777120 n=4]. 
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Fig 5.6 Expression of CGRP in the 
superficial lamina of the dorsal horn in 
MOG35-55 EAE of saline treated controls 
[A] and JNJ 7777120 [B] treated EAE mice. 
[C] Mean reactive immunointensity of the 
CGRP positive neurons detected in the 
dorsal horn of the spinal cord.   
P value =0.0407 
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The optical density of immunoreactivity was examined specifically in a region that 
encompassed the superficial lamina (I-II) of the dorsal horn. The level of background 
staining was determined for each section and subtracted for all optical density 
measurements using ImageJ software. Statistical analysis was carried out using 
GraphPad Prism, using the Student’s t-test and significance was set at p<0.05.  
 
5.3.7 Effect of JNJ 7777120 on in vitro anti-MOG35-55 serum concentration  
 
                        
 
Fig 5.7 Anti-MOG35-55 concentrations were measured in the serum of EAE D28 days p.i. JNJ 7777120 
was injected i.p. daily at a dose of 10 mg/kg. Controls received an equivalent volume (100 µl) of 
saline. (n=3 per group) 
Anti-MOG35-55 titration curves were comparable between the control and JNJ 
7777120 treat EAE mice. This signifies that there were no differences in antibody 
production in the sera of the EAE mice.     
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5.3.8 Effect of JNJ 7777120 on the in vitro proliferative reponse of lyphocytes and 
splenocytes  from EAE mice, in the presence of MOG35-55            
Lymphocytes [A] and splenocytes [B] were isolated, plated at 2 x10 5 cells/well and 
incubated with MOG35-55 at the indicated concentrations for 72 hours in the presence 
of 3[H] Thymidine for 12 hours. (n=3 per group)  
        
                                                                                                                        
 
           
Fig. 5.8 Proliferative response of lymphocytes [A] and splenocytes [B] in the presence of MOG35-55 
peptide 
In vitro proliferation of lymphocytes and splenocytes isolated at D28 p.i. were 
incubated for 72 hours with two doses of MOG35-55. Incorporation of
 3[H] Thymidine 
was used to measure the rate of lymphocyte and splenocyte T cell proliferation 
during the last 12 hours of culture.   
There was no significant difference in lymphocyte proliferation between isolates 
from untreated EAE and JNJ 7777120 treated mice in the presence of MOG 35-55 at 
the indicated concentrations. Therefore, the differences in disease score were not 
due to differences in T cell proliferative responses against the immunising antigen or 
T cell antigen-presenting cell migration in lymph nodes of the EAE mice. 
Cell proliferation statistical analysis was carried out using GraphPad Prism, using the 
Student’s t-test and significance was set at p<0.005. 
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 5.3.9 Effect of JNJ 7777120 on the in vitro cytokine concentrations in the lymph 
nodes of MOG35-55 immunised mice 
                                                                                                                                                                                                           
                                                                               
 
Fig. 5.9 Cytokine production in the lymph nodes in response to MOG35-55 peptide and 
phytohaemagglutinin (PHA). 
JNJ 7777120 treatment significantly increased IFNγ (p=0.01) release in the lymph 
node cells compared to controls, where as significantly less IL-4 (0.042) was released 
in the supernatants of LN cells. No significant differences were observed in IL-6 and 
IL-10 production (p=0.13).  
ELISA determination of  IFNγ, IL-6, IL-10 and IL-4 in the supernatants of Lymph node 
cells isolated at D18 p.i. Cells were cultured at 2.5 million cells /well in 24 well plates 
for 72 hours in the presence of MOG35-55 (50 µg/ml) or Phytohaemagglutinin (PHA) (5 
µg/ml) and then tested for the presence of IFNγ, IL-4, IL-10 and IL-6. (n=3 for control, 
n=5 for JNJ 7777120 treated mice). 
 
Analysis of in vitro cytokine concentrations in the lymph node cells was performed 
using the unpaired Student’s t-test, where P <0.05 was considered statistically 
significant.  
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5.3.10 Effect of JNJ 7777120 on the in vitro cytokine concentrations in the 
splenocytes of MOG35-55 immunised mice 
 
 
       
 
 
 
 
 
 
 
 
 
 
Fig 5.10 Cytokine production in the splenocytes in response to MOG35-55 peptide 
IFNγ and IL-6 concentrations were equivalent in JNJ 7777120 treated and saline 
treated EAE control mice. IL-4 concentrations were low in both treatment groups. 
However JNJ 7777120 treatment reduced production of IL-10. 
Splenocytes from EAE controls and JNJ 7777120 treated EAE mice were cultured at 
2.5 million/well in a 24 well plates for 72 hours in the presence of MOG35-55 
(50µg/ml). Supernatant were collected after 72 hours and tested by ELISA for the 
presence of cytokines. (n=3 per group).  
Analysis of in vitro cytokine concentrations in the splenocytes was performed using 
the unpaired Student’s t-test where p values ≤0.05 were considered statistically 
significant.  
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5.3.11 Effect of JNJ 7777120 on in vivo profile of CD4+ T lymphocytes infiltrating the 
spinal cord of EAE mice  
 
                              
 
 
Fig 5.11 The frequency of T cell mononculeaocytes (MNC) was determined in the spinal cord of the 
saline and JNJ 7777120 treated mice  
Analysis of T lymphocytes infiltrating the spinal cord of the EAE mice revealed the 
presence of H4 receptor positive cells, CD11c dendritic cells and macrophages. An 
increase in CD4+ H4R
+ T cells in JNJ 7777120 treated mice was observed, although not 
statistically significant. Comparisons of parameters between T cell frequencies were 
performed using the unpaired Student’s t-test. In all cases, p values ≤0.05 were 
considered statistically significant.  
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5.4 Discussion 
Histamine has been implicated in the pathogenesis of inflammatory autoimmune 
diseases of the CNS such as MS and its animal model, EAE (Jadidi-Niaragh and 
Mirshafiey, 2010) and the H1, H2 and H3 receptors have been shown to be involved in 
susceptibility to EAE. The recently discovered H4 receptor is mainly expressed on 
haematopoietic cells and is postulated to have an immunomodulatory function 
during allergic conditions and inflammation (Thurmond et al., 2008b). Clinical 
symptoms of MS include sensory disturbances, optic neuritis, diplopia, limb 
weakness, clumsiness, gait ataxia, neurogenic bladder, bowel symptom and also pain 
(Svendsen et al., 2005). Pain in MS can be ascribed to various conditions including 
musculoskeletal pain, tonic spasms and chronic neuropathic pain that results from 
sclerotic plaque lesions affecting sensory pathways (Truini et al., 2012). So far, the 
mechanisms underlying pain in MS remain unclear and its treatment remains 
difficult.   
EAE is used extensively as an animal model of human demyelinating disease and is 
induced by subcutaneous immunisation with myelin antigens emulsified in adjuvant 
or adoptive transfer of encephalitogenic T cells into susceptible animals, mainly mice 
(Stromnes and Goverman, 2006). Histamine and mast cell degranulating agents that 
cause its release have been shown to alter the permeability of the BBB. First 
generation antihistamines with the ability to cross the BBB are associated with 
reduced MS risk. For example, patients treated with the H1 receptor antagonist 
hydroxyzine were shown to remain stable or display improved neurological condition 
(Logothetis et al., 2005) and was shown to inhibit EAE and activation of brain mast 
cells (Dimitriadou et al., 2000). In the EAE model, increased histamine levels within 
the cerebral spinal fluid correlate with onset of disease and severity, which are 
reduced by H1 receptor antagonists (Orr and Stanley, 1989). The day of onset of 
clinical signs varies depending on the model but is usually between days 9 and 14 
days post-immunisation. The clinical features of acute fatal EAE in the commonly 
studied species include tail weakness and paralysis followed by hind limb weakness 
and sometimes paralysis. Forelimb weakness occasionally occurs (Stromnes and 
Goverman, 2006). 
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In our model, the severity of the MOG35-55-induced EAE was assessed daily using a 
previously validated scale (Stromnes et al., 2004). The clinical symptoms of EAE in 
the mice manifested at day 10 and peaked at day 16 post-immunisation in the saline 
treated EAE control mice; whereas the clinical severity peaked 20 days post-
immunisation in the JNJ 7777120 treated EAE mice. JNJ 7777120 has been used 
effectively in a variety of animal models of inflammatory disease (Coruzzi et al., 
2007, Coruzzi et al., 2012)  and has been the reference antagonist of choice to study 
the H4 receptor. Although it has a reasonable bioavailability (30%) (Thurmond et al., 
2004a), this compound has a short in vivo half-life and therefore, during the course 
of this study the assumption was made that repeated dosing was needed to maintain 
a therapeutically effective plasma concentration. In contrast to the hypothesis, JNJ 
7777120, an antagonist at the human H4 receptor appeared to exert agonist 
properties at the mouse H4 receptor by increasing and extending the severity of the 
disease. JNJ 7777120 treated mice displayed a worse disease phenotype compared 
to the saline-treated group. However, the clinical score of the saline treated EAE 
controls began to reduce at 17 days post-immunisation and this is consistent with 
the rapid neurological recovery and this has been previously reported (Pender, 
1989). In contrast, the clinical score of the JNJ 7777120 treated mice only reduced 
after day 20 and the reason for this could be reduced inflammation of the CNS as a 
result of cessation of drug administration. JNJ 7777120 was administered to the mice 
for only 10 days (from day D10-20) and the clinical score is possibly a result of 
inflammation in the CNS due to drug presence in the spinal cord.  
Studies have investigated the sensory properties of hind paws as a confirmation for 
the presence of hyperalgesia and allodynia, components of MS related pain.  Lu et al. 
(Lu et al., 2012) showed that during MOG35-55 induced EAE, animals develop 
significant thermal hyperalgesia and mechanical allodynia towards low intensity 
stimuli during disease onset and peak phase. A relapsing-remitting form of myelin 
proteolipid protein 131-155 (PLP131-155) induced EAE in the SJL mice found that this 
mice model of EAE develops thermal hyperalgesia in the clinically affected body 
regions emerging at the peak of neurological deficit (Aicher et al., 2004a).  A study by 
Olechowski et al. (2009) showed that there were no observable differences in 
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sensitivity to noxious heat in the hind paws of a group of MOG35-55 induced EAE. 
However, the same cohort indicated the presence of cold allodynia and robust tactile 
allodynia as shown by increased withdrawal latencies and reduced withdrawal 
threshold in response to acetone application and Von Frey filaments, respectively. As 
clinical symptoms worsen during the chronic phase of disease, withdrawal thresholds 
tend to decrease below those seen in the baseline, suggesting that cold and tactile 
allodynia are major sensory disturbances detected in MOG35-55 model of EAE. These 
symptoms develop prior to the onset of overt neurological symptoms neuropathic 
pain can be a major symptom just before, or simultaneous with onset of clinical 
deficits in the disease. On the other hand, this hypersensitivity is independent of the 
specific extent of neurological deficits that arise during the disease.  
The initial aim of this study was to observe the presumed anti-inflammatory effects 
of the H4 receptor antagonist JNJ 7777120 and evaluate whether it is a good 
candidate for preclinical neuropathic inflammatory conditions in a model of MOG35-
55 EAE. Histological assessment of the lumbar spinal cord shows JNJ 7777120 treated 
EAE mice have more clusters of mononuclear inflammatory infiltrates in the dorsal 
horn, ventral horn and intermediate regions of grey matter, compared to the saline 
treated EAE control mice. This is a result of increased permeability of the blood brain 
barrier in the diseased state, to circulating leukocytes. Following luxol fast blue 
staining, it was observed that JNJ 7777120 treated animals have increased neuron 
death and demyelination due to the presence of myelin plaques in the white matter 
of the lumbar spinal cord and this is an important cause of the neurological signs 
seen in the animals. These results show the presence of both demyelination and 
inflammation and are consistent with the higher clinical score in this group of 
animals and a subsequently worse off clinical/pathological state, as has been 
reported previously (Tafreshi et al., 2005). MOG35-55 induced EAE presents with 
increased Nissl substance in motor neurons, progressive axonal loss due to reduction 
of nerve fibres per mm2 and demyelination is observed simultaneously with 
symptom development (Kuerten et al., 2011). The ascending progression of 
weakness and tail nociception in EAE is partly accounted for by the demyelination of 
the small diameter afferent fibres in the sacrococcygeal DRGs, dorsal roots and 
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dorsal entry zones as previously described (Pender, 1986, Pender et al., 1991). These 
results are consistent with previously published data where H4 receptor has been 
shown to negatively regulate MOG35-55 induced EAE severity; mice lacking this 
receptor display heightened disease and immonopathology coupled with increased 
BBB permeability during the acute phase (del Rio et al., 2012). 
Treatment with JNJ 7777120 has no effect on production of anti-MOG35-55 serum 
antibodies, therefore the differences in clinical severity were not a result of antibody 
production. Dunford et al. (2006) showed that blocking H4 receptors on dendritic 
cells reduced the numbers of eosinophils and specific IgE antibodies in allergic mice.  
In light of these results, further immunological assessment was performed. EAE is 
mediated by inflammatory CD4+ T cells with the ability to infiltrate the CNS, activate 
resident microglia and recruit macrophages. Previous work has shown the peak of 
pathological disease corresponds to the peak in the number of myelin specific CD4+ T 
cells along with F4/80+ macrophages, dendritic cells, microglia and astrocytes 
(Olechowski et al., 2009). These innate cells lead to the subsequent destruction of 
the CNS myelin sheath and oligodendrocye death.  
Widespread glial activation is commonly noted in MS and high levels of both 
astrocytes and microglia/macrophage activation in both control mice and those 
treated with JNJ 7777120 have been demonstrated. Immunofluorescent staining of 
spinal cord sections from the lumbar region show increased astrocyte activation. 
However, H4 receptor expression was absent on the astrocyte populations of both 
treatment groups. Astrocyte functions include biochemical support and nutritional 
supply of the endothelia cells that form the BBB, as well as repair and maintenance 
of damaged CNS areas. Further studies revealed increased clusters of IFNγ activated 
microglia infiltration and macrophages in the white matter of the lumbar region of 
the spinal cord. Activated microglia are efficient antigen presenting cells (Chastain et 
al., 2011, Aloisi, 2001) and evidence shows that they readily up regulate MHC class II 
expression in all inflammatory and neurodegenerative disease (Kreutzberg, 1996). 
The increased macrophage presence, astrocyte and microglial activation observed in 
the spinal cords of JNJ 7777120 treated EAE mice confirms the presence of advanced 
inflammation-induced neurodegeneration (Ponomarev et al., 2007). Microglia are 
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activated earlier than astrocytes and both types of cells are considered to be the 
principal source of pro-inflammatory (IL-1, TNFα) and immune regulatory (IL-12) 
cytokines in the CNS (Luo and Chen, 2012). Resident glial cells within the spinal cord 
are recognised as critical mediators of central sensitisation (Joyce A DeLeoa, 2001) 
through their release of cytokines. Treatments that target glial cell metabolism and 
inhibit the activation and proliferation of astrocytes and microglia have proven to be 
effective at reversing or preventing neuropathic pain behaviours in animal models of 
spinal cord injury (Hains and Waxman, 2006). Intrathecal administration of 
antagonists specific for proinflammatory IL-6, TNF and IL-1 block and fully reverse 
the allodynia following sciatic inflammatory neuropathy (Milligan et al., 2003). This 
reflects that spinal proinflammatory cytokines are important in the creation and 
maintenance of neuropathic pain. In addition, suppression of astrocyte and 
microglial activation by over expression of the anti-inflammatory cytokine IL-10 was 
shown to reverse inflammation induced paralysis, to reduce disease associated 
reduction in sensitivity to touch and suppressed CNS glial activation observed in EAE 
(Sloane et al., 2009). 
To further understand the immune mechanisms associated with differential EAE 
severity observed between the two treatment groups, T cell responses to MOG35-55 
antigen restimulation were observed. The in vitro cytokine profile analysis of 
lymphocytes showed that JNJ 7777120 treated EAE mice produced significantly more 
IFNγ; IFNγ is a product of macrophages and during inflammation, it acts in an 
autocrine manner as a macrophage activator (Luo and Chen, 2012). Similarly, JNJ 
7777120 treatment appeared to have a pro-inflammatory effect by reducing levels of 
the anti-inflammatory cytokine, IL-4 and IL-10 levels. IL-4 and IL-10 have an anti-
inflammatory role within the CNS and this has been demonstrated in the mouse EAE 
model, where mice that are IL-10 -/- and IL-4 -/- exhibited a more severe clinical 
disease (Bettelli E, 1998, Ponomarev et al., 2007). IL-4 is suggested to regulate 
inflammation by influencing the phenotype and function of macrophages 
(Ponomarev et al., 2007). In support of this, treatment of mice with IL-4 in an 
adoptive transfer resulted in amelioration of EAE (Racke et al., 1994) whereas 
administration of IL-10 during the induction phase could suppress the clinical signs of 
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disease (Rott et al., 1994). IL-10 plays a central role in down-regulating IFN-γ and 
TNF-α production by auto-reactive T cells (Bettelli E, 1998) and lymphocytes and 
splenocytes from JNJ 7777120 treated EAE produce less IL-10 but have higher IFNγ 
levels compared to untreated EAE controls.  
It is plausible that the increase in activated spinal cord microglia and astrocytes 
caused by H4 receptor blockade, led to an increase in CNS IL-4 levels. Microglia and 
IL-4 mRNA increase during EAE inflammation in response to signals either from 
oligodendrocytes undergoing cell death or activated astrocytes (Ponomarev et al., 
2007). The outcome would be the increased production of an anti-inflammatory 
cytokine with the potential to regulate the pro-inflammatory activity of astrocytes. 
IL-10 is an anti-inflammatory cytokine that suppresses proinflammatory cytokine 
expression, from transcription to protein release, downregulates proinflammatory 
cytokine production (Moore et al., 2001). This approach has been shown to block 
and reverse pain arising from spinal inflammation. IL-6 production is higher in the 
splenocytes than the lymph nodes and this could be a result of increased 
macrophage expansion as macrophages are capable of releasing IL-6. 
Infiltrating leukocytes are critical for the establishment of spinal sensitisation in EAE 
and the abundant infiltration of T cells and monocytes has been observed (Aicher et 
al., 2004b).  The in vivo analysis of T lymphocytes infiltrating the spinal cord of the 
EAE mice revealed the presence of H4 receptor positive cells, CD11c dendritic cells 
and macrophages. An increase in CD4+ H4R
+ T cells in JNJ 7777120 treated mice was 
observed, although not statistically significant. H4 receptor activation has been 
shown to stimulate actin polymerisation, upregulation of adhesion molecules on the 
cell surface of leukocytes, chemotaxis and subsequent inflammation (Hofstra et al., 
2003, Ling et al., 2004). Cervical lymph node mononucleocytes show a higher 
proportion of CD3+ T cells in the JNJ 7777120 treated EAE mice, with suppressed 
expression of MNCs. However these cells are in low populations in the spinal cord 
which hosts a higher population of H4R
+ dendritic cells, H4R
+ T cells and macrophages. 
CD3+ T cells accumulate within the dorsal horn of mice with EAE early in the disease 
course when cold and tactile allodynia are observed (Olechowski et al., 2009) 
whereas neuropathic tactile allodynia is reduced in T cell deficient rag1-null mice.  
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Immunoreactivity of T cells, astrocytes, macrophages and microglia present in the 
dorsal horn is significantly up-regulated during EAE suggesting that inflammation and 
reactive gliosis in the spinal dorsal horn may be the crucial mechanism underlying 
the behavioural hypersensitivity observed in MOG35-55 EAE model. Due to the little 
evidence for direct injury to the peripheral nervous system in MOG35-55 induced EAE 
model, the most likely source of the activation of spinal gliosis in the disease in from 
trafficking of T cells into the CNS (Costigan et al., 2009). T cells have the ability to 
penetrate the BBB, enter the dorsal horn and are integral for the generation and 
maintenance of central sensitisation and neuropathic pain. Athymic “nude” mice 
lacking mature T cells do not develop neuropathic pain after peripheral nerve injury 
(Moalem et al., 2004). Our results show an abundance of CD3+ T cells in the 
superficial dorsal horn, correlating with the development of allodynia and these 
most likely affect sensory neurons through the release of pro-inflammatory 
cytokines that may directly sensitise dorsal horn neurons. T cells can also secrete 
neutrophins like brain-derived neurotrophic factor (BDNF) and this may explain the 
mechanism of immune-mediated neuroprotection following axonal injury (Serpe et 
al., 2005).  
Our results are in accordance of those of Del Rio et al. (del Rio et al., 2012) who 
showed direct evidence of a role for H4 receptor in the modulation of EAE severity. In 
this report, H4 receptor KO mice developed more severe EAE despite having T 
effector cell responses that were equal to those of wild type mice. The H4 receptor 
KO mice presented with augmented neuroinflammation and increased BBB 
permeability compared with wild type mice, despite comparable T effecter cell 
responses.   During disease progression, despite increased H4 receptor expressing 
immune cells in the CNS, antagonism of the H4 receptor would lead to a reduction in 
the absolute number of T regulatory cells as well as those in the CNS, as was the case 
with H4 receptor KO mice.  
Immunised H4 receptor KO mice showed a higher proportion of T helper 17 (Th17) 
memory cells within the CNS, consistent with fewer regulatory T cells (TR) due to the 
presence of a defect in the migration capacity of the lymphocytes. H4 receptor 
activation using 4-methylhistamine has been shown to influence TR migration into 
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the lung (Morgan et al., 2007). Our data and that of Del Rio et al. (2012) further 
demonstrate that histamine signals through the H4 receptor to induce TR migration 
to the site of inflammation. We cannot exclude the possibility that the increased 
presence of H4 receptor signalling in the CNS contributes to disease severity as a 
result of disrupted CNS-central function. The H1-and H3 receptors are also expressed 
in the CNS and histamine may be mediating its effects on hyperalgesia through these 
receptors as they remain unaffected by the selective and highly specific H4 receptor 
antagonist.  
H4 receptor signalling appears to negatively regulate EAE by controlling the 
infiltration and suppressive actions of TR cells during the acute phase of disease. This 
is critical in regulating the proliferation and expansion autoreactive pathogenic T 
cells. The observation that H4 receptor blockade with JNJ 7777120 and H4 receptor 
KO results in severe EAE compared to WT mice reflects the importance H4 receptor-
mediated TR cell migration in controlling the inflammatory response in the CNS. 
However, the use of both central and peripheral acting H4R agonists may be useful in 
treating patients with this syndrome.   
 Apart from the immunological pathology involved in MS, chronic neuropathic pain is 
a common but little understood symptom associated with the disease. Neuropathic 
pain caused by lesions and dysfunction of the CNS is the most prevalent and difficult 
to treat pain syndrome observed in MS patients. MS pain is thought to represent 
pain as a result of lesions of CNS regions that process pain, but it could also be due to 
a loss of descending inhibitory pathways generating enhanced responses to noxious 
stimuli (Sandyk, 1999).  
Recent evidence has shown the functional localisation of the H4 receptor in the CNS 
(Strakhova et al., 2009); located on the soma of small and medium diameter sensory 
neurons, lamina I-II of the lumbar spinal cord (Connelly et al., 2009) and also on 
microglia (Ferreira et al., 2012). JNJ 7777120 has been shown to exert analgesic 
effects on animal models of inflammatory and neuropathic pain (Hsieh et al., 2010a). 
Therefore, the possibility that antagonism of central H4 receptor contributes to the 
exacerbation of EAE cannot be excluded.  
 
 
161 
 
Several studies have showed that expression of the neuropeptides CGRP and galanin, 
which are located in the dorsal horn of the spinal cord, is elevated (via increased 
receptors or neuron sprouting) during neuropathic pain (Bennett et al., 2000) caused 
by spinal cord injury and peripheral nerve damage an inflammation. Galanin 
expression in the dorsal horn is elevated during neuropathic pain caused by 
peripheral nerve injury (Liu and Hokfelt, 2002b). However, neither neuropeptide is 
elevated at any time point during MOG35-55 model of EAE (Olechowski et al., 2009) 
therefore changes in sensory processing during disease progression cannot be 
accounted for by different expression patterns of these neuropeptides. 
 
CGRP mRNA levels increase in the motor neurons during the acute phase of EAE 
(Giardino et al., 2004) and this accumulation is attributed to increased synthesis, 
although accumulation because of the blocking of peripheral transport cannot be 
excluded (Caldero et al., 1992). Our analysis of CGRP expression on putative A fibres 
expression showed [apparent] up-regulation of CGRP staining in the superficial 
dorsal horn of JNJ 7777120 treated EAE.  Previous studies have shown that 
substance P-mediated signalling contributes to the maintenance of inflammation in 
the CNS during the chronic phase of EAE and EAE severity is reduced in NK1-/- 
animals (Reinke et al., 2006).  
 
Although JNJ777120 has been proven to have functional antagonism on calcium 
mobilisation and chemotaxis in leukocytes through the inhibition of adenylyl cyclase 
activation and cAMP (Thurmond et al., 2004b), it may have agonist properties in the 
CNS through activation of a pathway that does not involve calcium mobilisation. 
Rosethorne and Charltone (2011) have shown that JNJ777120 is a biased agonist at 
the human H4 receptor, acting as a neutral antagonist for [
35S] GTPγS binding and a 
partial agonist for β-arrestin recruitment. It is possible that in the EAE model, JNJ 
7777120 activates central H4 receptors through this mechanism. This is attributed to 
the existence of multiple active conformations, and each compound’s ability to 
stabilize a subtly different state over another and therefore activating a different 
pathway. They demonstrated that although JNJ 7777120 is an antagonist regarding G 
protein-dependent signalling, it acts as an agonist in a non–G protein-dependent 
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manner to recruit β-arrestin to the receptor, as demonstrated by the lack of 
sensitivity to pertussis toxin treatment (Rosethorne and Charlton, 2011).  
Due to the expression of the H4 receptor in the CNS, we cannot exclude the 
possibility that the absence of H4 receptor signalling contributes to the increased 
disease severity, because of disturbed CNS signalling functions.  Our current findings 
show that H4 receptor antagonism negatively regulates EAE by enhancing the 
infiltration of leukocytes and possibly, the suppressive activity of TR cells within the 
CNS. We hypothesise that increased CNS inflammation as a result of H4 receptor 
antagonism enhanced hyperalgesia and allodynia in this EAE model, because 
reduced inflammation reverses disease induced hyperalgesia and allodynia (Sloane 
et al., 2009). Similarly, H4 receptor KO mice develop more severe EAE than WT mice, 
highlighting the importance of temporal localisation of TR cells. On the other hand, 
JNJ 7777120 could be acting as an agonist via the recruitment of β-arrestin, 
therefore worsening the clinical state of the animals. It is possible that the agonism 
and antagonism of the centrally expressed H4 receptor may have different effects 
compared to the peripherally expressed H4 receptor. Further work is needed for 
elucidating the pathway activated during central H4 receptor agonism and 
antagonism, if specific H4 receptor ligands are to be among the group of potential 
drugs to treat inflammatory or autoimmune diseases and neuropathic pain 
secondary to CNS inflammatory disorders.  
 
The next chapter will investigate the central effects of H4R antagonism using a series 
of state-of-the art novel behavioural tests. This will validate the use or otherwise of 
centrally active H4R targeted analgesic drugs. 
 
 
 
 
Chapter 6 
The behavioural effects of histamine H4 receptor antagonism  
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6.1 Objectives  
The objective was to determine the potential central role of the histamine H4R in a 
range of behaviours, including anxiety, learning and memory. One of the aims was to 
determine if there were any changes in anxiety behaviours in CD1 (lo anxiety strain) 
and Balb/c (high anxiety strain) mice in the elevated platform test developed in our 
laboratory, following administration of the selective H4R antagonist JNJ 7777120. 
Another aim was to investigate the effects of H4R antagonism in motor activity, 
learning and memory in Balb/c mice.  
 
6.2 Introduction 
 
Strakhova et al. (2009) showed that in humans, H4R expression is highest in the 
spinal cord, followed by hippocampus, cerebellum and other brain regions (i.e. 
cerebellum, hypothalamus, amygdale, thalamus, and cortex). The 
Immunohistochemical detection of H4 receptors but lack of mRNA in the cortex 
implies that H4 receptors are expressed on fibres emanating from other brain 
regions. Similarly, H4 mRNA is expressed in the rat cortex, cerebellum and brain 
stem. Further immunohistological studies showed mouse H4 expression is evident in 
lamina I, II, III, IV and V of the cortex (peak in lamina IV) and the hippocampal 
formation (Connelly et al., 2009). This expression was shown to be functionally active 
through activation within layer IV neurons with 4-Methylhistamine; this effect was 
blocked by the selective H4 receptor antagonist JNJ10191584 (Connelly et al., 2009). 
This pattern of expression is similar with that of the H3R such as, overlap in the 
entorhinal cortex and deep lamina of the cortex but contrasts particularly with the 
high H4 expression in the thalamus.  
Due to the distribution of H4 receptors in critical areas of the brain, it is worthwhile 
to examine its possible involvement in behaviour.   
 
In the present study, we examined the effects of a H4 antagonist on a range of 
behaviours in mice. We used the elevated platform with slopes developed by our 
laboratory (Ennaceur et al.,2010) and the novel object recognition (NOR) task 
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developed by Ennaceur and Delacour (Ennaceur and Delacour, 1988). The first test 
consists of an elevated platform with steep slopes attached on two opposite sides. It 
has been demonstrated in this test that C57BL/6J and CD-1 mice do cross onto the 
slopes while Balb/c mice do not cross, but spend most of the test duration in the 
area adjacent to the slopes. This indicates that Balb/c mice display high levels of 
anxiety compared to C57BL/6J and CD-1 mice. Diazepam (clinically used anxiolytic) 
induced, in dose–dependent fashion, the Balb/C mice to enter the slopes indicating 
its anxiolytic effects (Michalikova et al., 2010). The NOR test is performed in an open-
field and performed in two stages. In the initial sample phase, animals are exposed 
to two identical objects. In the second stage, choice phase, animals are exposed 
again to two objects, one familiar, a copy of the one seen before, and the other 
novel, never seen before. A delay interval is interposed between the two test 
phases. At short (up to 1hr) but not at longer retention interval most animals 
discriminate between the two objects, they spend more time engaged with the novel 
than the familiar object. This latter test has been translated successfully to human 
clinical trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3 Experiment 1 
6.3.1 Materials and Methods 
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6.3.1.1 Animals: 32 BALB/c and 32 CD-1 male mice obtained from Charles River (UK) 
were used in the experiments described in this report. They were 56-62 days old at 
the date of arrival and were left to acclimatize to local laboratory conditions for one 
week. They were housed in a colony room that was held under a 12 h light/12 h dark 
cycle (light 0700-1900 h at 40 Lux) and at 23°C ±1. In order to avoid unequal light 
exposure, the upper shelf was occupied with plastic cages filled with clean sawdust. 
Mice were housed in a group of 4 per cage. Individual mice could be identified by 
their cage number and their ear tag code. All mice had ad libitum access to food and 
water. Animal treatment and husbandry were in accordance with approved use of 
animals in scientific procedures regulated by the Animals (Scientific Procedures) Act 
1986, UK. 
 
6.3.1.2 Drugs and treatments: 
JNJ 7777120 was purchased from Tocris (UK). It was dissolved in PBS with 2.5% 
dimethyl sulphoxide (DMSO). Both JNJ 7777120 and saline were freshly prepared on 
the days of the test and administered intraperitoneally (i.p) 30 minutes before the 
start of the test session in a volume of 10 ml/kg. Control mice received PBS with 
DMSO. The experiment consisted of 4 groups from each strain of mice. In each 
strain, one group was treated with saline (n=8), and separate groups were treated 
with JNJ777120 at 5 mg/kg (n=8), 10 mg/kg (n=8) and 20 mg/kg (n-8).  
 
6.3.1.3 Apparatus and testing procedures:  
It consists of a platform 80 cm x 80 cm wide, elevated 75 cm from the ground. Steep 
inclined panels made of rigid wire mesh are attached on two opposite sides of the 
platform (width: 80 cm x 25 cm). The platform was divided into a central area 
covered with a white tile (16 x 16 cm wide and 0.4 cm thick), an inner area 
surrounding the central area (16 cm wide), and an outer area (16 cm wide). The 
outer area was further divided into areas adjacent to the slopes and areas adjacent 
to void space. The surface of the platform was cleaned to minimize the effects of 
lingering olfactory cues. The illumination on the surface of the elevated platform was 
40 Lux. Mice were transported in a small bucket to the test apparatus where they 
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were tilted gently onto the tile, which forms the central area of the platform. They 
were left to explore the apparatus for 12 minutes.  
 
 
 
 
                      
 
                       
Figure 6.1 Description of the different areas of the elevated platform (top and frontal views)  
The recorded data consists of measures of the number of entries and duration into the central area, 
the inner area, the outer area and onto the slopes in addition to latency of first entry into these areas.  
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The record of outer area was further divided into measures related to areas adjacent to the slopes 
and areas adjacent to the void space 
 
6.3.1.4 Measurements and data analysis:  
The test session was video recorded and the behaviour of rats was analyzed with an 
in-house computer program, EventLog. The recording of the behaviour of rats was 
based on entries into defined areas of the apparatus. An entry was recorded 
whenever a rat crossed with all four paws into an area. EventLog records in 
sequential order the start and end of each crossing into an area of the open-field. It 
provides measures of latency, frequency and duration of entries. 
 
All data are expressed as mean ± S.E.M. Differences among group means values for 
each measurement were tested for significance with one-way ANOVA followed up 
with Newman–Keuls post-hoc comparisons (Statistica for Windows, version 5.5). 
Results were considered significant when p≤0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3.2 RESULTS: 
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6.3.2.1 Number of crossings on the platform: There were significant differences 
between groups (F7,56=20.08, p<0.0001). Saline and drug-treated Balb/c made 
significantly few crossings compared to saline and JNJ-treated CD-1 mice (p<0.01). 
Balb/c treated with JNJ 10 and 20 mg made significantly few crossings compared to 
Balb/c saline and Balb/c treated with JNJ 5 mg (p<0.03). 
 
6.3.2.2 Crossings onto central and inner areas: 
There were significant differences between groups for the number of crossings onto 
the central (F7,56=3.35, p<0.005) and inner (F7,56=5.13, p<0.0001). Balb/c treated 
with JNJ 7777120 10 and 20 mg made significantly less crossings onto the inner and 
central areas compared to Balb/c treated with saline and JNJ 7777120 5 mg, and to 
both saline and drug treated CD-1 mice (p<0.05).  
 
The latency of first crossing onto the inner area was not significant between groups 
(F7,56=2.03, p<0.07). There were however, significant differences between groups in 
the time spent in the central area (F7,56=6.02, p<0.009), inner area (F7,56=12.32, 
p<0.0001). Balb/c mice treated with saline and Balb/c treated with JNJ 7777120 5 mg 
spent more time in the inner and central areas compared to all other groups 
(p<0.01).  
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Figure 1a: Saline and JNJ treated Balb/c mice compared to saline and JNJ treated CD-1 mice (p<0.01). Balb/c treated with 
JNJ 10 and 20 reduced total number of crossings compared to Balb/c treated with saline or treated JNJ 5 mg 
(p<0.03);Figure 1b:No significant differences between groups (p<0.07); Figure 1c:Balb/c treated with JNJ 10 and 20 mg 
compared to Balb/c treated with saline and JNJ 5 mg, and to both saline and drug treated CD-1 mice (p<0.05) made less 
crossings in the inner and central areas; Figure 1d:Balb/c mice treated  with saline and JNJ 5 mg spent more time in the 
inner and central areas compared to all other groups (p<0.01). 
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6.3.2.3 Number of crossings onto the areas adjacent to void and slopes: There were 
significant differences between groups for the number of crossings onto the areas 
adjacent to the void (F7,56=15.66, p<0.0001) and areas adjacent to slopes 
(F7,56=22.37, p<0.0001). Saline and JNJ 7777120 treated Balb/c mice made 
significantly few crossings onto the areas adjacent to the void and the slopes 
compared to saline and JNJ 7777120 treated CD-1 mice (p<0.01). CD-1 treated with 
saline made also significantly few crossings compared to CD-1 mice treated JNJ 20 
mg (p<0.01). Balb/c treated with JNJ 7777120 10 mg made also significantly less 
crossings on both areas compared to Balb/c treated with saline or JNJ 7777120 5 mg 
(p<0.05). 
 
There were significant differences between groups for the time spent in the areas 
adjacent to void (F7,56=2.13, p<0.05) and areas adjacent to slopes (F7,56=12.20, 
p<0.0001). The time spent in the areas adjacent to the void space was low but not 
significant in Balb/c mice treated with JNJ 7777120 10 compared to Balb/c treated 
with saline (p<0.09), JNJ 7777120 5 (p<0.09) and JNJ 20 (p<0.06). It was also high but 
only significant compared to CD-1 mice treated with JNJ 7777120 5 and 20 mg 
(p<0.05). The time spent in the areas adjacent to the slopes was significantly high in 
Balb/c treated with JNJ 7777120 10 and 20 compared all other groups (p<0.001). 
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Figure 2a: For the areas adjacent to void and slopes - Saline and JNJ treated Balb/c mice made few crossings compared to 
saline and JNJ treated CD-1 mice (p<0.01). CD-1 treated with saline made few crossings compared to CD-1 mice treated JNJ 
20 mg (p<0.01). Balb/c treated with JNJ 10 mg made the fewest number of crossings compared to Balb/c treated with 
saline or JNJ 5 mg (p<0.05). 
Figure 2b: For the areas adjacent to void – Balb/c mice treated with JNJ10 was low but not significant compared to Balb/c 
treated with saline (p<0.09), JNJ 5 (p<0.09) and JNJ 20 (p<0.06), and compared to CD-1 mice treated with JNJ 5 and 20 mg 
(p<0.05). 
For the areas adjacent to slopes – Balb/c treated with JNJ 10 and 20 compared all other groups (p<0.001). 
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6.3.2.4 Crossings onto the slopes: There were significant differences between 
groups in the number of crossings onto (F7,56=4.95, p<0.0002) and time spent on 
the slopes (F7,56=6.56, p<0.0001). There were also significant differences between 
groups in the latency of first crossing onto a slope (F7,56=6.76, p<0.0001). In fact, all 
saline and drug-treated CD-1 mice crossed onto the slopes whereas only two Balb/c 
mice did cross onto the slopes. One Balb/c was from the saline group and the other 
was from JNJ 7777120 20mg. The duration of visits for these two mice was less than 
4sec. 
 
 
  
Fig. 3: Saline and JNJ treated CD-1 mice compared to saline and JNJ treated Balb/c mice (p<0.01) in all three figures 
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6.4 Experiment 2 
6.4.1 MATERIALS AND METHODS: 
6.4.1.1 Animals: 32 BALB/c male mice obtained from Charles River (UK) were used in 
the experiments described in this report. They were 56-62 days old at the date of 
arrival. All conditions as described in experiment 1. 
 
6.4.1.2 Drugs and treatments: 
JNJ 7777120 was purchased from Tocris (UK). It was dissolved In PBS with 2.5% 
dimethyl sulphoxide DMSO. Both JNJ 7777120 and saline were freshly prepared on 
the days of the test and administered i.p. 30 minutes before the start of the test 
session in a volume of 10ml/kg. Control mice received PBS with DMSO. The 
experiment consisted of 4 groups: saline (n=8), and JNJ 777120 at 5 mg/kg (n=8), 10 
mg/kg (n=8) and 20 mg/kg (n-8).  
 
6.4.1.3 Apparatus and testing procedures: It consisted of an open-field 80 cm x 80 
cm wide and 50 cm height. The floor was divided into nine equal squares. The central 
square was covered with a white tile. It was cleaned to minimize the effects of 
lingering olfactory cues. The illumination on the floor was 40 Lux. Mice were 
transported in a small bucket to the test apparatus where they were tilted gently 
onto the tile.  
 
Mice were first habituated to the open-field in 3 consecutive sessions, one session a 
day. Each session lasted 12 minutes. In the fourth day, mice were exposed to two 
identical objects, each located at one of the back corner of the box apparatus. The 
session lasted 10 minutes. In the fifth day, mice were re-exposed to two objects in 
the previous corner locations. One of the objects was an identical copy of the one 
shown in the previous session and the other was completely novel. The location of 
the familiar and novel object was counterbalanced between mice. 
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Figure 6.2 The layout for the object recognition experiment.  
During the sample phase (top panel), the mouse is expected to spend more time closer to the object 
than it does in any other areas of the elevated platform. During the choice phase (bottom panels), a 
novel object is introduced to the elevated platform in addition to the original familiar object. Object 
recognition is observed when the mouse spends less time with the familiar object (because it 
remembers the object from memory) and more time with the novel object. 
 
 
 
6.4.1.4. Measurements and data analysis: see experiment 1, 
All data are expressed as  ± S.E.M. Differences among group means values for each 
measurement were tested for significance with a one-way ANOVA followed up with 
Newman–Keuls post-hoc comparisons (Statistica for Windows, version 5.5). 
Discrimination between novel and familiar objects was assessed using paired student 
t-test for each group. Results were considered significant when p≤0.05. 
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6.5 OBJECT RECOGNITION 
6.5.1 Sample phase  
During the sample phase, animals are exposed to two identical objects. 
There were no significant differences between groups on the total number of 
crossings (F3,28=0.21, p>0.10), on the number of crossings onto the center 
(F3,28=0.07, p>0.10), corner (F3,28=0.21, p>0.10) and transition (F3,28=0.29, 
p>0.10) areas. There were also no significant differences between groups in the time 
spent in the center (F3,28=0.14, p>0.10), corner (F3,28=0.61, p>0.10) and transition 
(F3,28=1.26, p>0.10) areas. 
 
  
  
Figure 4: No significant differences between groups (p>0.10) 
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6.5.2 Choice phase 
During the choice phase, animals are exposed again to two objects, one familiar, a 
copy of the one seen before, and the other novel, never seen before.  
There were no significant differences between groups on the total number of 
crossings (F3,28=2.57, p<0.07), on the number of crossings onto the centre 
(F3,28=1.52, p>0.10), corner (F3,28=2.44, p<0.08) and transition (F3,28=2.33, 
p<0.09) areas. There were also no significant differences between groups in the time 
spent in the centre (F3,28=1.51, p>0.10), corner (F3,28=1.74, p>0.10) and transition 
(F3,28=1.76, p>0.10) areas. 
 
 
  
Figure 5: No significant differences between groups (p>0.10) 
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6.5.3 Discrimination 
There were no significant differences between groups in the latency of first crossing 
onto the center (F3,28=1.59, p>0.10) and onto the corners with a familiar 
(F3,28=1.71, p>0.10) or novel object (F3,28=1.52, p>0.10). 
 
There were also no significant differences between groups in the number of 
crossings onto and time spent in the corner with a familiar (F3,28=0.53, p>0.10 and 
F3,28=0.51, p>0.10, respectively) and the corner with a novel (F3,28=0.43, p>0.10 
and F3,28= 0.88, p>0.10, respectively) object. 
 
 
  
Figure 6: No significant differences between groups (p>0.10) 
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The table below indicates that neither mice treated with saline nor mice treated with 
JNJ discriminated between objects. 
 
 
 
Crossings Time 
Doses mg/kg 
 
t p t p 
0 n=8 0.6 >0.10 0.03 >0.10 
5 n=8 0.17 >0.10 0.52 >0.10 
10 n=8 0.96 >0.10 1.73 >0.10 
20 n=8 0.97 <0.02 0.48 >0.10 
Table 1: p values for the number of crossings (see fig. 6b) onto and time spent ((see fig. 6c) in the 
corners occupied with a familiar object compared to corners occupied with a novel object.  
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6.6 Discussion  
The role of the histamine H4R in the brain is poorly understood, despite its 
distribution in critical areas of the brain. Therefore, it is important to examine its 
potential role in motor activity, anxiety and memory. This chapter describes the 
behaviour of mice in an anxiety test based upon exposure to an elevated platform 
with steep panels attached on two opposite sides. Anxiety is defined as the result of 
a conflict between the drive to approach a threatening stimulus and the drive to 
avoid the same stimulus.   
 
The elevated platform is divided into the central area covered with a thin white tile, 
an inner area surrounding the central area and an outer area. The outer area is 
further divided into areas that are adjacent to the downward slopes and areas 
adjacent to the void space. The surface of the inner area is equal in size to that of the 
outer area, validating the comparisons between these two areas. The central area 
defined by the white tile was justified by reports that the open space of an open-
field is anxiogenic to the animals, preventing them entering the space. Minus a tile, 
the central area has no physical boundaries and the tile is sufficient to attract both 
rats and mice to explore the central area. During the test, anxious animals were 
expected to make few or no entries onto the downward slopes, and to spend most 
of their time away from the platform edge.  
 
Balb/c mice treated with JNJ 7777120 at 10 mg and 20 mg made fewer crossings 
onto the inner and central areas and spent less time in these areas, compared to the 
CD-1 mice. In the elevated platform, JNJ 7777120 at 10 and 20 mg appears to affect 
the behaviour of Balb/c mice but there is no indication of reducing anxiety. Their 
total number of crossings on the platform was very low. This behaviour was 
observed in a previous study (Ennaceur et al., 2010b). These results show that JNJ 
7777120 administration did not facilitate crossing onto the slopes in Balb/c mice, as 
only one animal from the control and treated groups crossed onto the slopes. 
Similarly, it did not affect the crossings of CD-1 mice. 
 
 
 
180 
 
Our results show that the saline and JNJ 7777120 animals made fewer entries and 
spent less time in the inner and central areas of the platform. This contrasts with 
previously published data which demonstrated that both Balb/c and CD-1 mice made 
frequent entries, and spent more time in the outer and inner areas of the platform 
(Michalikova et al., 2010). Frequent entries to these areas represent a response 
strategy adopted by animals in an unfamiliar environment, as they look for an escape 
route and assess their safety. In an open space lacking a protective area to escape to, 
anxiety is experienced in any part of the apparatus and the slopes provide an escape 
route, but are also a handicap that the animals need to overcome. In this model, the 
behaviour of the animals is controlled by the natural desire to explore the different 
areas of the platform and slopes, as well as the drive to escape from the platform 
and the slopes. Therefore, if they want to find an escape route, they need to explore.  
Despite the 12 minute length of a session, animals remained active and did not show 
signs of decreased motor exploration when exposed for three sessions or more to 
the apparatus.  
 
This test is comparable to the open-field, the plus-maze and the light dark box which 
measure fear-induced avoidance (Dere et al., 2002).  It has been suggested that 
different areas of the elevated platform with downward slopes induce different 
degrees of anxiety, especially when animals move away from a protected space. In 
the elevated platform, the slopes provide an incentive for the animals as they can 
cross onto the platforms and get closer to the ground. Mice exposed to an elevated 
platform try to escape by jumping onto the ground when the platform is not 
sufficiently raised (unpublished data). Therefore, the platform is raised by 75 cm 
from the ground and animals show preference for the areas adjacent to slopes which 
provide a potential route for escape. Balb/c mice appear to be more anxious than 
CD-1 and c57 mice as they did not cross onto the slopes. This cannot be accounted 
for by physical abilities because a previous study using diazepam treated Balb/c mice 
did cross frequently and spent more time on the slopes (Ennaceur et al., 2010a). The 
least anxious strains of mice, the CD-1 cross onto the slopes and venture to the far 
end of the slopes to get closer to the ground as do diazepam treated Balb/c mice. 
Our results show that unlike the saline and drug treated CD-1 mice which crossed 
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onto the slopes, Balb/c mice did not. They spent a significant amount of time in the 
areas adjacent to the slopes than in areas adjacent to the void, which indicates that 
the Balc/c mice were aware of the presence of the slopes. 
Novel object recognition has been used to assess anxiety and memory in animals. It 
has previously postulated that when you expose a familiar object alongside a novel 
object, both young and adult mice approach and spend more time exploring the 
novel, rather than the familiar object. This is considered an indication that a 
representation of the familiar object exists in memory.  The habituation sessions are 
necessary because anxiety is predominant during the initial stages and this prevents 
object recognition, but this subsides following repeated exposures (Ennaceur et al., 
2009) thereby allowing the animal to recognize a novel from a familiar object.  
In the object recognition test following the habituation, JNJ 7777120 had no effect 
on any test parameter. It had no effect on the number of crossings and time spent in 
the centre, corners and transition areas of the platform at the administered 
concentrations during the sample and choice phase.  JNJ 7777120 did not facilitate 
discrimination between novel and familiar object. In this study, we used a 24 hour 
delay interval but mice were exposed to the sample object for 10 min. Data from our 
laboratory using this model demonstrated that rats ventured into the centre of the 
field, made more approaches to and spent more time on a novel object (Ennaceur et 
al., 2009). On the other hand, a study in which Balb/c H4R knockout mice were 
subjected to spatial learning and memory test in the Morris water maze and showed 
better performance, compared to the poor performance of the wild type in this 
experimental setting. The H4R knockout mice appeared to react with hyperactivity to 
handling, showing the potential differences in behavioral phenotype between H4R 
knockout and wild type mice (Rossbach et al., 2012).  
 
A recent study using the H4R agonist VUF 8430 reported this drug to dose-
dependently prolong the time spent in the light chamber of the light/dark box, 
indicating its potential anxiolytic effect (Galeotti et al., 2013).  On the other hand, 
the H4 antagonist JNJ 10191584 had no effect but pre-treatment antagonized the 
effect of VUF 8430 further confirming selectivity if H4R activation. However, the H4R 
agonist at the dose that increased the time spent in the light compartment reduced 
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significantly the crossings between the two compartments of light/dark box.  In this 
experiment mice were released in the middle of the light compartment. Hence, it is 
possible that the time spent in this compartment is due to freezing a response than 
reduced anxiety. The effects of H4R activation on memory in the passive avoidance 
paradigm, using mice with scopolamine impaired memory were also investigated. In 
the passive avoidance task mice treated with the H4R agonist at the dose that 
increased the time spent in the light compartment did not facilitate crossing onto 
the dark compartment. The authors interpret this as a lack of effect of the drug on 
memory but with holding a response toward the dark compartment can be 
considered as indicative of increased anxiety (McNaughton and Corr, 2004). 
 
At present, the role of the central H4R in anxiety, learning and memory remains 
unclear. Our results show that antagonism of the H4R with JNJ 7777120 had no 
anxiolytic or sedative effects on the Balb/c mice, hence reduced entry to the center 
of the platform with increasing JNJ 7777120, cannot be accounted for by reduced 
motor activity. However, the work of Galeotti et al. (2013) shows the potential 
anxiolytic effects of receptor activation with the agonist VUF8430. The role of the 
receptor in memory requires further investigation because JNJ 7777120 
administration did not produce any improvements in the novel object recognition 
memory task, after a 24 hour delay, whereas H4R knockout mice showed a better 
performance in the Morris water maze test, compared to the wild type counterparts. 
There was some doubt on the suitability of the wild-type mice used in the latter 
study which requires clarity (Johnson & Johnson, personal communication). In order 
to improve consistency, the same methodology needs to be employed in order to 
understand the effects of receptor absence, antagonism and activation on anxiety, 
learning and memory. In conclusion, our studies provides evidence for central H4Rs 
(significant effects on entries to central region of elevated platform), but limited 
evidence for roles in overall motor activity, anxiety or NOR memory.  
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CHAPTER 7 
GENERAL DISCUSSION 
During the course of this PhD, the previously generated antibody for the full length 
histamine H4 receptor (Shenton, 2007) has been used to locate the expression and 
distribution of the histamine H4 receptor in the rodent periphery and central nervous 
system. H4R ligands have been used to determine the effects of receptor activation 
and antagonism. A number of key hypotheses have been addressed: 
1) The histamine H4 receptor is expressed on C-fibre sensory neurones  
The H4 receptor is expressed in the rodent and human CNS with mRNA 
expression highest the in the spinal cord.  Immunohistochemical studies 
confirmed protein expression in the rodent and human spinal cord, mostly 
observed in lamina I and II of the dorsal horn. Using immunological probes, the 
H4R has been detected on substance P-positive C-fibres and CGRP-positive Aδ 
fibres innervating the dermis as well as surrounding the blood vessels in the 
dermis of the skin. The observation that the histamine-induced itch and the 
inhibitory effects of the H4R antagonists were unaltered in mast cell-deficient 
mice (which have few or no mast cells in skin), indicated that the H4R on mast 
cells was not required for initiation of H4R-mediated pruritus. The observation of 
the H4R expression on substance P and CGRP positive neurons in the rat skin 
supports the hypothesis of a peripheral acting site for the H4R antagonists which 
have analgesic  (Hsieh et al., 2010a), and anti-pruritic (Dunford et al., 2007). 
The double labelling immunofluorescence approach was used to determine the 
possible co-localisation of H4Rs on peptidergic C-(substance P) and Aδ (CGRP) 
nociceptive fibres at the level of the skin, dorsal root ganglia (DRG) and the 
dorsal horn neurons of the spinal cord in the rat. At all levels of the sensory 
pathway tested, our results show H4R expression on both C and Aδ fibres, with 
the latter particularly prominent at the level of the skin and DRG. This 
expression profile contrasts with the H3R, which was found to be expressed 
only on a subset of Aδ fibres, but is undetectable on C-fibres (Cannon, Chazot 
et al., 2007). Through preliminary functional analysis, we have demonstrated 
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that the H4R is functionally expressed on primary rat DRG sensory neurones 
using the new potent highly selective agonist VUF 8430. This compound is a full 
agonist at human and rodent H4R in both endogenous and recombinant H4R 
expressing systems (Lim et al., 2009) and selective activation of the H4R on 
primary isolated neurons elicits a dose-dependent [Ca2+] influx, providing a 
robust new useful functional model for studying sensory neuronal H4 
receptors. The presence of the H4R on peripheral and central sensory neurones 
suggests both peripheral and central acting sites for H4R antagonists that have 
antinociceptive and antipruritic effects. 
 
2) The histamine H4 receptor expression is differentially effected in acute and 
chronic pain conditions 
Immunoblotting using the anti-H4R antibody directed toward the full length 
receptor was used to determine the changes in H4R expression following the 
induction of acute and chronic, inflammatory and neuropathic pain conditions. 
Peripheral administration of CFA induces localised inflammation and 
inflammatory pain. Similarly, chronic constriction injury (CCI) of the sciatic nerve 
reduced the paw withdrawal latency to mechanical stimulation, consistent with 
the induction of mechanical allodynia. 
Quantification of the protein extracted from skin excised from the plantar hind 
surface during the acute phase of inflammation revealed significant increase in 
expression of the H4R. This is consistent with H4R expressing leukocytes such as 
neutrophils, eosinophils, dendritic and mast cells infiltrating the site of the acute 
phase of inflammation. Pre-treatment with JNJ 7777120 during inflammatory 
conditions has been shown to prevent signs of inflammation, cellular chemotaxis 
(Coruzzi et al., 2012, Coruzzi et al., 2007) and inflammatory pain (Hsieh et al., 
2010a). Since the H4R is functionally expressed on the sensory neurons (Chapter 
3), there is a strong possibility that the anti-nociceptive effects of antagonism are 
mediated through action on sensory pain pathway.   
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Current literature depicts the H4R as having a role in inflammatory pain conditions 
(Hsieh et al., 2010a), where antagonists such as JNJ 7777120 exhibit anti-
hyperalgesic activity in models of inflammatory (Coruzzi et al., 2007, Coruzzi et al., 
2012) and neuropathic pain (Hsieh et al., 2010a). The observed analgesic effect 
appears secondary to the anti-inflammatory activity induced by H4R antagonism 
on immune cells through inhibition of chemotaxis (Ling et al., 2004) and cytokine 
production (Cowden et al., 2010b).  In addition, receptor levels change with 
progression of the pathophysiological response, for example, inﬂammatory 
stimuli have been shown to up-regulate H4R expression in monocytes (Dijkstra et 
al., 2007). However, the results obtained in Chapter 3 suggest a potential 
neuronal acting site for the H4R antagonists. While the significance of the 
differential changes remains unclear, it would be interesting to demonstrate the 
potential changes in expression of the closely related H3R. H3Rs are inhibitory 
heteroreceptors that are functionally expressed on a subset of DRG neurons and 
may regulate the release of histamine and other neurotransmitters such as 
substance P from DRG neurons. Immunohistochemical analysis revealed that the 
H3R is expressed on Aδ sensory fibres of the superficial spinal cord. Based on the 
results obtained in Chapter 4 with the anti-hH4R antibody, it may underestimate 
the observed changes in H4R expression that occur in the rat CNS during pain 
states. This is because the antibody used was generated towards the human H4R, 
which shares 69% with the rat H4R (Liu et al., 2001) and  therefore an antibody 
specific to the rat H4R is required.   
Further experiments are required to observe H4R expression during the 
pathogenesis of CFA-induced inflammation, comparing animal behaviour to H4R 
expression in the skin and spinal cord during the chronic phases of acute and 
neuropathic inflammatory pain. It would be interesting to observe potential 
differential expression of the H4R in the spinal cord during progression of 
pathogenesis. In addition, molecular experiments are required to find out if there 
is a relationship between H4R activation and release of neuropeptides such as 
substance P and CGRP from nociceptive afferent terminals during conditions of 
inflammatory pain. Since JNJ777120 has been shown to dose-dependently reverse 
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carrageenan induced thermal hyperalgesia (Hsieh et al., 2010a), it would be of 
interest to observe the relationship between activation of the neuronal H4R and 
ion channels such as the capsaicin receptor TRPV1, which is involved in the 
development of thermal hyperalgesia (Caterina et al., 1997, Linley et al., 2010).  
3) Antagonism of the central histamine H4 receptor exacerbates EAE 
Much of the current published research into the pre-clinical effect of H4R 
antagonism has revealed anti-inflammatory effects, in rodent models of 
inflammation. In contrast, H4R antagonism with JNJ 7777120 aggravated central 
inflammation in the EAE mouse model of multiple sclerosis, exemplified by a 
higher number of inflammatory infiltrates and a higher rate of demyelination in 
the lumbar spinal cord. The H4 receptor appears to have modulatory role within 
the CNS as H4R KO mice develop more severe EAE despite having T effector cell 
responses that were equal to those of wild type mice. The H4 receptor KO mice 
present with augmented neuroinflammation and increased BBB permeability 
compared with wild type mice, despite comparable T effecter cell responses.   
Although JNJ777120 has been proven to have functional antagonism on calcium 
mobilisation and chemotaxis in leukocytes through the inhibition of adenylyl 
cyclase activation and cAMP (Thurmond et al., 2004b), and inhibition of calcium 
mobility in DRG cells (Chapter 3), it may have agonist properties in the CNS 
through activation of a pathway that does not involve calcium mobilisation. JNJ 
7777120 has been demonstrated to be an antagonist at the human H4R and a 
partial agonist at the mouse H4R. We cannot exclude the possibility that the 
absence of H4 receptor signalling contributes to the increased disease severity, 
because of disturbed CNS signalling functions. On the other hand, JNJ 7777120 
could be acting as an agonist via the recruitment of β-arrestin (Rosethorne and 
Charlton, 2011, Wall, 1978), therefore worsening the clinical state of the animals. 
It is possible that the agonism and antagonism of the centrally expressed H4 
receptor may have different effects compared to the peripherally expressed H4 
receptor. Further work is needed for elucidating the pathway activated during 
central H4 receptor agonism and antagonism, if specific H4 receptor ligands are to 
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be among the group of potential drugs to treat inflammatory or autoimmune 
diseases and neuropathic pain secondary to CNS inflammatory disorders. 
 
4) Antagonism of the H4 receptor has a central effect but no effect on anxiety 
or novel object recognition memory 
 
The elevated platform is a novel validated paradigm used to assess a number of 
behaviours such as anxiety, mobility, learning and memory. Despite the 
confirmed expression in the rodent and human brain (Connolly et al., 2009), the 
role of the H4R is still unclear due to the lack of research. In the elevated 
platform, the slopes provide an incentive for the animals as they can cross onto 
the slopes and get closer to the ground. Mice exposed to an elevated platform 
do try to escape; animals show preference for the areas adjacent to slopes 
which provide a potential route for escape by jumping onto the ground when 
the platform is not sufficiently raised. Antagonism of the H4R with JNJ 7777120 
did not facilitate crossing onto the slopes of the platform, in contrast to 
diazepam treated where Balb/c mice did cross frequently and spent more time 
on the slopes (Ennaceur et al., 2010a). On the other hand, a study by Galeotti et 
al. (2013) showed that the H4R agonist VUF 8430 had apparent anxiolytic effects 
by increasing the time spent in the lit compartment of the light/dark box. This 
effect was attributed to H4R activation because antagonist JNJ 10191584 
antagonised the effects of VUF 8430.  Our laboratory has provided evidence that 
this latter test is not an accurate measure of anxiety, but rather an indication of 
avoidance responses, which may account for the differences in results 
(reference). In the novel object recognition test (non-spatial working memory 
task), JNJ 7777120 did not facilitate discrimination between novel and familiar 
object.  JNJ 7777120 had no effect on any test parameter of the novel object 
recognition test including the number of crossings and time spent in the 
different areas of the platform. This suggests that antagonising the H4R has no 
anxiolytic or novel object recognition memory enhancing effects in Balb/c mice. 
These studies however did provide preliminary evidence for central 
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behavioural effects with regard to time spent in central part of the platform, 
which is difficult to interpret at this stage. In order to fully understand the role 
of the central H4R in behaviour, future experiments are required to investigate 
effects on other forms of memory, including use of scopolamine-induced 
amnesias, spatial tasks and social interactions (the latter studied with newer 
tests currently under development in our laboratory).  
 
Understanding the biology of histamine and its respective receptors is vital for 
the development of novel therapies. Drugs targeting the histamine H1R and 
histamine H2R have been available for many years for the treatment of allergies 
and gastric inflammation, respectively. Expectations for similarly clinically 
effective drugs are expected for both the H3R and H4R. The discovery of the H4R 
on haematopoietic cells suggested its potential as a target for the treatment of 
inflammation and allergies. The data obtained from pre-clinical models of 
chronic inflammatory pain and pruritus, show that H4R antagonists relieve these 
symptoms with greater efficacy than clinically prescribed H1R antagonists.   
 
The involvement of the H4 receptor in the sensory pathway has been further 
supported by the expression of H4R on peripheral afferent fibres. While the H4 
receptor clearly has potential as a therapeutic target, predicting the effect of 
any ligand is difficult when faced with the complexity observed within and 
between species. This thesis has furthered the understanding of the H4 receptor 
expression and pharmacological profile within the peripheral and central 
nervous system. The experiments described will need to be extended to 
investigate the full range of receptor function and how they interact with other 
cellular components, whilst incorporating the use of H4R-/- animals. Whether 
alternative slicing in H4 receptors has functional relevance in the CNS is yet to be 
seen. The functional expression of this G protein coupled receptor in the CNS 
will enable the characterisation of the H4R involvement in neurological diseases 
particularly pain disorders and dermatitis where inflammation plays an active 
role.  
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